

CITATION REPORT

List of articles citing

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients

DOI: 10.1016/j.radonc.2009.04.014
Radiotherapy and Oncology, 2009, 92, 4-14.

Source: <https://exaly.com/paper-pdf/47047877/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

2293 Adjuvante Therapie bei Kopf-Hals-Tumoren. **2010**, 3, 25-29

2292 Update on role of chemotherapy in head and neck squamous cell cancer. **2010**, 1, 85-95 8

2291 Human papillomavirus: changing paradigms in oropharyngeal cancer. **2010**, 12, 115-20 23

2290 Transoral robotic surgery and a paradigm shift in the management of oropharyngeal squamous cell carcinoma. **2010**, 4, 79-86 7

2289 Predictive factors of isolated distant metastasis after primary definitive surgery without systemic treatment for head and neck squamous cell carcinoma. **2010**, 46, 504-8 29

2288 TGFbeta1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis. **2010**, 46, 369-72 13

2287 Postoperative strategies after primary surgery for squamous cell carcinoma of the head and neck. **2010**, 46, 577-85 35

2286 Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol. **2010**, 10, 651 6

2285 Intensity-modulated radiotherapy outcomes for oropharyngeal squamous cell carcinoma patients stratified by p16 status. **2010**, 116, 2645-54 33

2284 ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous cell carcinomas. **2010**, 34, 175-92 4

2283 Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma. **2010**, 78, 1373-80 22

2282 In regards to Barkati et'al. (Int J Radiat Oncol Biol Phys 2010;76:410-416). **2010**, 78, 639-40 2

2281 Age is not a limiting factor for brachytherapy for carcinoma of the node negative oral tongue in patients aged eighty or older. **2010**, 5, 116 11

2280 A single centre experience with sequential and concomitant chemoradiotherapy in locally advanced stage IV tonsillar cancer. **2010**, 5, 121 25

2279 Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer. **2010**, 5, 37 31

2278 Concurrent radiochemotherapy in advanced hypopharyngeal cancer. **2010**, 5, 39 11

2277 Intensity modulated radiotherapy (IMRT) in the management of locally advanced oropharyngeal squamous cell carcinomata (SCC): disease control and functional outcome using the therapy outcome measure (TOM) score--report from a single U.K. institution. **2010**, 2, 28 7

2276 Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience. **2010**, 2, 34 22

2275	Evidence-based management of oropharyngeal cancer. 2010 , 35, 273-6	3
2274	Therapeutic Ratio of Reirradiation with Cytotoxic Drugs and Other Response-Modifying Agents. 2010 , 37-57	
2273	Si on reparlait du protocole CHART. 2010 , 97, 741-742	
2272	[Minutes of the 51st Meeting of the American Society for Therapeutic Radiology and Oncology (Astro). Chicago (USA), November 1-5, 2009]. 2010 , 97, 170-6	
2271	Cetuximab in locally advanced head-and-neck cancer: defining the population. 2010 , 17, 48-51	5
2270	Current management strategy of nasopharyngeal carcinoma. 2010 , 3, 1-12	65
2269	Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v184-6	391
2268	Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. 2010 , 28, 3336-43	61
2267	Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial. 2010 , 21, 2272-2277	64
2266	Induction chemotherapy for head and neck cancer: recent data. 2010 , 15 Suppl 3, 3-7	33
2265	A new look at induction chemotherapy in locally advanced head and neck cancer. 2010 , 15 Suppl 3, 1-2	3
2264	Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. 2010 , 28, 2989-95	290
2263	Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. 2010 , 21, 2284-2289	23
2262	Emerging drugs to treat squamous cell carcinomas of the head and neck. 2010 , 15, 355-73	88
2261	Cautionary tales in the interpretation of clinical studies involving older persons. 2010 , 170, 587-95	63
2260	Radiotherapy for laryngeal squamous cell carcinoma: current standards. 2010 , 10, 1461-9	9
2259	Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries. 2010 , 7, 616-8	
2258	Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. 2010 , 28, 2181-90	1176

2257	Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. 2010 , 28, 5294-300	116
2256	Oropharyngeal cancer, human papilloma virus, and clinical trials. 2010 , 28, 1-3	65
2255	TPF sequential therapy: when and for whom?. 2010 , 15 Suppl 3, 13-8	80
2254	Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer. 2010 , 21 Suppl 7, vii246-51	9
2253	Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. 2010 , 22, 206-11	20
2252	Advances in radiotherapy of head and neck cancers. 2010 , 22, 194-9	28
2251	Chemo-Radiation Association in Head and Neck Squamous Cell Carcinoma: Evidences and Criticisms. 2010 , 5, 164-171	
2250	Head and neck cancer--Part 2: Treatment and prognostic factors. 2010 , 341, c4690	56
2249	Chemotherapy: Chemoradiation in head-and-neck cancer-are we any closer?. 2010 , 7, 247-9	
2248	The role of chemotherapy in the management of patients with head and neck cancer. 2010 , 24, 137-47	5
2247	Therapie der Plattenepithelkarzinome von Kopf und Hals. 2010 , 31, 74-77	1
2246	¹⁸ F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. 2010 , 51, 866-74	134
2245	Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. 2010 , 28, 35-42	283
2244	Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. 2010 , 70, 1987-2010	43
2243	Handbook of Evidence-Based Radiation Oncology. 2010 ,	32
2242	The prognostic significance of p16 overexpression in oropharyngeal squamous cell carcinoma: implications for treatment strategies and future clinical studies. 2010 , 21, 1931-1934	33
2241	Vincristine-resistant human laryngeal carcinoma cells demonstrate increased Rous sarcoma virus promoter activity. 2010 , 87, 468-74	3
2240	[Minutes of the 51st meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO). Chicago (USA), November 1-5, 2009]. 2010 , 14, 155-9	0

2239	Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?. 2010 , 46, 1979-89		22
2238	Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation. <i>Radiotherapy and Oncology</i> , 2010 , 95, 209-17	5:3	86
2237	The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. <i>Radiotherapy and Oncology</i> , 2010 , 95, 371-80	5:3	131
2236	Diagnostic performance of response assessment FDG-PET/CT in patients with head and neck squamous cell carcinoma treated with high-precision definitive (chemo)radiation. <i>Radiotherapy and Oncology</i> , 2010 , 97, 194-9	5:3	44
2235	The role of adaptive and functional imaging modalities in radiation therapy: approach and application from a radiation oncology perspective. 2010 , 31, 444-61		6
2234	[Paranasal sinus carcinoma]. 2010 , 14 Suppl 1, S52-60		1
2233	Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. 2010 , 11, 66-74		71
2232	Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. 2010 , 11, 21-8		1465
2231	PET-CT for response assessment and treatment adaptation in head and neck cancer. 2010 , 11, 661-9		93
2230	Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?. 2010 , 11, 312-3		14
2229	Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. 2010 , 11, 553-60		90
2228	The IAEA-ACC study: a commendable start. 2010 , 11, 503-4		3
2227	Human papillomavirus and survival of patients with oropharyngeal cancer. 2010 , 363, 24-35		4358
2226	Chemotherapy regimens and treatment protocols for laryngeal cancer. 2010 , 11, 1305-16		7
2225	Hyperthermia for locally advanced breast cancer. 2010 , 26, 618-24		36
2224	Emerging applications of stereotactic body radiation therapy for head and neck cancer. 2011 , 11, 1429-36		18
2223	The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). 2011 , 22, 1878-85		85
2222	Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions. 2011 , 81, 21-9		20

2221	PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. 2011 , 8, 233-42		73
2220	Re-irradiation: New Frontiers. 2011 ,		3
2219	Intracranial yolk sac tumor in a patient with Down syndrome. 2011 , 7, 604-8		11
2218	Inguinal recurrence following therapeutic lymphadenectomy for node positive penile carcinoma: outcome and implications for management. 2011 , 185, 888-93		53
2217	Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT. 2011 , 11, 182		18
2216	Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. 2011 , 10, 5232-41		87
2215	Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. 2011 , CD006386		61
2214	Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons. 2011 , 37, 185-201		68
2213	Organ-sparing radiation therapy for head and neck cancer. 2011 , 8, 639-48		60
2212	Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. 2011 , 64, 985-92		47
2211	A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. 2011 , 64, 949-67		118
2210	Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. 2011 , 12, 153-9		297
2209	Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. 2011 , 12, 127-36		1106
2208	Delivering affordable cancer care in high-income countries. 2011 , 12, 933-80		476
2207	Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. 2011 , 17, 3733-41		72
2206	Patterns of relapse following definitive treatment of head and neck squamous cell cancer by intensity modulated radiotherapy and weekly cisplatin. <i>Radiotherapy and Oncology</i> , 2011 , 98, 34-7	5-3	15
2205	A phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2011 , 98, 42-7	5-3	7
2204	Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2011 , 100, 22-32	5-3	337

2203	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. <i>Radiotherapy and Oncology</i> , 2011 , 100, 33-40	5-3	422
2202	Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2011 , 99, 356-61	5-3	67
2201	Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: a cohort study based on 994 patients. <i>Radiotherapy and Oncology</i> , 2011 , 100, 108-15	5-3	45
2200	Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. <i>Radiotherapy and Oncology</i> , 2011 , 100, 70-5	5-3	59
2199	Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial. <i>Radiotherapy and Oncology</i> , 2011 , 100, 56-61	5-3	16
2198	Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. <i>Radiotherapy and Oncology</i> , 2011 , 100, 62-9	5-3	43
2197	Advancing radiation oncology through scientific publication--100 volumes of Radiotherapy and Oncology. <i>Radiotherapy and Oncology</i> , 2011 , 100, 1-6	5-3	5
2196	Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio?. 2011 , 81, 346-52		51
2195	Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382). 2011 , 81, 719-25		42
2194	Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. 2011 , 81, 915-22		117
2193	Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic. 2011 , 81, 923-9		50
2192	Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas. 2011 , 81, e237-43		30
2191	Clinical applications of Telerobotic ENT-Head and Neck surgery. 2011 , 9, 277-84		20
2190	Non-Skull Base Head and Neck Cancer. 2011 , 251-265		
2189	Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer. 2011 , 52, 47-53		13
2188	42 Influence of (Chemo-)Radiotherapy on Salivary Gland Function and Its Impact on Quality of Life. 2011 ,		
2187	Impact of HPV in Oropharyngeal Cancer. 2011 , 2011, 509036		47
2186	Metabolic tumour volume. Prognostic value in locally advanced squamous cell carcinoma of the head and neck. 2011 , 50, 141-6		10

2185	A specific approach for elderly patients with head and neck cancer. 2011 , 22, 647-55	16
2184	Induction chemotherapy in head and neck cancer: a new paradigm. 2011 , 22, 613-20	19
2183	Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck. 2011 , 6, 246-57	7
2182	Head and neck cancers. 2011 , 9, 596-650	141
2181	The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms?. 2011 , 9, 665-73	158
2180	Controversies in the locoregional management of head and neck cancer. 2011 , 9, 653-62	9
2179	Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. 2012 , 27, 467-74	11
2178	Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients. 2011 , 7, 287-92	21
2177	The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. 2011 , 7, 236-51	15
2176	Contemporary clinical management of oral squamous cell carcinoma. 2011 , 57, 89-101	15
2175	The impact of comorbidity on treatment-related side effects in older patients with laryngeal cancer. 2011 , 47, 56-61	36
2174	Co-morbidity and treatment outcomes of elderly pharyngeal cancer patients: a matched control study. 2011 , 47, 1159-64	16
2173	Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies. 2011 , 18, 3479-85	4
2172	Sequential FDG-PET/CT after neoadjuvant chemotherapy is a predictor of histopathologic response in patients with head and neck squamous cell carcinoma. 2011 , 13, 368-77	28
2171	Objective assessment of swallowing function after definitive concurrent (chemo)radiotherapy in patients with head and neck cancer. 2011 , 26, 399-406	47
2170	Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. 2011 , 268, 165-79	90
2169	Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma. 2011 , 268, 1349-55	15
2168	Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study. 2011 , 187, 645-50	13

2167	Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab. 2011 , 187, 373-7	19
2166	Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. 2011 , 38, 2083-95	267
2165	Was geht zur Qualitätssicherung?. 2011 , 6, 1-1	
2164	Chemoradiotherapy for cervical cancer in 2010. 2011 , 13, 77-85	21
2163	Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer. 2011 , 6, 120	6
2162	Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN). 2011 , 6, 122	14
2161	Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy. 2011 , 6, 54	55
2160	Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?. 2011 , 6, 89	22
2159	Mammalian target of rapamycin and head and neck squamous cell carcinoma. 2011 , 3, 22	24
2158	Oncological results after surgical treatment of squamous cell cancer of the lateral wall of the oropharynx. 2011 , 121, 1449-54	15
2157	Evidence-based review of treatment options for patients with glottic cancer. 2011 , 33, 1638-48	104
2156	Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer. 2011 , 33, 1551-6	8
2155	Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. 2011 , 117, 2926-38	94
2154	Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. 2011 , 79, 46-51	68
2153	RapidArc planning and delivery in patients with locally advanced head-and-neck cancer undergoing chemoradiotherapy. 2011 , 79, 429-35	69
2152	Prospective assessment of patterns of failure after high-precision definitive (chemo)radiation in head-and-neck squamous cell carcinoma. 2011 , 80, 522-31	13
2151	Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. 2011 , 80, 514-21	58
2150	Treatment outcomes of locally advanced oropharyngeal cancer: a comparison between combined modality radio-chemotherapy and two variants of single modality altered fractionation radiotherapy. 2011 , 80, 1030-6	6

2149	Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy. 2011 , 81, 118-25	22
2148	Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer. 2011 , 81, 126-34	61
2147	Hypofractionated accelerated radiotherapy with concurrent carboplatin for locally advanced squamous cell carcinoma of the head and neck. 2011 , 23, 34-9	17
2146	The role of split-course hypofractionated palliative radiotherapy in head and neck cancer. 2011 , 23, 141-8	23
2145	Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study. 2011 , 23, 149-58	8
2144	Uroporphyrinogen decarboxylase: optimizing radiotherapy for head and neck cancer. 2011 , 7, 595-7	3
2143	Grading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation required. 2011 , 22, 2157-9	7
2142	[Treatment related swallowing dysfunction and the potentialities of IMRT]. 2011 , 90, 657-62	4
2141	Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. 2011 , 22, 2482-2488	11
2140	Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck. 2011 , 131, 1333-40	7
2139	XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. 2011 , 17, 5513-22	44
2138	A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. 2011 , 22, 2304-9	46
2137	Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. 2011 , 29, 2590-7	38
2136	Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland. 2011 , 95, 1483-9	25
2135	Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. 2011 , 3, 67ra7	25
2134	Population-based study of competing mortality in head and neck cancer. 2011 , 29, 3503-9	141
2133	Cetuximab in the treatment of squamous cell carcinoma of the head and neck. 2011 , 11, 511-24	29
2132	Cetuximab in head and neck cancer. 2011 , 48, 145-7	1

2131	Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?. 2011 , 48, 148-53	14
2130	Lack of a correlation between H2AX foci kinetics in lymphocytes and the severity of acute normal tissue reactions during IMRT treatment for head and neck cancer. 2011 , 87, 46-56	21
2129	Empowering induction therapy for locally advanced head and neck cancer. 2011 , 22, 773-781	12
2128	Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy. 2011 , 22, 1894-901	21
2127	Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. 2011 , 22, 712-717	53
2126	Nanotechnology in oncology: Characterization and in vitro release kinetics of cisplatin-loaded albumin nanoparticles: Implications in anticancer drug delivery. 2011 , 43, 409-13	16
2125	Ablative surgery and free flap reconstruction for elderly patients with oral or oropharyngeal cancer: oncologic and functional outcomes. 2011 , 131, 1104-9	14
2124	Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience. 2011 , 84, 367-74	23
2123	Carcinoma base of tongue: single institution 15 year experiences. 2012 , 49, 220-4	1
2122	Biologic therapy in head and neck cancer: a road with hurdles. 2012 , 2012, 163752	16
2121	Hyperfractionated radiotherapy with concurrent cisplatin/5-Fluorouracil for locoregional advanced head and neck cancer: analysis of 105 consecutive patients. 2012 , 2012, 754191	4
2120	Treatment of hypopharyngeal carcinoma with primary chemoradiotherapy: functional morbidity. 2012 , 20, 89-96	11
2119	Transoral laser surgery for hypopharyngeal carcinomas. 2012 , 20, 97-102	12
2118	Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. 2012 , 18, 1404-14	65
2117	Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. 2012 , 23, 1825-32	17
2116	Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription. 2012 , 23 Suppl 10, x178-85	32
2115	[Systemic therapy strategies for head-neck carcinomas: current status]. 2012 , 91 Suppl 1, S123-43	4
2114	Systemische Therapiestrategien bei Kopf-Hals-Karzinomen. 2012 , 33, 339-359	

2113	Radiobiological compensation: A case study of uterine cervix cancer with concurrent chemotherapy. 2012,	
2112	Reirradiation for recurrent head and neck cancer. 2012, 12, 1177-89	20
2111	Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. 2012, 30, 2102-11	359
2110	Salvage Neck Dissection after Chemoradiation in Head and Neck Cancer: Practice and Pitfalls. 2012, 3, 15-21	0
2109	Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. 2012, 17, 673-81	14
2108	Neoadjuvant chemoradiation in squamous cell carcinoma of the maxillary sinus: a 26-year experience. 2012, 2012, 413589	15
2107	Functional organ preservation for laryngeal cancer: past, present and future. 2012, 42, 155-60	17
2106	Senior adult oncology. 2012, 10, 162-209	85
2105	Neck Dissection nach primärer Strahlenchemotherapie?. 2012, 15, 40-41	
2104	Cancers de la paroi postérieure du pharynx. 2012, 7, 1-12	
2103	Chimiothérapie et thérapies ciblées dans le traitement des cancers des voies aérodigestives supérieures (lymphome malin exclu). 2012, 7, 1-16	
2102	Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma. 2012, 4, 898-904	0
2101	Non-surgical interventions for human papilloma virus-positive local advanced oropharyngeal squamous cell cancer. 2012,	1
2100	[Role of French teams in the development of clinical and translational research in radiation oncology]. 2012, 16, 386-91	0
2099	Facteurs pronostiques cliniques et histologiques des cancers localement avancés de la cavité buccale traités par chirurgie première. 2012, 129, 339-344	
2098	Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. 2012, 13, 145-53	235
2097	Easing acceleration of head and neck chemoradiotherapy. 2012, 13, 113-5	3
2096	What price cure?. 2012, 13, e2	1

2095	Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive?. 2012 , 13, e292-300	77
2094	Histological assessment of cervical lymph node identifies patients with head and neck squamous cell carcinoma (HNSCC): who would benefit from chemoradiation after surgery?. 2012 , 122, 2712-22	11
2093	Swallowing, nutrition and patient-rated functional outcomes at 6 months following two non-surgical treatments for T1-T3 oropharyngeal cancer. 2012 , 20, 2073-81	12
2092	Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. 2012 , 82, e67-75	139
2091	Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study. 2012 , 82, 270-5	72
2090	Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. 2012 , 82, 548-53	106
2089	Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). 2012 , 82, 524-31	30
2088	Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. 2012 , 82, 1845-50	26
2087	Definitive radiotherapy for T1-2 hypopharyngeal cancer: a single-institution experience. 2012 , 82, e129-35	14
2086	Predictors of severe acute and late toxicities in patients with localized head-and-neck cancer treated with radiation therapy. 2012 , 82, 1454-62	58
2085	Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. 2012 , 83, 385-93	25
2084	Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. 2012 , 83, 1514-20	78
2083	Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. 2012 , 83, e377-83	25
2082	Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis. 2012 , 84, 983-9	49
2081	Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review. 2012 , 84, 581-9	65
2080	Rehabilitation needs of patients with oropharyngeal cancer. 2012 , 45, 863-78	3
2079	Chemioterapia e terapie mirate nel trattamento delle neoplasie delle vie aerodigestive superiori (escluso il linfoma maligno). 2012 , 11, 1-16	
2078	De-intensification of treatment for human papilloma virus associated oropharyngeal squamous cell carcinoma: A discussion of current approaches. 2012 , 2, 282-287	8

2077	EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2012 , 105, 238-40	5.3	15
2076	Sequence of Radiotherapy and Chemotherapy in Breast Cancer After Breast-Conserving Surgery: Jobsen JJ, van der Palen J, Brinkhuis M, et al (Medisch Spectrum Twente, Enschede, the Netherlands; Univ of Twente, the Netherlands; Laboratory for Pathology Oost Nederland, Enschede, the Netherlands, et al) <i>Int J Radiat Oncol Biol Phys</i> 82:e811-e817, 2012. 2012 , 23, 388-390		
2075	Quimioterapia y terapias dirigidas en el tratamiento de los cánceres de las vías aerodigestivas superiores (excluido el linfoma maligno). 2012 , 41, 1-18		
2074	Systematic review of cancer presentations with a median survival of six months or less. 2012 , 15, 175-85		44
2073	Evidence-based practice: management of glottic cancer. 2012 , 45, 1143-61		18
2072	Dose-response analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction chemotherapy followed by concomitant chemo-IMRT for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2012 , 103, 88-91	5.3	41
2071	Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). <i>Radiotherapy and Oncology</i> , 2012 , 104, 213-8	5.3	22
2070	Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. <i>Radiotherapy and Oncology</i> , 2012 , 104, 343-8	5.3	190
2069	Micronucleus formation kinetics in buccal mucosa cells of head and neck cancer patients undergoing radiotherapy. 2012 , 212, 33-7		12
2068	The role of PET imaging in overcoming radiobiological challenges in the treatment of advanced head and neck cancer. 2012 , 38, 185-93		4
2067	Low level laser therapy for concurrent chemoradiotherapy induced oral mucositis in head and neck cancer patients - a triple blinded randomized controlled trial. <i>Radiotherapy and Oncology</i> , 2012 , 104, 349-54	5.3	59
2066	Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. 2012 , 34, 1681-703		77
2065	IMRT and carbon ion boost for malignant salivary gland tumors: interim analysis of the COSMIC trial. 2012 , 12, 163		8
2064	Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). 2012 , 12, 483		9
2063	From chemoprevention and organ preservation programs to post-operative management: major achievements and strategies of the EORTC Head and Neck Cancer Group. 2012 , 10, 76-81		
2062	Clinical and histological prognostic factors in locally advanced oral cavity cancers treated with primary surgery. 2012 , 129, 291-6		12
2061	Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target. 2012 , 44, 1852-61		69
2060	Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity. 2012 , 16, 601-3		17

2059	Current issues in combined modality therapy in locally advanced head and neck cancer. 2012 , 84, 261-73	18
2058	Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. 2012 , 38, 1033-49	82
2057	Oropharynx cancer. 2012 , 36, 334-415	5
2056	Risk factors for osteoradionecrosis after head and neck radiation: a systematic review. 2012 , 113, 54-69	157
2055	Low level helium neon laser therapy for chemoradiotherapy induced oral mucositis in oral cancer patients - a randomized controlled trial. 2012 , 48, 893-7	32
2054	Primary chemoradiotherapy for oral cavity squamous cell carcinoma. 2012 , 48, 1014-1018	28
2053	Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. 2012 , 48, 1051-1057	39
2052	Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. 2012 , 48, 1076-84	74
2051	Treatment intensification for head and neck carcinoma: do we have a verdict?. 2012 , 48, e49-50	1
2050	Head and neck cancer in the elderly population. 2012 , 22, 321-33	31
2049	Radiation therapy is well tolerated and produces excellent control rates in elderly patients with locally advanced head and neck cancers. 2012 , 3,	7
2048	New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). 2012 , 29, 2481-91	43
2047	Future challenges in head and neck cancer: from the bench to the bedside?. 2012 , 84 Suppl 1, e90-6	10
2046	PET in Decision Making for Neck Dissection After Radiation Treatment. 2012 , 7, 411-23	2
2045	Extended voice-sparing surgery in selected pyriform sinus carcinoma: techniques and outcomes. 2013 , 35, 1482-9	8
2044	Definitive radiotherapy for squamous cell carcinoma of the pyriform sinus. <i>Radiotherapy and Oncology</i> , 2012 , 105, 232-7	53 11
2043	Nasopharyngeal Carcinoma. 2012 , 145-159	
2042	[Development of methods and instruments for radiation therapy. The most important developments from the viewpoint of a physicist]. 2012 , 188 Suppl 3, 245-52	1

2041	[Concurrent radiochemotherapy for the treatment of solid tumors]. 2012 , 188 Suppl 3, 263-71	5
2040	Larynx preservation: what is the standard treatment?. 2012 , 84 Suppl 1, e97-e105	8
2039	Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors. 2012 , 7, 78	8
2038	Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial. 2012 , 7, 57	5
2037	Pure accelerated radiation versus concomitant chemoradiation in selected cases of locally advanced carcinoma cervix: a prospective study. 2012 , 62, 679-86	0
2036	Cancers ORL localement évolués : chimioradiothérapie ou accélération de la radiothérapie ?. 2012 , 99, 901-902	
2035	Definitive Radiotherapy versus Postoperative Radiotherapy of Patients with Oro- and Hypopharyngeal Cancer: Impact of Prognostic Factors. 2012 , 2012, 391917	2
2034	Ten years of progress in head and neck cancers. 2012 , 10, 806-10	35
2033	Competing causes of death in patients with oropharyngeal cancer treated with radiotherapy. 2012 , 3, 835-840	2
2032	Treatment of recurrent metastatic head and neck cancer: focus on cetuximab. 2012 , 5, 1-16	14
2031	Metastasis of Head and Neck Squamous Cell Carcinoma. 2012 ,	3
2030	Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies. 2012 , 34, 872-6	18
2029	Patterns of failure and histopathologic outcome predictors following definitive radiotherapy and planned neck dissection with residual disease. 2012 , 34, 913-22	9
2028	Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. 2012 , 34, 1147-52	46
2027	Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer. 2012 , 34, 1363-8	3
2026	Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial. 2012 , 118, 1811-7	26
2025	Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. 2012 , 118, 3519-30	188
2024	A population-based study of therapy and survival for patients with head and neck cancer treated in the community. 2012 , 118, 4452-61	39

2023	Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN). 2012 , 118, 5783-92	40
2022	[Neck dissection of the residually positive neck after primary radiochemotherapy for locally advanced head and neck cancer]. 2012 , 188, 444-5	2
2021	[New aspects of primary radiochemotherapy in head and neck cancer. Highlights from the 2011 ASCO Congress]. 2012 , 60, 393-7	0
2020	Does weight loss predict accuracy of setup in head and neck cancer patients treated with Intensity-Modulated Radiation Therapy?. 2012 , 117, 885-91	7
2019	Functional outcomes after chemoradiotherapy of laryngeal and pharyngeal cancers. 2012 , 14, 158-65	75
2018	Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. 2012 , 22, 128-42	200
2017	The role of chemotherapy in locally advanced head and neck squamous cell carcinoma. 2012 , 22, 198-206	13
2016	Neoadjuvant cisplatin for head and neck cancer: Simulation of a novel schedule for improved therapeutic ratio. 2012 , 297, 41-7	5
2015	The anti-tumour effect of cisplatin and ifosfamide on xenografted squamous cell carcinoma of the head and neck is schedule-dependent. 2012 , 48, 61-6	3
2014	Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. 2012 , 118, 711-21	45
2013	Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. 2012 , 34, 270-81	185
2012	Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets. 2012 , 34, 282-90	17
2011	Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients. 2012 , 188, 49-55	26
2010	[Recent advances in the treatment of laryngeal and hypopharyngeal carcinoma]. 2012 , 60, 6-18	1
2009	10e biennale monégasque de cancérologie : nouveautés ORL. 2012 , 14, 24-27	
2008	The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy. 2012 , 269, 275-82	27
2007	Functional outcome in patients with advanced head and neck cancer: surgery and reconstruction with free flaps versus primary radiochemotherapy. 2012 , 269, 629-38	20
2006	Chemoradiation for advanced hypopharyngeal carcinoma: a retrospective study on efficacy, morbidity and quality of life. 2012 , 269, 939-46	32

2005	Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. 2013 , 35, 286-93	77
2004	Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer. 2013 , 35, 381-7	12
2003	Emerging understanding of dosimetric factors impacting on dysphagia and nutrition following radiotherapy for oropharyngeal cancer. 2013 , 35, 1211-9	19
2002	Prognostic factors for supraglottic laryngeal carcinoma: Importance of the unfit patient. 2013 , 35, 949-58	11
2001	Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck. 2013 , 22, 32-40	2
2000	Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis. 2013 , 11, 67	38
1999	The role of systemic treatment before, during, and after definitive treatment. 2013 , 46, 645-56	2
1998	Feasibility and efficacy of chemoradiotherapy for elderly patients with locoregionally advanced nasopharyngeal carcinoma: results from a matched cohort analysis. 2013 , 8, 70	26
1997	Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02. 2013 , 8, 40	5
1996	Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. 2013 , 8, 21	75
1995	Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR)--study protocol for a randomized phase II trial. 2013 , 13, 133	100
1994	Is open surgery for head and neck cancers truly declining?. 2013 , 270, 2793-802	16
1993	Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin. 2013 , 15, 321-6	11
1992	Early evaluation of neoadjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma. 2013 , 18, 402-10	38
1991	Criteria to choose between distal or proximal venous port device insertion in HNC patients. 2013 , 36, 874-5	
1990	Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer: final results from a single institution. 2013 , 189, 842-8	8
1989	Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy. Outcome in patients with locally advanced head and neck cancer. 2013 , 189, 618-24	9
1988	MicroRNA-17-5p post-transcriptionally regulates p21 expression in irradiated betel quid chewing-related oral squamous cell carcinoma cells. 2013 , 189, 675-83	15

1987	[Primary curative radiochemotherapy in nasopharyngeal carcinomas. Cumulative total cisplatin dose of prognostic significance]. 2013 , 189, 269-70		1
1986	Transoral robotic surgery and transoral laser microsurgery for oropharyngeal squamous cell cancer. 2013 , 7, 377-83		4
1985	The effect of induction chemotherapy on tumor volume and organ-at-risk doses in patients with locally advanced oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2013 , 109, 269-74	5:3	2
1984	Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. 2013 , 4, 327-33		27
1983	Physical examination during chemoradiation predicts outcome of locally advanced head and neck cancer. Secondary results of a randomized phase III trial (SAKK 10/94). 2013 , 49, 1006-9		1
1982	Patterns of care in older patients with squamous cell carcinoma of the head and neck: a surveillance, epidemiology, and end results-medicare analysis. 2013 , 4, 262-70		25
1981	A predictive model for dysphagia following IMRT for head and neck cancer: introduction of the EMLasso technique. <i>Radiotherapy and Oncology</i> , 2013 , 107, 295-9	5:3	28
1980	Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. 2013 , 14, 257-64		473
1979	Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: a phase III randomised trial. <i>Radiotherapy and Oncology</i> , 2013 , 107, 317-24	5:3	19
1978	Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. 2013 , 31, 845-52		772
1977	Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. 2013 , 52, 1257-71		42
1976	Long-term outcomes with high-dose-rate brachytherapy for the management of base of tongue cancer. 2013 , 12, 535-41		22
1975	Advances in radiation oncology for the management of oropharyngeal tumors. 2013 , 46, 629-43		5
1974	Contemporary radiotherapy in head and neck cancer: balancing chance for cure with risk for complication. 2013 , 22, 579-98		13
1973	Cñceres de la pared posterior de la faringe. 2013 , 42, 1-12		
1972	Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. 2013 , 13, 1065-72		6
1971	Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer. 2013 , 49, 249-54		7
1970	[IMRT and head and neck tumors: does differential fractionation have a role?]. 2013 , 17, 502-7		0

1969	Current status and future directions in induction chemotherapy for head and neck cancer. 2013 , 88, 57-74	8
1968	ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. 2013 , 109, 2096-105	46
1967	Head and Neck Squamous Cell Cancer. 2013 , 61-75	
1966	Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study. 2013 , 49, 634-42	89
1965	Larynx preservation: what is the best non-surgical strategy?. 2013 , 88, 447-58	10
1964	Low-dose fractionated radiation with induction chemotherapy for locally advanced head and neck cancer: 5 year results of a prospective phase II trial. 2013 , 2, 35-42	6
1963	Strategies for non-resectable head and neck cancer. 2013 , 14, 492-504	11
1962	[Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma]. 2013 , 189, 1058-9	2
1961	Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful?. 2013 , 21, 3433-9	26
1960	Dysphagia after definitive radiotherapy for head and neck cancer. Correlation of dose-volume parameters of the pharyngeal constrictor muscles. 2013 , 189, 230-6	33
1959	Induction chemotherapy meta-analysis in head and neck cancer: right answer, wrong question. 2013 , 31, 2844-6	20
1958	A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. 2013 , 119, 766-73	25
1957	Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. 2013 , 49, 352-9	19
1956	How to generalize efficacy results of randomized trials: recommendations based on a systematic review of possible approaches. 2013 , 19, 638-43	23
1955	Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer. 2013 , 189, 26-32	11
1954	Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. 2013 , 31, 744-51	196
1953	Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity. 2013 , 123, 164-70	50
1952	Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines. 2013 , 49, 872-877	52

1951	Radiation-free weekend rescued! Continuous accelerated irradiation of 7-days per week is equal to accelerated fractionation with concomitant boost of 7 fractions in 5-days per week: report on phase 3 clinical trial in head-and-neck cancer patients. 2013 , 85, 741-6		6
1950	Cancri della laringe. 2013 , 12, 1-15		
1949	The effect of concomitant chemotherapy on parotid gland function following head and neck IMRT. <i>Radiotherapy and Oncology</i> , 2013 , 106, 346-51	5:3	15
1948	Equivalence of cisplatin and carboplatin-based chemoradiation for locally advanced squamous cell carcinoma of the head and neck: a matched-pair analysis. 2013 , 49, 615-9		22
1947	Protons in head-and-neck cancer: bridging the gap of evidence. 2013 , 85, 1282-8		56
1946	The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis. 2013 , 25, 647-53		5
1945	Head and neck cancer in the south west of England, Hampshire, and the Isle of Wight: trends in survival 1996-2008. 2013 , 51, 19-24		14
1944	Cancro dell'ipofaringe. 2013 , 12, 1-17		
1943	Radioterapia dei tumori otorinolaringoiatrici. 2013 , 12, 1-12		
1942	Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. 2013 , 85, 112-20		17
1941	Cáncer de la hipofaringe. 2013 , 42, 1-18		
1940	Induction chemotherapy challenges for head and neck cancer. 2013 , 14, 188-9		5
1939	Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2013 , 106, 112-7	5:3	33
1938	Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. 2013 , 31, 2854-60		187
1937	Squamous cell carcinoma of the head and neck in the elderly. 2012 , 18, 16-25		51
1936	Volumetric-modulated arc therapy (RapidArc) vs. conventional fixed-field intensity-modulated radiotherapy for ¹⁸ F-FDG-PET-guided dose escalation in oropharyngeal cancer: a planning study. 2013 , 38, 18-24		6
1935	Radioterapia de los cánceres otorrinolaringológicos. 2013 , 42, 1-14		
1934	Cáncer de la laringe. 2013 , 42, 1-16		

1933	Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma. 2013 , 49, 283-6	23
1932	Induction chemotherapy for squamous cell head and neck cancer: a neverending story?. 2013 , 49, 747-52	10
1931	An analysis of intracranial epidermoid tumors with malignant transformation: treatment and outcomes. 2013 , 115, 1071-8	26
1930	Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer. 2013 , 34, 631-5	35
1929	mTHPC mediated photodynamic therapy (PDT) of squamous cell carcinoma in the head and neck: a systematic review. 2013 , 49, 192-210	41
1928	Multidisciplinary care of the patient with head and neck cancer. 2013 , 22, 179-215	15
1927	Cancri della parete posteriore della faringe. 2013 , 12, 1-12	
1926	Target volume definition for intensity-modulated radiotherapy after induction chemotherapy and patterns of treatment failure after sequential chemoradiotherapy in locoregionally advanced oropharyngeal squamous cell carcinoma. 2013 , 25, 162-70	13
1925	Matched-pair analysis in patients with advanced oropharyngeal cancer: surgery versus concurrent chemoradiotherapy. 2013 , 84, 290-8	10
1924	Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcome (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. 2013 , 13, 84	74
1923	DeCIDE and PARADIGM: nails in the coffin of induction chemotherapy in head and neck squamous cell carcinoma?. 2013 , 15, 248-51	12
1922	RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. 2013 , 8, 37	42
1921	Toxicity and outcome of intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy for oropharyngeal cancer: a matched-pair analysis. 2013 , 12, 123-30	29
1920	Oral cancer: Current role of radiotherapy and chemotherapy. 2013 , 18, e233-40	150
1919	Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma. 2013 , 49, 830-4	28
1918	Emerging insights into head and neck cancer metastasis. 2013 , 35, 1669-78	37
1917	A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach. <i>Radiotherapy and Oncology</i> , 2013 , 106, 333-40	5.3 56
1916	Concordance measures in shared frailty models: application to clustered data in cancer prognosis. 2013 , 32, 4803-20	7

1915	Multidisciplinary clinic care improves adherence to best practice in head and neck cancer. 2013 , 34, 57-60	79
1914	Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection. 2013 , 49, 55-9	21
1913	Preoperative vs. postoperative radiochemotherapy in patients with N2 squamous cell carcinoma of the oral cavity: in regard to Kreppel et al. published in Oral Oncol 2012 May 2 [Epub ahead of print]. 2013 , 49, e1	
1912	The role of sequential chemoradiation for local advanced oropharyngeal carcinoma. 2013 , 18, 808-16	2
1911	Podoplanin expression in cutaneous head and neck squamous cell carcinoma--prognostic value and clinicopathologic implications. 2013 , 107, 376-83	30
1910	Acute multiple arterial thrombosis after cisplatin in base of tongue carcinoma: case report. 2013 , 35, E269-71	6
1909	[Errors and hazards in oncology: radiation oncology]. 2013 , 92 Suppl 1, S199-204	
1908	[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]. 2013 , 100, 983-97	7
1907	Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. 2013 , 3, 5	4
1906	Can radiobiological parameters derived from squamous cell carcinoma of the head and neck be used to predict local control in anal cancer treated with chemoradiation?. 2013 , 86, 20120372	5
1905	Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments. 2013 , 2013, 817279	4
1904	Effets secondaires, complications et s�quelles de la chimioth�rapie. 2013 , 125-147	
1903	Risk factors for non-cancer health events in patients with head and neck squamous cell carcinoma. 2013 , 24, 1049-54	24
1902	The impact of comorbidity on outcome in 12 623 Danish head and neck cancer patients: a population based study from the DAHANCA database. 2013 , 52, 285-93	70
1901	Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis. 2013 , 50, 135-41	31
1900	Emerging tyrosine kinase inhibitors for head and neck cancer. 2013 , 18, 445-59	6
1899	Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?. 2013 , 31, 287-8	14
1898	Treatment of older patients with head and neck cancer: a review. 2013 , 18, 568-78	83

1897	Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future?. 2013 , 18, 288-93	21
1896	Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. 2013 , 12, 1112-21	28
1895	Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer. 2013 , 54, 1110-7	11
1894	Functional outcomes of chemoradiation in patients with head and neck cancer. 2013 , 148, 64-8	28
1893	Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer. 2013 , 54, 679-83	3
1892	Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. 2013 , 31, 543-50	454
1891	The potential of helical tomotherapy in the treatment of head and neck cancer. 2013 , 18, 697-706	17
1890	Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy. 2013 , 12, 383-9	11
1889	Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients. 2013 , 24, 623-9	10
1888	Controversies and challenges regarding the impact of radiation therapy on survival. 2013 , 24, 38-46	25
1887	Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response. 2013 , 9, 392-6	1
1886	NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. 2013 , 105, 11-24	49
1885	HPV Prevalence and Prognostic Value in a Prospective Cohort of 255 Patients with Locally Advanced HNSCC: A Single-Centre Experience. 2013 , 2013, 437815	20
1884	Genome stability pathways in head and neck cancers. 2013 , 2013, 464720	16
1883	Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen. 2013 , 35, 1683-8	16
1882	Rationality and the generalization of randomized controlled trial evidence. 2013 , 19, 644-7	10
1881	Can radiological changes in lymph node volume during treatment predict success of radiation therapy in patients with locally advanced head and neck squamous cell carcinoma?. 2013 , 57, 603-9	2
1880	Intensity-modulated radiotherapy using simultaneous-integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: outcomes from a single-institution series. 2013 , 57, 356-63	7

1879	Addition of taxane to induction therapy in head and neck malignancies: a systematic review and meta-analysis of randomized controlled trials. 2013 , 59, 435-40	5
1878	Intensity-modulated radiotherapy followed by a brachytherapy boost for oropharyngeal cancer. 2013 , 35, 1689-97	16
1877	Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck cancer: our experience in one hundred and twenty-five patients. 2013 , 38, 69-74	19
1876	Funding UK cancer care: time for a level playing field?. 2013 , 67, 195-7	1
1875	Does fluorodeoxyglucose PET add to the management of the neck following curative radiotherapy in head and neck cancer compared with computed tomography?. 2013 , 13, 279-84	2
1874	Monoclonal Antibodies Targeting EGFR/HER2 and Clinical Outcomes in Cancer Treatment. 2013 ,	
1873	Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma. 2013 ,	
1872	Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma. 2013 , 85, 290-6	41
1871	Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. 2013 , 2013,	30
1870	Cancers du larynx. 2013 , 8, 1-15	5
1869	Cancer de l'hypopharynx. 2013 , 8, 1-17	2
1868	Are anti-vitamin K drugs contraindicated with cetuximab during head-and-neck cancer concomitant radiotherapy?. 2013 , 68, 237-9	0
1867	Welche prognostische Bedeutung hat die Cisplatin-Dosis?. 2013 , 16, 20-21	
1866	Radiothérapie des cancers oto-rhino-laryngologiques. 2013 , 8, 1-13	2
1865	The impact of treatment modality and radiation technique on outcomes and toxicity of patients with locally advanced oropharyngeal cancer. 2013 , 123, 386-93	50
1864	Can (18)F-FDG PET/CT reliably assess response to primary treatment of head and neck cancer?. 2013 , 38, 263-5	20
1863	The Role of Palliative Care in Head and Neck Cancer. 2013 , 126-144	
1862	[Progress in chemotherapy of head and neck cancers]. 2013 , 116, 767-78	

1861	. 2013,	1
1860	Cetuximab: its unique place in head and neck cancer treatment. 2013, 7, 77-90	52
1859	[Minutes of the second ESTRO forum held in Geneva (Switzerland), 19-23 April 2013]. 2013, 100, 1053-8	
1858	Nedaplatin: a cisplatin derivative in cancer chemotherapy. 2013, 5, 67-76	69
1857	Dysphagia in Head and Neck Cancer Patients: Pretreatment Evaluation, Predictive Factors, and Assessment during Radio-Chemotherapy, Recommendations. 2013, 6, 117-26	73
1856	Efficacy of intensity-modulated radiotherapy combined with chemotherapy or surgery in locally advanced squamous cell carcinoma of the head-and-neck. 2013, 7, 223-9	4
1855	Panoramic Radiobiological Modelling of the Contribution of Concomitant Chemotherapy to Biological Effective Dose in Squamous Cell Carcinoma. 2014, 3,	
1854	Outcomes of laryngectomy in elderly patients with laryngeal carcinoma. 2014, 13, 1955-63	2
1853	Voluntary exercise prevents cisplatin-induced muscle wasting during chemotherapy in mice. 2014, 9, e109030	27
1852	Development and validation of a prediction model for tube feeding dependence after curative (chemo-) radiation in head and neck cancer. 2014, 9, e94879	25
1851	Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. 2014, 9, e112880	31
1850	The Rapalogue, CCI-779, improves salivary gland function following radiation. 2014, 9, e113183	20
1849	IMRT-SIB with Concurrent and Neo-Adjuvant Platinum-Based Chemotherapy for Locally Advanced Head and Neck Squamous Cell Cancer: Analysis of Clinical Outcomes in a Retrospective Series of a Single Institution. 2014, 100, 652-659	1
1848	[Minutes of the 33rd Congress of ESTRO held in Vienna (Austria), 4-8 April 2014]. 2014, 101, 896-900	
1847	Tanshinone IIA induces apoptosis in human oral cancer KB cells through a mitochondria-dependent pathway. 2014, 2014, 540516	17
1846	Intensity-Modulated Radiotherapy with a Simultaneous Integrated Boost Combined with Chemotherapy in Stages III-IV Hypopharynx-Larynx Cancer: Treatment Compliance and Clinical Outcomes. 2014, 2014, 1-7	1
1845	Salvage Stereotactic Re-irradiation with CyberKnife for Locally Recurrent Head and Neck Cancer: A Single Center Experience. 2014, 100, 278-283	4
1844	Concurrent chemoradiotherapy with weekly versus three-weekly cisplatin in locally advanced head and neck squamous cell carcinoma. 2014,	1

1843	Response to concurrent cetuximab: radiotherapy following failure of platinum-based induction chemotherapy in squamous cell carcinoma of the larynx. 2014 , 13, 93-97	
1842	Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options. 2014 , 15, 595-610	13
1841	Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. 2014 , 25, 2134-2146	72
1840	[Not Available]. 2014 , 190, 970-2	
1839	Induktionschemotherapie ermöglicht Larynxerhalt bei Hypopharynxkarzinomen. 2014 , 17, 24-25	
1838	The use of MuGard®Caphosol® and Episil® in patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck. 2014 , 13, 218-225	7
1837	Clinical update on cancer: molecular oncology of head and neck cancer. 2014 , 5, e1018	123
1836	Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer. 2014 , 23, 1637-54	4
1835	Prognostic model for survival of local recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy. 2014 , 110, 297-303	58
1834	Induction chemotherapy followed by concurrent chemoradiotherapy for advanced stage oropharyngeal squamous cell carcinoma with HPV and P16 testing. 2014 , 123, 365-73	9
1833	Stereotactic body radiotherapy as primary therapy for head and neck cancer in the elderly or patients with poor performance. 2014 , 4, 274	14
1832	A new combined therapy for functional organ preservation and survival in lateral oropharyngeal wall cancer. 2014 , 134, 872-80	
1831	In squamous cell head and neck cancer: which platinum, how much and how often?. 2014 , 14, 1033-9	8
1830	Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes. 2014 , 59, 50-5	7
1829	Indian Council of Medical Research consensus document for the management of buccal mucosa cancer. 2014 , 35, 136-9	9
1828	Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer. 2014 , 4, 214	28
1827	Toxicity and disease-related outcomes after radiotherapy for head and neck cancer in human immunodeficiency virus-positive patients. 2014 , 4, 316	4
1826	Radiation oncology in vitro: trends to improve radiotherapy through molecular targets. 2014 , 2014, 461687	12

1825	Dose-volume response in acute dysphagia toxicity: Validating QUANTEC recommendations into clinical practice for head and neck radiotherapy. 2014 , 53, 1305-11	11
1824	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma. 2014 , CD010271	23
1823	Minimally invasive surgery versus radiotherapy/chemoradiotherapy for early-stage oropharyngeal carcinoma. 2014 ,	1
1822	State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013. 2014 , 86, 212-29	53
1821	Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013. 2014 , 10, 1635-48	23
1820	[Head and neck cancers in HIV patients]. 2014 , 101, 1030-3	0
1819	Induction chemotherapy in head and neck cancer: are we too ambitious?. 2014 , 10, 337-40	3
1818	Treatment complications and survival in advanced laryngeal cancer: a population-based analysis. 2014 , 124, 2707-13	29
1817	Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. 2014 , 36, 617-23	17
1816	Quel traitement (laryngectomie totale ou pr̄servation laryngè) envisagerait un sp̄cialiste otorhinolaryngologiste s'il fait atteint d'un cancer du larynx de stade avanc? 2014 , 131, 328-332	
1815	Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. 2014 , 32, 3858-66	278
1814	Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. 2014 , 203, 897-903	39
1813	ENT Board Prep. 2014 ,	
1812	Outcomes after primary chemoradiotherapy for N3 (>6 cm) head and neck squamous cell carcinoma after an FDG-PET--guided neck management policy. 2014 , 36, 1200-6	17
1811	Long-term functional and quality of life evaluation after treatment for advanced pharyngolaryngeal carcinoma. 2014 , 36, 1604-10	12
1810	Dose-volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment. 2014 , 87, 20140543	46
1809	Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments. 2014 , 41, 798-806	23
1808	Factors affecting swallow outcome following treatment for advanced oral and oropharyngeal malignancies. 2014 , 36, 47-54	17

1807	Efficacy of induction selection chemotherapy vs primary surgery for patients with advanced oral cavity carcinoma. 2014 , 140, 134-42	25
1806	Molecular Determinants of Head and Neck Cancer. 2014 ,	2
1805	[Oral cavity cancer, an update on behalf of Intergroupe ORL]. 2014 , 101, 424-8	1
1804	[Squamous cell carcinoma of the hypopharynx and larynx: evidence-based care]. 2014 , 101, 438-44	2
1803	[Oropharyngeal cancer]. 2014 , 101, 429-37	2
1802	[Main results of studies on primary therapy of head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014]. 2014 , 62, 781-6	
1801	Squamous carcinoma of the ovary. 2014 , 16, 413	6
1800	Human papillomavirus-related oropharyngeal squamous cell carcinoma: a new context for dysphagia rehabilitation. 2014 , 2, 231-240	2
1799	Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. 2014 , 15, 469	23
1798	Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group. 2014 , 9, 264	63
1797	A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study. 2014 , 25, 970-5	6
1796	Radiotherapy alone or combined with chemotherapy for the treatment of squamous cell carcinoma of the base of the tongue. 2014 , 37, 535-8	3
1795	Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas. 2014 , 25, 1220-6	4
1794	Is there still a role for induction chemotherapy in locally advanced head and neck cancer?. 2014 , 26, 247-51	11
1793	The Cancer Genome Atlas findings in head and neck cancer: a renewed hope. 2014 , 26, 245-6	4
1792	Taxanes as radiosensitizers. 2014 , 25, 502-11	15
1791	Taxanes in cancer of the head and neck. 2014 , 25, 561-70	13
1790	Usefulness of ⁶⁴ Cu-ATSM in head and neck cancer: a preliminary prospective study. 2014 , 39, e59-63	30

1789	Concurrent radiotherapy with Carboplatin and cetuximab for the treatment of medically compromised patients with locoregionally advanced head and neck squamous cell carcinoma. 2014 , 4, 165		3
1788	Medical management of head and neck cancers. 2014 , 465-475		
1787	Long-term hearing loss after chemoradiation in patients with head and neck cancer. 2014 , 124, 2720-5		12
1786	Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. 2014 , 7, 311-38		52
1785	BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts. 2014 , 9, 207		39
1784	The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it a potentially curative treatment? A practical approach. 2014 , 40, 178-89		32
1783	Total laryngectomy or laryngeal preservation for advanced laryngeal cancer. Impact of the functional risk upon the patient's preferences. 2014 , 131, 93-7		20
1782	Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. <i>Radiotherapy and Oncology</i> , 2014 , 110, 91-7	5-3	71
1781	Impact of concomitant chemotherapy on outcomes of radiation therapy for head-and-neck cancer: a population-based study. 2014 , 88, 115-21		10
1780	Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. 2014 , 134, 497-507		127
1779	Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?. 2014 , 9, 279-284		
1778	Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis. 2014 , 190, 256-62		10
1777	Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial. 2014 , 190, 250-5		11
1776	Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma. 2014 , 16, 555-60		2
1775	Multimodal treatment strategies for elderly patients with head and neck cancer. 2014 , 40, 465-75		29
1774	Improving the efficacy of chemoradiation with targeted agents. 2014 , 4, 280-91		65
1773	Current concepts in clinical radiation oncology. 2014 , 53, 1-29		109
1772	Multidisciplinary approach for the treatment of head and neck cancer. 2014 , 19, 209-10		1

1771	Aktuelle Aspekte der radioonkologischen Behandlung lokal fortgeschrittener Kopf-Hals-Tumoren. 2014 , 20, 139-143		2
1770	Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer. 2014 , 110, 1793-800		34
1769	A systematic review of current and emerging approaches in the field of larynx preservation. <i>Radiotherapy and Oncology</i> , 2014 , 110, 16-24	5:3	38
1768	Local ablative treatments of oligometastases from head and neck carcinomas. 2014 , 91, 47-63		48
1767	What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?. 2014 , 120, 1462-70		47
1766	Incidence of osteoradionecrosis in patients who have undergone dental extraction prior to radiotherapy: A systematic review and meta-analysis. 2014 , 26, 269-275		9
1765	Preventing pharyngo-cutaneous fistula in total laryngectomy: a systematic review and meta-analysis. 2014 , 124, 1150-63		104
1764	Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab. 2014 , 190, 832-8		10
1763	Should patients with HPV-positive or negative tumors be treated differently?. 2014 , 16, 384		4
1762	A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. 2014 , 25, 216-25		220
1761	Health-related quality of life of patients treated with primary chemoradiotherapy for oral cavity squamous cell carcinoma: a comparison with surgery. 2014 , 52, 111-7		17
1760	Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-fluorouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. 2014 , 50, 52-8		14
1759	Volumetric PET/CT parameters predict local response of head and neck squamous cell carcinoma to chemoradiotherapy. 2014 , 3, 1368-76		37
1758	Trends in epidemiology and treatment and outcome for head and neck cancer: a population-based long-term analysis from 1996 to 2011 of the Thuringian cancer registry. 2014 , 50, 1157-64		22
1757	Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. 2014 , 25, 462-6		58
1756	Study of induction chemotherapy efficacy in oral squamous cell carcinoma using pseudotargeted metabolomics. 2014 , 13, 1994-2004		63
1755	Phase II study of concurrent chemoradiotherapy with S-1 in patients with stage II (T2N0M0) squamous cell carcinoma of the Pharynx or Larynx. 2014 , 44, 1158-63		7
1754	Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio. 2014 , 7, 479-83		4

1753	[Metabolic tailoring in radiotherapy for head and neck cancer]. 2014 , 18, 565-71		1
1752	[Intensity-modulated radiation therapy and stereotactic body radiation therapy for head and neck tumors: evidence-based medicine]. 2014 , 18, 468-72		0
1751	Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. 2014 , 32, 2735-43		352
1750	Translational genomics and head and neck cancer: toward precision medicine. 2014 , 86, 412-21		17
1749	Treatment, survival, and costs of laryngeal cancer care in the elderly. 2014 , 124, 1827-35		31
1748	A systematic review of transoral robotic surgery and radiotherapy for early oropharynx cancer: a systematic review. 2014 , 124, 2096-102		168
1747	Milestones in the use of combined-modality radiation therapy and chemotherapy. 2014 , 32, 1173-9		30
1746	[Which choice would the radiation oncologist consider if facing an advanced stage laryngeal cancer?]. 2014 , 18, 649-54		1
1745	Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. 2014 , 32, 2940-50		547
1744	High-dose reirradiation with intensity-modulated radiotherapy for recurrent head-and-neck cancer: disease control, survival and toxicity. <i>Radiotherapy and Oncology</i> , 2014 , 111, 388-92	5-3	34
1743	A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014 , 111, 382-7	5-3	59
1742	Economic analyses in squamous cell carcinoma of the head and neck: a review of the literature from a clinical perspective. 2014 , 89, 989-996		9
1741	Human Papillomavirus (HPV)-associated Oral Cancers and Treatment Strategies. 2014 , 93, 29S-36S		45
1740	Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. 2014 , 50, 765-9		15
1739	Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. 2014 , 50, 884-7		14
1738	Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. 2014 , 32, 2486-95		133
1737	Multiple cervical lymph node involvement and extra-capsular extension predict for contralateral nodal recurrence after ipsilateral radiotherapy for squamous cell carcinoma of the tonsil. 2014 , 50, 901-6		30
1736	Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. 2014 , 50, 863-8		19

1735	Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. 2014 , 50, 2263-70	6
1734	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. 2014 , 50, 2636-48	207
1733	Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers. 2014 , 50, 1089-97	16
1732	Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. 2014 , 50, 1041-8	88
1731	Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). 2014 , 50, 947-55	40
1730	Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. 2014 , 190, 823-31	37
1729	Long-term trends in gender, T-stage, subsite and treatment for laryngeal cancer at a single center. 2014 , 271, 3233-9	14
1728	New biological markers in the decision of treatment of head and neck cancer patients. 2014 , 16, 849-58	2
1727	Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: a survey of centres participating in a national randomised controlled trial. 2014 , 50, 141-6	6
1726	Souhait et impact de l'information avant laryngectomie totale ou prŕservation laryngŕe dans les cancers du larynx de stade avancŕ. 2014 , 131, 76-82	
1725	Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014 , 110, 435-40	5.3 37
1724	Head and Neck Cancer in the Older Adult: Approaches in Evaluation and Management. 2014 , 3, 209-219	1
1723	Testing the treatment effect on competing causes of death in oncology clinical trials. 2014 , 14, 72	5
1722	Otorhinolaryngologists' personal treatment preferences (total laryngectomy or laryngeal preservation) when faced with advanced stage laryngeal cancer. 2014 , 131, 339-343	4
1721	Cŕncer de la orofaringe. 2014 , 43, 1-18	
1720	Effectiveness of chemoradiation for head and neck cancer in an older patient population. 2014 , 89, 30-7	34
1719	Patterns-of-failure after helical tomotherapy-based chemoradiotherapy for head and neck cancer: implications for CTV margin, elective nodal dose and bilateral parotid sparing. 2014 , 50, 520-6	22
1718	c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation. 2014 , 88, 701-7	35

1717	Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. 2014 , 143, 337-49		15
1716	Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma - a systematic review. <i>Radiotherapy and Oncology</i> , 2014 , 110, 81-90	53	62
1715	A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. 2014 , 50, 570-81		57
1714	Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost (SIB-VMAT): An analysis for complex head-neck, high-risk prostate and rectal cancer cases. 2014 , 39, 108-16		22
1713	NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. 2014 , 26, 344-7		42
1712	Cancro dell'orofaringe. 2014 , 13, 1-17		
1711	Integrating pretreatment diffusion weighted MRI into a multivariable prognostic model for head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2014 , 110, 429-34	53	70
1710	Sensorineural Hearing Loss after Treatment for Head and Neck Cancer: A Review of the Literature. 2014 , 45, 316-322		3
1709	Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer. 2014 , 134, 24-8		10
1708	Lymph node density--prognostic value in head and neck cancer. 2014 , 36, 266-72		21
1707	[Significant factors for surgical site infection: analysis of 203 head and neck surgeries]. 2014 , 117, 103-10		3
1706	Effect of postradiotherapy neck dissection on nonregional disease sites. 2014 , 140, 12-21		2
1705	Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. 2014 , 12, 1454-87		162
1704	Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers. 2014 ,		4
1703	Cancer of the head and neck. 2014 , 158-183		
1702	Helper T-cell based immunotherapy combined with adjuvants in head and neck squamous cell carcinoma. 2014 , 32, 185-190		
1701	Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. 2014 , 36, 1120-5		35
1700	Radiation-induced signaling pathways that promote cancer cell survival (review). 2014 , 45, 1813-9		112

- 1699 Aspiration pneumonia related deaths in head and neck cancer patients: a retrospective analysis of risk factors from a tertiary care centre in North India. **2015**, 129, 710-4 14
- 1698 Friday 30 October 2015. **2015**, 59, 38-72
- 1697 Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies. **2015**, 4, 699-712 13
- 1696 Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis. **2015**, 5, 10798 30
- 1695 ??????????? ?????? **2015**, 118, 1369-1-1374
- 1694 Determinants of Medicare Costs for Elderly Patients With Oral Cavity and Pharyngeal Cancers. **2015**, 141, 628-35 23
- 1693 Doch keine therapeutische Revolution beim Kopf-Hals-Karzinom. **2015**, 18, 25-26
- 1692 CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. **2015**, 15, 725 9
- 1691 G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy. **2015**, 15, 875 54
- 1690 Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer. **2015**, 10, 158 26
- 1689 Definitive and adjuvant radiotherapy for sinonasal squamous cell carcinomas: a single institutional experience. **2015**, 10, 190 15
- 1688 Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety. **2015**, 4, 208 10
- 1687 Impact of transcutaneous neuromuscular electrical stimulation on dysphagia in patients with head and neck cancer treated with definitive chemoradiation. **2015**, 37, 1051-6 18
- 1686 Speech-language pathology care and short- and long-term outcomes of laryngeal cancer treatment in the elderly. **2015**, 125, 2756-63 18
- 1685 The progress of multimodality treatment for head and neck cancer with special reference to chemoradiotherapy. **2015**, 25, 155-159
- 1684 A case of multiple oral cancer whose life was prolonged by radiotherapy with cetuximab for trachea invasion due to metastasis of the upper mediastinal lymph node: a case report. **2015**, 27, 135-139 2
- 1683 Cisplatin, cetuximab, and radiation in locally advanced head and neck squamous cell cancer: a retrospective review. **2015**, 9, 1-7 14
- 1682 Management of oropharyngeal mycosis in head and neck cancer occurring during (chemo) radiotherapy: an Italian radio-oncologist survey. **2015**, 101, 312-7 2

1681	Oropharyngeal squamous cell carcinoma in the veteran population: Association with traditional carcinogen exposure and poor clinical outcomes. 2015 , 37, 1246-53	22
1680	Impact of the addition of chemotherapy to radiotherapy for oropharyngeal cancer in 2003-2004: Population-based study from the Province of Ontario, Canada. 2015 , 37, 1461-9	5
1679	Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design. 2015 , 37, 1583-9	16
1678	Definitive radiotherapy for cervical esophageal cancer. 2015 , 37, 151-5	30
1677	Immunohistochemical expression of p16 and p53 in oral and oropharyngeal squamous cell carcinoma. 2015 , 35, 81-86	1
1676	Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma. 2015 , 38, 588-94	6
1675	Management of cancer of the head and neck. 132-169	
1674	The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies. 2015 , 19, 313-22	10
1673	Definitive Radiotherapy Following Induction Chemotherapy for Hypopharyngeal Cancer: Selecting Candidates for Organ-Preserving Treatment Based on the Response to Induction Chemotherapy. 2016 , 62, 1-8	5
1672	Five-year follow-up of concomitant accelerated hypofractionated radiation in advanced squamous cell carcinoma of the buccal mucosa: a retrospective cohort study. 2015 , 2015, 963574	4
1671	Chemoradiation for Oropharyngeal Carcinoma for Organ Preservation. 2015 , 11, 33-37	
1670	Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy. 2015 , 5, 256	14
1669	Tumor Volumes and Prognosis in Laryngeal Cancer. 2015 , 7, 2236-61	24
1668	Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma. 2015 , 9, 6203-10	19
1667	Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC). 2015 , 10, e0116965	27
1666	Follow-Up in Head and Neck Cancer: A Management Dilemma. 2015 , 2015, 1-4	17
1665	Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm ² to Predict Response to Induction Chemotherapy. 2015 , 14, 337-45	12
1664	Concurrent chemoradiotherapy with weekly versus three-weekly cisplatin in locally advanced head and neck squamous cell carcinoma. 2015 ,	

1663	Neoadjuvant Chemotherapy of Three Cycles or More Improve Survival of Patients with N2-3 Nasopharyngeal Carcinoma. 2015 , 04,	
1662	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. 2015 , 95, 191-213	28
1661	Head and Neck Cancer. 2015 , 61-89	
1660	Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. 2015 , 37, 281-92	45
1659	Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases. 2015 , 20, 455-62	16
1658	Effectiveness of chemotherapy and radiotherapy for laryngeal preservation in advanced laryngeal cancer: a meta-analysis and systematic review. 2015 , 120, 1153-69	15
1657	Oncological and functional outcomes of transoral surgery for the treatment of oropharyngeal cancer. 2015 , 184, 825-30	5
1656	Reply to s. Chakraborty et al. 2015 , 33, 968	
1655	Reply to D. Adkins et al. 2015 , 33, 1224-5	
1654	A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer. 2015 , 24, 711-29	28
1653	Sequential and Concurrent Chemoradiation: State of the Art. 2015 , 29, 1061-74	1
1652	Analysis of loco-regional failures in head and neck cancer after radical radiation therapy. 2015 , 51, 1051-1055	35
1651	Target volume delineation after induction chemotherapy in locally advanced head and neck cancer. 2015 , 51, e81	0
1650	Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer. 2015 , 51, 1113-9	14
1649	Short- and long-term outcomes of laryngeal cancer care in the elderly. 2015 , 125, 924-33	28
1648	Nasopharyngeal carcinoma patients with retropharyngeal lymph node metastases: a minimum axial diameter of 6 mm is a more accurate prognostic predictor than 5 mm. 2015 , 204, 20-3	10
1647	Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. 2015 , 51, 291-8	105
1646	The current role of systemic chemotherapy in the primary treatment of head and neck cancer. 2015 , 41, 217-21	18

1645	[18F]-FDG PET-CT prediction of response to induction chemotherapy in head and neck squamous cell carcinoma: preliminary findings. 2015 , 132, 3-7	14
1644	Chemoradiation in elderly patients with head and neck cancers: a single institution experience. 2015 , 36, 117-21	11
1643	Intérêt prédictif de la TEP-TDM au [18F]-FDG pour la réponse à la chimiothérapie d'induction dans le traitement des carcinomes épidermoïdes des voies aéro-digestives supérieures : résultats préliminaires. 2015 , 132, 3-8	
1642	Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. 2015 , 121, 1599-607	123
1641	Drug radiotherapy combinations: review of previous failures and reasons for future optimism. 2015 , 41, 105-13	56
1640	Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. 2015 , 16, 221-32	117
1639	Chemoradiation therapy for squamous cell carcinoma of the external auditory canal: A meta-analysis. 2015 , 37, 1073-80	53
1638	EGFR-based bioradiotherapy in SCCHN. 2015 , 16, 129-30	4
1637	Bioanalytical methods for metabolomic profiling: Detection of head and neck cancer, including oral cancer. 2015 , 26, 407-415	13
1636	Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. 2015 , 37, 1665-71	33
1635	Impact of indication-shift of primary and adjuvant chemo radiation in advanced laryngeal and hypopharyngeal squamous cell carcinoma. 2015 , 272, 2017-25	6
1634	Systemic Chemotherapy. 2015 , 307-318	
1633	Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. 2015 , 91, 916-24	27
1632	Factors associated with gastrostomy tube dependence after concurrent chemoradiotherapy for hypopharyngeal cancer. 2015 , 23, 457-62	5
1631	18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes. 2015 , 10, 125-45	18
1630	Health-related quality of life of head and neck cancer patients with successful oncological treatment. 2015 , 272, 2415-23	9
1629	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. 2015 , 33, 836-45	279
1628	Different strokes for different folks: new paradigms for staging oropharynx cancer. 2015 , 33, 817-8	13

1627	Cytoplasmic DRAK1 overexpressed in head and neck cancers inhibits TGF- β tumor suppressor activity by binding to Smad3 to interrupt its complex formation with Smad4. 2015 , 34, 5037-45	21
1626	Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. 2015 , 51, 704-8	22
1625	Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. 2015 , 26, 198-205	11
1624	Oropharyngeal Cancer. 2015 , 171-192	
1623	Secular trends in the survival of patients with laryngeal carcinoma, 1995-2007. 2015 , 22, e85-99	16
1622	Macrophage polarisation changes within the time between diagnostic biopsy and tumour resection in oral squamous cell carcinomas--an immunohistochemical study. 2015 , 113, 510-9	47
1621	Endoscopy-guided brachytherapy for sinonasal and nasopharyngeal recurrences. 2015 , 14, 419-25	17
1620	An audit of fiducial marker placement within the prostate for radiotherapy treatment verification; and its potential impact on margin generation. 2015 , 27, S2	
1619	Outcomes of radically treated locally advanced head and neck (H&N) cancer patients in Southampton. 2015 , 27, S2-S3	
1618	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. 2015 , 96, 167-82	39
1617	IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2015 , 116, 15-20	5.3 31
1616	Prise en charge globale des carcinomes pidermoïdes de la tte et du cou (CETEC) en 2015. 2015 , 17, 215-219	
1615	La chimiothapie d'induction dans les carcinomes pidermoïdes des voies aodigestives suprieures. 2015 , 17, 232-238	
1614	Primary Surgery vs Chemoradiation Treatment of Advanced-Stage Hypopharyngeal Squamous Cell Carcinoma. 2015 , 141, 636-40	33
1613	Late toxicity after radical treatment for locally advanced head and neck cancer. 2015 , 51, 795-9	25
1612	Impact of weight loss in patients with head and neck carcinoma undergoing radiotherapy: is it an underestimated phenomenon? A radiation oncologist's perspective. 2015 , 69, 757-60	7
1611	Does DeCIDE give a decisive answer against induction chemotherapy in head and neck cancers?. 2015 , 33, 967	4
1610	[Radioresistance parameters in head and neck cancers and methods to radiosensitize]. 2015 , 19, 337-46; quiz 360-1, 363	5

1609	Tropical Hemato-Oncology. 2015,	2
1608	HPV and Head and Neck Cancers. 2015,	
1607	RETRACTED: Laryngeal Function After Radiation Therapy. 2015, 48, 585-99	4
1606	Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. 2015, 54, 1001-7	67
1605	Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis. 2015, 121, 2083-9	42
1604	Oral Cavity Cancer: Risk Factors, Pathology, and Management. 2015, 89, 187-95	28
1603	A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. 2015, 121, 294-301	90
1602	Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. 2015, 54, 88-98	16
1601	Summary of major radiation fractionation and chemotherapy trials for organ preservation therapy in locally advanced head and neck squamous cell carcinoma. 2015, 5, 343-349	6
1600	Second primary lung cancers following a diagnosis of primary head and neck cancer. 2015, 88, 94-9	19
1599	Epidemiology of head and neck cancer. 2015, 24, 379-96	234
1598	[Accelerated versus conventional fractionation in combined chemoradiotherapy of head and neck tumors]. 2015, 191, 384-6	
1597	Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study. 2015, 191, 635-41	28
1596	Early percutaneous endoscopic gastrostomy and nutritional supplementation for patients with head and neck cancer: an Italian survey of head and neck radiation oncologists. 2015, 23, 3539-43	2
1595	Reirradiation and stereotactic body radiotherapy for recurrent or second primary squamous cell carcinoma of the head and neck. 2015, 4, 117-128	
1594	Emerging drugs for head and neck cancer. 2015, 20, 313-29	23
1593	Nuclear expression of p65 (RelA) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck. 2015, 15, 102	2
1592	Prospective longitudinal assessment of parotid gland function using dynamic quantitative pertechnetate scintigraphy and estimation of dose-response relationship of parotid-sparing radiotherapy in head-neck cancers. 2015, 10, 67	12

1591	Cancer of the oropharynx. 2015 , 24, 509-20	10
1590	Definitive radiotherapy for head and neck squamous cell carcinoma: update and perspectives on the basis of EBM. 2015 , 45, 235-43	6
1589	Radiation treatment of head and neck cancer. 2015 , 24, 423-36	7
1588	Systemic therapy for squamous cell carcinoma of the head and neck. 2015 , 24, 437-54	11
1587	Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck. 2015 , 91, 934-41	16
1586	Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study. 2015 , 20, 1086-92	6
1585	Anti-EGFR-Therapie in Kombination mit Radiotherapie ff. Patienten mit Kopf-Hals-Karzinomen □ doch keine therapeutische Revolution. 2015 , 191, 619-622	
1584	Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients. 2015 , 10, 93	23
1583	Intensity-Modulated Radiation Therapy. 2015 ,	3
1582	Oral Cancer. 2015 ,	2
1581	Feasibility and response of concurrent weekly docetaxel with radical radiotherapy in locally advanced head and neck squamous cell carcinoma. 2015 , 9, XC01-XC04	2
1580	Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. 2015 , 350, h1088	36
1579	Predictive factors of survival and treatment tolerance in older patients treated with chemotherapy and radiotherapy for locally advanced head and neck cancer. 2015 , 51, 521-8	25
1578	[Individual patient data meta-analyses of randomized trials for the treatment of non-metastatic head and neck squamous cell carcinomas: Principles, results and perspectives]. 2015 , 19, 198-204; quiz 228-9, 233	0
1577	Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients. 2015 , 56, 849-55	9
1576	When is definitive radiotherapy the preferred treatment for head and neck squamous cell carcinoma?. 2015 , 272, 2583-6	
1575	Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706). 2015 , 106, 726-33	14
1574	Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study. 2015 , 33, 4202-9	65

1573	Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives. 2015 , 51, 1069-75		15
1572	Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. 2015 , 51, 2596-603		44
1571	How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck?. 2015 , 135, 1079-85		3
1570	Pharmacotherapy of head and neck cancer. 2015 , 16, 2409-22		6
1569	A phase 2 randomized study to compare short course palliative radiotherapy with short course concurrent palliative chemotherapy plus radiotherapy in advanced and unresectable head and neck cancer. <i>Radiotherapy and Oncology</i> , 2015 , 117, 145-51	5.3	12
1568	Oral Lapacho-Based Medication: An Easy, Safe, and Feasible Support to Prevent and/or Reduce Oral Mucositis During Radiotherapy for Head and Neck Cancer. 2015 , 67, 1247-53		8
1567	[Radiation therapy for elderly patients]. 2015 , 19, 391-6		0
1566	Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions. 2015 , 93, 507-15		26
1565	Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy. 2015 , 141, 810-5		12
1564	Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. 2015 , 191, 656-64		20
1563	Human Papillomavirus-Negative Pharyngeal Cancer. 2015 , 33, 3251-61		40
1562	[The most important study results concerning nonsurgical primary treatment of locally advanced head and neck cancer: Highlights of the ASCO Meeting 2015]. 2015 , 63, 606-11		1
1561	The Effects of Pulsed Radiation Therapy on Tumor Oxygenation in 2 Murine Models of Head and Neck Squamous Cell Carcinoma. 2015 , 92, 820-8		12
1560	Helical tomotherapy in head and neck cancer: a European single-center experience. 2015 , 20, 279-90		2
1559	Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. 2015 , 20, 431-7		4
1558	Predictive value of diffusion-weighted imaging without and with including contrast-enhanced magnetic resonance imaging in image analysis of head and neck squamous cell carcinoma. 2015 , 84, 108-116		35
1557	Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. 2015 , 37, 763-70		82
1556	Treatment deintensification and symptom burden in patients with human papillomavirus-associated head and neck cancer. 2015 , 121, 1147-8		

1555	Prospective clinical study on long-term swallowing function and voice quality in advanced head and neck cancer patients treated with concurrent chemoradiotherapy and preventive swallowing exercises. 2015 , 272, 3521-31	50
1554	Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large series. 2015 , 37, 1403-9	31
1553	Cervical esophageal cancer: a population-based study. 2015 , 37, 808-14	41
1552	Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. 2015 , 136, 1494-503	155
1551	Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis. 2015 , 37, 670-6	10
1550	When is chemotherapy in head and neck squamous cell carcinoma not indicated?. 2015 , 272, 781-787	5
1549	Functional outcomes after TORS for oropharyngeal cancer: a systematic review. 2015 , 272, 463-71	142
1548	Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer. 2015 , 37, 655-61	26
1547	Radiation Therapy for Head and Neck Cancers. 2015 ,	4
1546	Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. 2015 , 37, 386-92	26
1545	Lymph node ratio influence on risk of head and neck cancer locoregional recurrence after initial surgical resection: implications for adjuvant therapy. 2015 , 37, 777-82	47
1544	Radiotherapy for head and neck cancer in nonagenarian patients: a possible cornerstone?. 2015 , 272, 719-25	6
1543	Disease control and clinicopathological prognostic factors of total pharyngolaryngectomy for hypopharyngeal cancer: a single-center study. 2015 , 20, 290-7	9
1542	Improved overall survival and mortality in head and neck cancer with adjuvant concurrent chemoradiotherapy in national databases. 2016 , 38, 208-15	24
1541	Impact of Residual Adenopathy Following Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck: A Retrospective Analysis of 51 Consecutive Cases. 2016 , 01,	
1540	Avaliaço do estado nutricional e da caquexia em pacientes diagnosticados com carcinoma epidermoide de cabea e pescoo tratados com inteno curativa com quimiorradiao. 2016 , 95, 51	
1539	A Randomized Prospective Study of Concurrent Chemo-Radiotherapy vs Accelerated Hyperfractionation in Advanced Cancer of Head and Neck. 2016 , 10, XC15-XC18	1
1538	MicroRNA-17-5p regulated apoptosis-related protein expression and radiosensitivity in oral squamous cell carcinoma caused by betel nut chewing. 2016 , 7, 51482-51493	12

1537	Cancer Stem Cell Signaling during Repopulation in Head and Neck Cancer. 2016 , 2016, 1894782	9
1536	Overexpression of E-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma. 2016 , 2016, 5378567	32
1535	ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy). 2016 , 8, 336-43	31
1534	Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. 2016 , 9, 1927-43	38
1533	Did the addition of concomitant chemotherapy to radiotherapy improve outcomes in hypopharyngeal cancer? A population-based study. 2016 , 23, 266-72	13
1532	Nucleotide Excision Repair and head and neck cancers. 2016 , 21, 55-69	4
1531	Effect of resveratrol on cancer progression through the REG11 expression pathway in head and neck cancer cells. 2016 , 49, 1553-1560	8
1530	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. 2016 , 31, 570-8	26
1529	Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. 2016 , 6, 165	4
1528	Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck. 2016 , 6, 199	46
1527	Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas. 2016 , 8,	33
1526	HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. 2016 , 8,	69
1525	How to minimize morbidity in radiotherapy of pharyngolaryngeal tumors?. 2016 , 24, 163-9	5
1524	Neoadjuvant Systemic Chemotherapy in the Management of Extensive Eyelid Sebaceous Gland Carcinoma: A study of 10 Cases. 2016 , 32, 35-9	22
1523	Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. 2016 , 38 Suppl 1, E1521-7	18
1522	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. 2016 , 122, 1702-7	13
1521	Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab. 2016 , 38 Suppl 1, E165-71	21
1520	Feasibility and potential value of lipofilling in post-treatment oropharyngeal dysfunction. 2016 , 126, 2672-2678	4

1519	Comorbidity and performance status as independent prognostic factors in patients with head and neck squamous cell carcinoma. 2016 , 38, 736-42	26
1518	Molecular targeting in combination with platinum-based chemoradiotherapy in head and neck cancer treatment. 2016 , 38 Suppl 1, E2173-81	5
1517	Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. 2016 , 38 Suppl 1, E844-52	16
1516	Clinical parameters predicting development of pulmonary malignancies in patients treated for head and neck squamous cell carcinoma. 2016 , 38 Suppl 1, E1277-80	4
1515	Association between multidisciplinary team care approach and survival rates in patients with oral cavity squamous cell carcinoma. 2016 , 38 Suppl 1, E1544-53	31
1514	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. 2016 , 38 Suppl 1, E1554-61	9
1513	Curative-Intent Aggressive Treatment Improves Survival in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma and High Comorbidity Index. 2016 , 95, e3268	55
1512	Clinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy. 2016 , 38, 846-51	11
1511	Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. 2016 , 38 Suppl 1, E1618-24	5
1510	Curative treatment of head and neck squamous cell carcinoma : Organ preservation strategies in clinical routine in German-speaking countries. 2016 , 64, 501-7	4
1509	Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, + Docetaxel for Larynx Preservation. 2016 , 108,	59
1508	ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. 2016 , 38, 1299-309	8
1507	Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck. 2016 , 39, 27-31	45
1506	A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN). 2016 , 39, 522-7	1
1505	Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. 2016 , 122, 1533-43	73
1504	Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base. 2016 , 122, 1853-60	28
1503	Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer. 2016 , 38 Suppl 1, E1575-81	14
1502	Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma. 2016 , 38 Suppl 1, E1770-6	11

1501	Preoperative Chemotherapy and Metronomic Scheduling of Chemotherapy in Locally Advanced Oral Cancers. 2016 , 91 Suppl 1, 35-40		14
1500	Current Role of Surgery in the Management of Oropharyngeal Cancer. 2016 , 12, 1176-1183		15
1499	Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer. 2016 , 45, 62		8
1498	The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer. 2016 , 1, 8		6
1497	Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab. 2016 , 78, 320-333		3
1496	Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group. <i>Radiotherapy and Oncology</i> , 2016 , 118, 257-66	5-3	25
1495	Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2016 , 120, 76-80	5-3	40
1494	Radiotherapy in head and neck cancer management: United Kingdom National Multidisciplinary Guidelines. 2016 , 130, S66-S67		13
1493	Laryngeal cancer: United Kingdom National Multidisciplinary guidelines. 2016 , 130, S75-S82		67
1492	Oral cavity and lip cancer: United Kingdom National Multidisciplinary Guidelines. 2016 , 130, S83-S89		67
1491	Investigation and management of the unknown primary with metastatic neck disease: United Kingdom National Multidisciplinary Guidelines. 2016 , 130, S170-S175		37
1490	Chemotherapy: United Kingdom National Multidisciplinary Guidelines. 2016 , 130, S71-S74		4
1489	Management of Widely Metastatic and Unresectable Cutaneous Squamous Cell Carcinoma. 2016 , 213-222		
1488	Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma. 2016 , 77, 1315-9		5
1487	Hypopharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. 2016 , 130, S104-S110		34
1486	Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model. 2016 , 102, 101-10		9
1485	Concurrent chemoradiotherapy in older adults with squamous cell head & neck cancer: Evidence and management. 2016 , 7, 145-53		9
1484	Altered fractionation radiotherapy in head and neck squamous cell carcinoma. 2016 , 28, 73-80		8

1483	Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?. 2016 , 57, 40-5		8
1482	High-Risk Cutaneous Squamous Cell Carcinoma. 2016 ,		4
1481	Is There a Role for Robotic Surgery in the Treatment of Head and Neck Cancer?. 2016 , 17, 29		20
1480	Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society. <i>Radiotherapy and Oncology</i> , 2016 , 119, 213-20	5-3	15
1479	Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence. 2016 , 28, 141-8		2
1478	Combined treatment with X-ray irradiation and 5-aminolevulinic acid elicits better transcriptomic response of cell cycle-related factors than X-ray irradiation alone. 2016 , 92, 774-789		13
1477	Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma. 2016 , 115, 825-30		11
1476	Salivary gland-sparing helical tomotherapy for head and neck cancer: Preserved salivary function on quantitative salivary gland scintigraphy after tomotherapy. 2016 , 133, 257-62		5
1475	Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. 2016 , 62, 28-33		97
1474	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. <i>Radiotherapy and Oncology</i> , 2016 , 120, 48-55	5-3	129
1473	Radiation-Induced Microvascular Injury as a Mechanism of Salivary Gland Hypofunction and Potential Target for Radioprotectors. 2016 , 186, 189-95		23
1472	Overview. 2016 , 561-569.e3		
1471	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. 2016 , 67, 174-182		46
1470	The Impact of Radiation Treatment Time on Survival in Patients With Head and Neck Cancer. 2016 , 96, 967-975		49
1469	Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation. 2016 , 27, 2262-2268		34
1468	Return of induction chemotherapy in head and neck squamous cell cancers: is this time different?. 2016 , 17, 1465-1467		1
1467	Osteoradionecrosis and intensity modulated radiation therapy: An overview. 2016 , 107, 39-43		35
1466	Locally advanced head and neck cancer in either the older or the vulnerable adult: Making the case for a team-based, "gero-centric" approach. 2016 , 7, 334-40		3

1465	[Study results of primary therapy for head and neck tumors : Highlights of the 2016 ASCO Annual Meeting]. 2016 , 64, 717-22	1
1464	A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients. 2016 , 57, 301-6	10
1463	Intensity-modulated radiotherapy in the treatment of locoregionally advanced head and neck cancer: implementation and outcomes in a New Zealand community hospital. 2016 , 63, 96-103	2
1462	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. 2016 , 375, 1856-1867	2647
1461	A closer look at strategies for preserving salivary gland function after radiotherapy in the head and neck region. 2016 , 60, 137-41	5
1460	Impact of Molecular Predictors on the Response Rates in Head and Neck Cancer Patients - an Observational Study. 2016 , 7, 380-385	1
1459	Therapeutic Ratio of Reirradiation with Cytotoxic Drugs and Other Response-Modifying Agents. 2016 , 47-73	
1458	Use of systemic therapy with definitive radiotherapy for elderly patients with head and neck cancer: A National Cancer Data Base analysis. 2016 , 122, 3472-3483	27
1457	Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications. 2016 , 35, 457-74	38
1456	[Radiotherapy for oral cavity cancers]. 2016 , 20 Suppl, S116-25	4
1455	Treatment of head and neck cancer in the elderly. 2016 , 17, 1903-21	11
1454	Risk factors associated with competing mortality among patients with head and neck cancer in Japan. 2016 , 136, 325-9	6
1453	IMRT for head and neck cancer: reducing xerostomia and dysphagia. 2016 , 57 Suppl 1, i69-i75	60
1452	PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. 2016 , 61, 31-40	19
1451	Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis. 2016 , 16, 689	25
1450	Safety of drug treatments for head and neck cancer. 2016 , 15, 1527-1539	3
1449	Cancer of the Oral Cavity, Pharynx and Larynx. 2016 ,	
1448	Tratamiento no quirúrgico en cáncer epidermoide de orofaringe avanzado. Análisis de resultados oncológicos en función del subsitio tumoral y fraccionamiento de radioterapia. 2016 , 68, 355-362	

1447	Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF- κ B/mTOR and ERK1/2 signaling pathways. 2016 , 83, 1164-1174	50
1446	Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers. 2016 , CD011112	32
1445	Transoral robotic surgery: The radiation oncologist's perspective. 2016 , 60, 96-102	21
1444	miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5. 2016 , 12, 2701-2712	17
1443	Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. 2016 , 40, 244-257	10
1442	Re-irradiation in Head and Neck Cancer. 2016 , 151-168	
1441	Multidisciplinary Care of Laryngeal Cancer. 2016 , 12, 717-24	27
1440	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. 2016 , 96, 959-966	28
1439	DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer. 2016 , 37, 13435-13443	6
1438	Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. 2016 , 44, 1436-40	4
1437	The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma. 2016 , 57, 1843-1850	38
1436	Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?. 2016 , 59, 50-57	18
1435	Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?. 2016 , 59, 67-72	8
1434	IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged \geq 80. 2016 , 192, 526-36	9
1433	Tomothérapie hlicographique des cancers ORL : valuation prospective scintigraphique de la prservation des glandes salivaires. 2016 , 133, 230-236	
1432	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. 2016 , 96, 994-1002	1
1431	Management of Inoperable Malignant Neoplasms. 2016 , 78, 157-67	
1430	The survival rate and larynx preservation in elderly cancer patients who received surgical operation: A retrospective cohort study. 2016 , 36, 342-346	6

1429 HNO Fragen und Antworten. **2016**,

1428	Cost analysis of cetuximab (Erbix) plus radiotherapy (ERT) versus concomitant cisplatin plus radiotherapy (CRT) within an NHS oncology unit (single institution): a pilot study. 2016 , 89, 20160105	3
1427	Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. 2016 , 62, 114-121	23
1426	Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. 2016 , 115, 1328-1334	65
1425	Treatment de-intensification strategies for head and neck cancer. 2016 , 68, 125-133	81
1424	Management of Oropharyngeal Cancer in the HPV Era. 2016 , 23, 197-207	6
1423	Mouth Cancer for Clinicians Part 12: Cancer Treatment (Chemotherapy and Targeted Therapy). 2016 , 43, 567-9, 571-2, 574	2
1422	Saturday 15 October 2016. 2016 , 60, 95-135	
1421	Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m ² for definitive radiochemotherapy of locally advanced head-and-neck cancers. 2016 , 16, 437	16
1420	Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer. 2016 , 1, 4	13
1419	Effectiveness of FDG-PET/CT for evaluating early response to induction chemotherapy in head and neck squamous cell carcinoma: A systematic review. 2016 , 95, e4450	11
1418	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. 2016 , 38, 277-84	10
1417	Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. 2016 , 38 Suppl 1, E2151-8	107
1416	Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer. 2016 , 38 Suppl 1, E905-10	7
1415	Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. 2016 , 38, 863-70	19
1414	Treatment of squamous cell carcinoma of the posterior pharyngeal wall: Radiotherapy versus surgery. 2016 , 38 Suppl 1, E1722-9	6
1413	Effectiveness of honey on radiation-induced oral mucositis, time to mucositis, weight loss, and treatment interruptions among patients with head and neck malignancies: A meta-analysis and systematic review of literature. 2016 , 38, 1119-28	32
1412	Efficacy and safety of vinorelbine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma patients. 2016 , 27, 349-52	1

1411	Xanthogranuloma in the heavily irradiated low neck in a patient with head and neck cancer. 2016 , 45, 20	1
1410	Prediction of critical weight loss during radiation treatment in head and neck cancer patients is dependent on BMI. 2016 , 24, 2101-2109	29
1409	Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. 2016 , 14, 86	7
1408	Molecular Radio-Oncology. 2016 ,	1
1407	Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM. 2016 , 33, 76	4
1406	Human Papilloma Virus as a Biomarker for Personalized Head and Neck Cancer Radiotherapy. 2016 , 198, 143-61	2
1405	Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94). 2016 , 192, 552-60	13
1404	Gefitinib concurrente con quimiorradiaci3n en el c3ncer de cabeza y cuello localmente avanzado. 2016 , 15, 138-144	1
1403	Treatment in elderly patients with head and neck cancer : A challenging dilemma. 2016 , 64, 217-20	9
1402	Induction Chemotherapy. 2016 ,	3
1401	Gefitinib with concurrent chemoradiation in locally advanced head neck cancer. 2016 ,	1
1400	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. 2016 , 96, 9-17	95
1399	Image guided volumetric response during chemoradiotherapy for head and neck squamous cell carcinoma as a predictor of disease outcomes. 2016 , 37, 304-10	2
1398	Total Mucosal Irradiation with Intensity-modulated Radiotherapy in Patients with Head and Neck Carcinoma of Unknown Primary: A Pooled Analysis of Two Prospective Studies. 2016 , 28, e77-e84	24
1397	Primary Intracranial Epidermoid Carcinoma with Diffuse Leptomeningeal Carcinomatosis: Report of Two Cases. 2016 , 88, 692.e9-692.e16	13
1396	A scoping review of indirect comparison methods and applications using individual patient data. 2016 , 16, 47	23
1395	Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients. 2016 , 16, 124	45
1394	Status quo and directions in deep head and neck hyperthermia. 2016 , 11, 21	43

1393	Interaction of Chemotherapy and Radiation. 2016 , 63-79.e4	3
1392	Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. 2016 , 16, 37	20
1391	Oncologic treatment landscape for head and neck squamous cell carcinoma : Treatment infrastructure in German-speaking countries. 2016 , 64, 494-500	3
1390	Reply to P. Blanchard et al. 2016 , 34, 2318-9	1
1389	Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. 2016 , 122, 2021-30	20
1388	Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up. 2016 , 38 Suppl 1, E1271-6	11
1387	CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma. 2016 , 38 Suppl 1, E1392-403	13
1386	Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results. 2016 , 38 Suppl 1, E1481-7	57
1385	Six-year analysis of compliance to weekly concurrent chemoradiotherapy in head and neck carcinomas. 2016 , 41, 442-7	4
1384	Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial. 2016 , 38, 202-7	31
1383	Prognostic factors for local control in patients receiving radiation therapy for early glottic cancer: anterior commissure involvement and effect of chemoradiotherapy. 2016 , 273, 1011-7	24
1382	Impact of human papillomavirus and smoking on survival outcomes after transoral robotic surgery. 2016 , 38, 380-6	12
1381	Late follow-up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer. 2016 , 38 Suppl 1, E488-93	8
1380	Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. 2016 , 53, 10-6	55
1379	Trends in cancer of the head and neck in the elderly in Denmark, 1980-2012. 2016 , 55 Suppl 1, 13-8	3
1378	Chemotherapy in locally advanced head and neck squamous cell carcinoma. 2016 , 44, 10-6	18
1377	Use of pentoxifylline and tocopherol in the management of osteoradionecrosis. 2016 , 54, 342-5	35
1376	Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. 2016 , 34, 396-8	11

1375	The management of head and neck tumors with high technology radiation therapy. 2016 , 16, 99-110	11
1374	Taselisib (GDC-0032), a Potent E^{5} sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations. 2016 , 22, 2009-19	50
1373	Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. 2016 , 34, 427-35	154
1372	Post-treatment weight change in oral cavity and oropharyngeal squamous cell carcinoma. 2016 , 24, 2333-2340	4
1371	Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. 2016 , 99, 100-6	45
1370	Postoperative Complications in Elderly Patients Undergoing Head and Neck Surgery: Opportunities for Quality Improvement. 2016 , 154, 518-26	22
1369	Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: Rationale, complications, toxicity rates, and oncological outcomes - A systematic review. <i>Radiotherapy and Oncology</i> , 2016 , 119, 185-93	5-3 18
1368	[Observance and results of concurrent chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers]. 2016 , 20, 83-90	
1367	Radiation oncology in the era of precision medicine. 2016 , 16, 234-49	438
1366	Contacting authors to retrieve individual patient data: study protocol for a randomized controlled trial. 2016 , 17, 138	8
1365	Immunotherapy for head and neck cancer: latest developments and clinical potential. 2016 , 8, 168-75	12
1364	T-status and an oral fluoropyrimidine, S-1, adjuvant chemotherapy are prognostic factors in reduced-RADPLAT for resectable hypopharyngeal cancer. 2016 , 136, 834-40	1
1363	A genetic view of laryngeal cancer heterogeneity. 2016 , 15, 1202-12	21
1362	Transoral Surgery or Radiotherapy for Oropharyngeal Carcinoma - Is It Either Or? 2016 , 28, 413-20	5
1361	Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?. 2016 , 54, 54-7	39
1360	[Human papillomavirus and squamous cell cancer of the head and neck region : Prognostic, therapeutic and prophylactic implications]. 2016 , 64, 450-9	4
1359	Retrospective analysis of the clinical efficacy of definitive chemoradiotherapy for patients with hypopharyngeal cancer. 2016 , 46, 344-9	6
1358	Volumetric modulated arc therapy (VMAT) and simultaneous integrated boost in head-and-neck cancer: is there a place for critical swallowing structures dose sparing?. 2016 , 89, 20150764	5

1357	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. 2016 , 100, 147-66		92
1356	Hyperthermia and radiotherapy in the management of head and neck cancers: A systematic review and meta-analysis. 2016 , 32, 31-40		79
1355	Targeting Oral Cancer. 2016 ,		
1354	Prognostic value of the distance between the primary tumor and brainstem in the patients with locally advanced nasopharyngeal carcinoma. 2016 , 16, 114		12
1353	Immunotherapy in Head and Neck Cancers. 2016 , 211-224		
1352	Optimize and refine therapeutic index in radiation therapy: Overview of a century. 2016 , 45, 58-67		42
1351	Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis. 2016 , 54, 58-67		11
1350	Outcomes of Induction Chemotherapy for Head and Neck Cancer Patients: A Combined Study of Two National Cohorts in Taiwan. 2016 , 95, e2845		19
1349	Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial. 2016 , 125, 317-24		24
1348	[The role of microRNAs in head and neck squamous cell carcinoma : Biomarkers for prognosis, therapy selection, and novel therapeutics]. 2016 , 64, 296-302		1
1347	Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. 2016 , 52, 77-84		25
1346	Validation of the total dysphagia risk score (TDRS) in head and neck cancer patients in a conventional and a partially accelerated radiotherapy scheme. <i>Radiotherapy and Oncology</i> , 2016 , 118, 293-7	5.3	3
1345	[Value of neck dissection before definitive radiation therapy for locoregionally advanced squamous cell carcinoma of the head and neck]. 2016 , 20, 18-23		2
1344	Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis. 2016 , 21, 59-71		12
1343	EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?. 2016 , 99, 170-9		12
1342	Oropharyngeal Cancer. 2016 , 597-628.e6		
1341	Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. <i>Radiotherapy and Oncology</i> , 2016 , 118, 238-43	5.3	61
1340	Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?. 2016 , 273, 2877-94		18

1339	Treatment strategies in early-stage oropharyngeal squamous cell carcinoma: a French national survey. 2016 , 273, 2201-7	8
1338	Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy. 2016 , 121, 229-37	5
1337	Usefulness of Prophylactic Percutaneous Gastrostomy Placement in Patients with Head and Neck Cancer Treated with Chemoradiotherapy. 2016 , 31, 84-9	10
1336	Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?. 2016 , 37, 3969-78	52
1335	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. 2016 , 97, 131-42	57
1334	Concurrent chemo-radiotherapy in elderly patients: tolerance and compliance in a series of 137 patients. 2016 , 18, 571-5	3
1333	Cancer of Unknown Primary. 2016 ,	6
1332	The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis. 2016 , 273, 2305-17	12
1331	Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. 2016 , 28, 50-61	14
1330	Outcomes in Advanced Head and Neck Cancer Treated with Up-front Neck Dissection prior to (Chemo)Radiotherapy. 2016 , 154, 300-8	9
1329	Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status. 2016 , 273, 2157-69	28
1328	Decision Trees Predicting Tumor Shrinkage for Head and Neck Cancer: Implications for Adaptive Radiotherapy. 2016 , 15, 139-45	20
1327	Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma: an open question. 2016 , 273, 263-5	0
1326	Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma. 2016 , 38 Suppl 1, E559-65	16
1325	Matted nodes: High distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer. 2016 , 38 Suppl 1, E805-14	33
1324	Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: A dose-volume analysis. 2016 , 38 Suppl 1, E815-9	19
1323	Integrating chemoradiation and molecularly targeted therapy. 2017 , 109, 74-83	14
1322	Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer. 2017 , 116, 185-192	19

1321	Age-adjusted Charlson comorbidity index as a prognostic factor of hypopharyngeal cancer treated with chemoradiation therapy. 2017 , 137, 668-673	4
1320	Management of acute skin toxicity with Hypericum perforatum and neem oil during platinum-based concurrent chemo-radiation in head and neck cancer patients. 2017 , 34, 30	5
1319	Interobserver Variability in the Delineation of Gross Tumour Volume and Specified Organs-at-risk During IMRT for Head and Neck Cancers and the Impact of FDG-PET/CT on Such Variability at the Primary Site. 2017 , 48, 184-192	22
1318	Risk Profiles for Sensorineural Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin-based Chemoradiation. 2017 , 48, 61-67	6
1317	Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. 2017 , 143, 355-366	21
1316	The latest prospects of investigational drugs for head and neck cancer. 2017 , 26, 265-268	3
1315	Proton beam therapy for olfactory neuroblastoma. <i>Radiotherapy and Oncology</i> , 2017 , 122, 368-372	5-3 25
1314	Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma. 2017 , 98, 186-195	16
1313	Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival. 2017 , 21, 171-177	24
1312	Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. 2017 , 98, 948-954	3
1311	Image-guided interstitial high-dose-rate brachytherapy in the treatment of inoperable recurrent head and neck malignancies: An effective option of reirradiation. 2017 , 39, E61-E68	8
1310	Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer. 2017 , 67, 70-76	18
1309	Patterns of Care in Adjuvant Therapy for Resected Oral Cavity Squamous Cell Cancer in Elderly Patients. 2017 , 98, 758-766	7
1308	High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck. 2017 , 67, 24-28	6
1307	Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. 2017 , 127, 2260-2264	3
1306	Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol. 2017 , 12, 45	23
1305	New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors. 2017 , 67, 119-123	17
1304	Retrospective analysis of self-reporting pain scores and pain management during head and neck IMRT radiotherapy: A single institution experience. 2017 , 23, 103-106	2

1303	[Ototoxicity in head and neck cancers after radiotherapy and chemoradiotherapy: From primary prevention to tertiary prevention]. 2017 , 21, 77-83	5
1302	Hypofractionated Accelerated Chemoradiation for Oropharyngeal Cancer and the 2016 Royal College of Radiologists' Fractionation Guidelines. 2017 , 29, e138	1
1301	Survival Patterns in Elderly Head and Neck Squamous Cell Carcinoma Patients Treated With Definitive Radiation Therapy. 2017 , 98, 793-801	14
1300	Predictors of distant metastasis in human papillomavirus-associated oropharyngeal cancer. 2017 , 39, 940-946	20
1299	Revisiting induction chemotherapy before radiotherapy for head and neck cancer, part I: carcinoma of non-nasopharyngeal sites. 2017 , 13, 469-475	7
1298	Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology. 2017 , 34, 86	4
1297	Impact of microRNA dynamics on cancer hallmarks: An oral cancer scenario. 2017 , 39, 1010428317695920	36
1296	Neoplasms of the Head and Neck. 2017 , 1-37	
1295	Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. 2017 , 79, 1087-1097	6
1294	The role of Next-Generation Sequencing in tumoral radiosensitivity prediction. 2017 , 3, 16-20	6
1293	Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1). 2017 , 70, 58-64	11
1292	Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. <i>Radiotherapy and Oncology</i> , 2017 , 124, 526-532	5-3 84
1291	Meta-analyses and Systematic Reviews: Can They Solve Contentious Clinical Questions?. 2017 , 23, 84-85	0
1290	Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis. 2017 , 23, 79-83	17
1289	Combination radiotherapy and cantharidin inhibits lung cancer growth through altering tumor infiltrating lymphocytes. 2017 , 13, 1173-1180	6
1288	[Immunotherapy Against Head and Neck Cancer Stem Cells]. 2017 , 96, 216-224	
1287	Tongue-out versus tongue-in position during intensity-modulated radiotherapy for base of tongue cancer: Clinical implications for minimizing post-radiotherapy swallowing dysfunction. 2017 , 39, E85-E91	2
1286	Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure. <i>Radiotherapy and Oncology</i> , 2017 , 123, 424-430	5-3 13

1285	Chemotherapy for localized head and neck squamous cell cancers. 2017 , 28, 362-368	5
1284	Oropharyngeal Cancer. 2017 , 202-226	
1283	Cervical Nodes with Unknown Primary Carcinomas. 2017 , 300-312	
1282	Head and Neck Radiation Therapy Sequelae and Late Complications and the Role of IMRT. 2017 , 335-348	
1281	Carcinoma of the Oral Cavity. 2017 , 175-201	
1280	Assessing cumulative acute toxicity of chemoradiotherapy in head and neck cancer with or without induction chemotherapy. 2017 , 38, 456-461	9
1279	Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. 2017 , 115, 50-58	26
1278	Efficacy and toxicity profiles of two chemoradiotherapies for stage II laryngeal cancer - a comparison between late course accelerated hyperfractionation (LCAHF) and conventional fractionation (CF). 2017 , 137, 883-887	3
1277	Management of elderly patients with locoregionally confined head and neck cancer. 2017 , 18, e274-e283	38
1276	Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression. 2017 , 34, 107	13
1275	An update on larynx cancer. 2017 , 67, 31-50	274
1274	Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy. 2017 , 98, 858-867	13
1273	"But We Are Already Geriatric Oncologists"-Why Older Patients Need a Special Approach (A View from a United Kingdom Cancer Center). 2017 , 98, 964-965	1
1272	The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment. 2017 , 98, 868-883	30
1271	A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)?. 2017 , 71, 1-10	7
1270	Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials. 2017 , 71, 61-66	8
1269	Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5-year results of a phase II study. 2017 , 193, 733-741	3
1268	p16, HPV, and Cetuximab: What Is the Evidence?. 2017 , 22, 811-822	16

1267	Improving Consistency and Quality of Care for Older Adults With Cancer: The Challenges of Developing Consensus Guidelines for Radiation Therapy. 2017 , 98, 721-725	10
1266	Head and Neck Cancer. 2017 , 91-126	2
1265	Prolonged Overall Treatment Time and Lack of Skin Rash Negatively Impact Overall Survival in Locally Advanced Head and Neck Cancer Patients Treated with Radiotherapy and Concomitant Cetuximab. 2017 , 12, 505-512	5
1264	[Prognostic factors for head and neck cancer reirradiation: A systematic review]. 2017 , 21, 316-338	2
1263	Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients. 2017 , 25, 3417-3423	6
1262	The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?. 2017 , 18, 39	7
1261	Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis. 2017 , 71, 11-15	61
1260	High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer. 2017 , 39, 1364-1370	17
1259	Adjuvant Chemoradiation After Surgical Resection in Elderly Patients With High-Risk Squamous Cell Carcinoma of the Head and Neck: A National Cancer Database Analysis. 2017 , 98, 784-792	18
1258	Unknown primary head and neck squamous cell carcinoma in the era of fluorodeoxyglucose-positron emission tomography/CT and intensity-modulated radiotherapy. 2017 , 39, 1382-1391	9
1257	Patterns of Care for Elderly Patients With Locally Advanced Head and Neck Cancer. 2017 , 98, 767-774	20
1256	Comparison cisplatin with cisplatin plus 5FU in head and neck cancer patients received postoperative chemoradiotherapy. 2017 , 69, 11-14	3
1255	Treatment outcome of advance staged oral cavity cancer: concurrent chemoradiotherapy compared with primary surgery. 2017 , 274, 2567-2572	19
1254	Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review. 2017 , 46, 29	29
1253	Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy. 2017 , 274, 2883-2889	4
1252	Cardiovascular sequel of neck irradiation in head and neck cancer patients. 2017 , 93, 711-716	6
1251	MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. 2017 , 77, 3-12	34
1250	Risk factors for and the role of dental extractions in osteoradionecrosis of the jaws: A national-based cohort study. 2017 , 39, 1313-1321	38

1249	Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review. 2017 , 13, 554-566	21
1248	Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. 2017 , 39, 1155-1165	12
1247	Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma. 2017 , 39, 1327-1332	13
1246	Follow-up program in head and neck cancer. 2017 , 113, 151-155	26
1245	Radiotherapy plus EGFR inhibitors: synergistic modalities. 2017 , 2, 2	3
1244	Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 2017 , 123, 1259-1271	40
1243	Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer. 2017 , 123, 1555-1565	9
1242	Comprehensive Overview: Definitive Radiotherapy and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer. 2017 , 151-176	3
1241	Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. 2017 , 39, 679-683	28
1240	A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck. 2017 , 35, 23-31	5
1239	Geriatric Assessment as a Predictor of Tolerance, Quality of Life, and Outcomes in Older Patients With Head and Neck Cancers and Lung Cancers Receiving Radiation Therapy. 2017 , 98, 850-857	34
1238	Critical Issues in Head and Neck Oncology. 2017 ,	
1237	Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis. 2017 , 274, 1683-1690	27
1236	The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era. 2017 , 123, 1345-1353	17
1235	Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival. 2017 , 274, 1691-1700	8
1234	A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2017 , 122, 217-223	53
1233	Try to Avoid Tri-Modality Treatment. 2017 , 97, 3	
1232	The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics. 2017 , 16, 540-550	20

1231	Long-term Functional and Quality-of-Life Outcomes After Transoral Robotic Surgery in Patients With Oropharyngeal Cancer. 2018 , 144, 18-27	24
1230	Impact of hypoxia in head and neck cancer radiotherapy. 2017 , 5, 497-505	3
1229	Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. 2017 , 73, 65-69	28
1228	Extracapsular extension is associated with worse distant control and progression-free survival in patients with lymph node-positive human papillomavirus-related oropharyngeal carcinoma. 2017 , 74, 56-61	19
1227	Transoral Oropharyngeal Resection Classification: Proposal of the SCORL Working Group. 2017 , 68, 289-293	
1226	A predictive model for residual disease after (chemo) radiotherapy in oropharyngeal carcinoma: Combined radiological and clinical evaluation of tumor response. 2017 , 6, 1-6	4
1225	Regional Neck Control in Head and Neck Squamous Cell Carcinoma with Positive Neck Disease Treated with Primary Chemoradiation. 2017 , 75, e330-e331	
1224	Metabolic tumor volume of primary tumor predicts survival better than T classification in the larynx preservation approach. 2017 , 108, 2030-2038	14
1223	Hypoxia PET imaging techniques: data acquisition and analysis. 2017 , 5, 489-496	3
1222	Patterns of care and impact of brachytherapy boost utilization for squamous cell carcinoma of the base of tongue in a large, national cohort. 2017 , 16, 1205-1212	2
1221	[Role of induction chemotherapy in head and neck cancer: Cons]. 2017 , 21, 510-514	3
1220	The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis. 2017 , 90, 20170442	17
1219	The Role of Radiotherapy in the Definitive and Postoperative Treatment of Advanced Head and Neck Cancer. 2017 , 40, 347-352	15
1218	Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. 2017 , 123, 4583-4593	13
1217	Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPV-ve Oropharynx cancer? A population-based study. 2017 , 117, 1105-1112	6
1216	Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer. 2017 , 56, 1571-1576	17
1215	[Role and interest of induction chemotherapy for head and neck cancers]. 2017 , 21, 505-509	0
1214	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. 2017 , 73, 138-146	61

1213	[Radiotherapy for head and neck squamous cell carcinoma: State of the art and future directions]. 2017 , 21, 498-504	4
1212	Cáncer de cabeza y cuello. 2017 , 12, 1833-1848	
1211	Treatment of late sequelae after radiotherapy for head and neck cancer. 2017 , 59, 79-92	105
1210	Metastatic cutaneous apocrine carcinoma: Multidisciplinary approach achieving complete response with adjuvant chemoradiation. 2017 , 3, 259-262	6
1209	Trials in head and neck oncology: Evolution of perioperative adjuvant therapy. 2017 , 72, 80-89	2
1208	Assessment and management of radiotherapy induced toxicity in older patients. 2017 , 8, 421-427	17
1207	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. 2017 , 18, 1221-1237	156
1206	The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity. 2017 , 116, 82-88	6
1205	Accelerated Radiation Therapy Using Weekend Boost with Concurrent Cisplatin in Head and Neck Squamous Cell Cancers: An Indian Institutional Experience. 2017 , 48, 307-315	1
1204	Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma. 2017 , 47, 1038-1046	5
1203	Transoral oropharyngeal resection classification: Proposal of the SCORL working group. 2017 , 68, 289-293	5
1202	Quantification of Dose-Volume and Dose-Length Parameters for Cervical Esophageal Stricture in Head and Neck Irradiation with the 3DCRT and IMRT Technique. 2017 , 48, 288-293	
1201	The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma. 2017 , 274, 3757-3765	20
1200	Redistributed versus homogenous radiotherapy dose for head and neck cancer; a treatment planning study. 2017 , 3, 17-20	1
1199	Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters. <i>Radiotherapy and Oncology</i> , 2017 , 124, 256-262	5-3 32
1198	Exclusive concurrent radiochemotherapy for advanced head and neck cancers with 'fractionated' 5-fluorouracil and cisplatin. 2017 , 28, 213-221	1
1197	Trends in net survival from head and neck cancer in six European Latin countries: results from the SUDCAN population-based study. 2017 , 26 Trends in cancer net surviv, S16-S23	7
1196	The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. 2017 , 36, 449-461	31

1195	Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. 2017 , 39, 2329-2349	15
1194	Zervikale Lymphknotenmetastasen bei unbekanntem Primärtumor. 2017 , 23, 986-992	2
1193	Treatment Deintensification for Human Papillomavirus-Associated Oropharyngeal Cancer. 2017 , 24, 3463-3465	
1192	Geometric Image Biomarker Changes of the Parotid Gland Are Associated With Late Xerostomia. 2017 , 99, 1101-1110	19
1191	Elderly patients affected by head and neck squamous cell carcinoma unfit for standard curative treatment: Is de-intensified, hypofractionated radiotherapy a feasible strategy?. 2017 , 74, 142-147	17
1190	Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review. 2017 , 120, 98-110	31
1189	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. 2017 , 7, 28-35	12
1188	Distant metastases in head and neck cancer. 2017 , 39, 1733-1743	99
1187	Impact of combined modality treatment with radiotherapy and S-1 on T2N0 laryngeal cancer: Possible improvement in survival through the prevention of second primary cancer and distant metastasis. 2017 , 71, 54-59	12
1186	Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma. 2017 , 19, 1337-1349	15
1185	Concurrent chemoradiotherapy with S-1 in patients with stage III-IV oral squamous cell carcinoma: A retrospective analysis of nodal classification based on the neck node level. 2017 , 7, 140-144	4
1184	TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. 2017 , 28, 2219-2224	13
1183	Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. 2017 , 28, 2206-2212	100
1182	Induction chemotherapy for nasopharyngeal cancer: An 'eternally unfinished issue?'. 2017 , 82, 153-154	
1181	Perioperative changes in osteopontin and TGF β plasma levels and their prognostic impact for radiotherapy in head and neck cancer. 2017 , 17, 6	2
1180	HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation. 2017 , 17, 86	19
1179	Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study. 2017 , 12, 97	14
1178	Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer. 2017 , 123, 3933-3942	70

1177	The treatment results of definitive radiotherapy for cervical esophageal cancer: a single-institution experience. 2017 , 14, 254-261	2
1176	Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status. 2017 , 71, 150-155	61
1175	Role of transoral robotic surgery in current head & neck practice. 2017 , 15, 147-154	14
1174	Erufosine increases RhoB expression in oral squamous carcinoma cells independent of its tumor suppressive mode of action - a short report. 2017 , 40, 89-96	11
1173	Prophylactic exercises among head and neck cancer patients during and after swallowing sparing intensity modulated radiation: adherence and exercise performance levels of a 12-week guided home-based program. 2017 , 274, 1129-1138	32
1172	Comparison between weekly cisplatin-enhanced radiotherapy and cetuximab-enhanced radiotherapy in locally advanced head and neck cancer: first retrospective study in Asian population. 2017 , 13, 195-203	8
1171	Pretreatment factors associated with functional oral intake and feeding tube use at 1 and 6 months post-radiotherapy (+/- chemotherapy) for head and neck cancer. 2017 , 274, 507-516	7
1170	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group R522. 2017 , 97, 687-693	29
1169	Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study. 2017 , 44, 104-110	5
1168	CT image biomarkers to improve patient-specific prediction of radiation-induced xerostomia and sticky saliva. <i>Radiotherapy and Oncology</i> , 2017 , 122, 185-191	53 59
1167	Predictive value of hypoxia in advanced head and neck cancer after treatment with hyperfractionated radio-chemotherapy and hypoxia modification. 2017 , 19, 419-424	12
1166	Placebo-Controlled, Double-Blind, Randomized Study of a Dry Guarana Extract in Patients with Head and Neck Tumors Undergoing Chemoradiotherapy: Effects on Fatigue and Quality of Life. 2017 , 14, 32-41	7
1165	American Brachytherapy Society Task Group Report: Combined external beam irradiation and interstitial brachytherapy for base of tongue tumors and other head and neck sites in the era of new technologies. 2017 , 16, 44-58	17
1164	Extrapolation of Survival Curves from Cancer Trials Using External Information. 2017 , 37, 353-366	25
1163	Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥ 70 years. 2017 , 8, 50-55	21
1162	Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. 2017 , 274, 1021-1027	6
1161	Radiotherapy for elderly patients and cetuximab, a monocentric study. 2017 , 274, 1061-1065	6
1160	HPV Infection in Head and Neck Cancer. 2017 ,	3

1141	Head and neck cancer: improving outcomes with a multidisciplinary approach. 2017 , 9, 363-371	87
1140	Can Intensity-Modulated-Radiotherapy Reduce Toxicity in Head and Neck Squamous Cell Carcinoma?. 2017 , 9,	33
1139	Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. 2017 , 8,	21
1138	Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"?. 2017 , 7, 205	6
1137	Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with head and neck tumors, a systematic review and meta-analysis. 2017 , 12, e0177986	16
1136	¹⁸ F-FDG-PET/CT for the detection of disease in patients with head and neck cancer treated with radiotherapy. 2017 , 12, e0182350	14
1135	Survival impact of pre-treatment neutrophils on oropharyngeal and laryngeal cancer patients undergoing definitive radiotherapy. 2017 , 15, 168	15
1134	Clinical outcomes of retrograde intra-arterial chemotherapy concurrent with radiotherapy for elderly oral squamous cell carcinoma patients aged over 80 years old. 2017 , 12, 112	11
1133	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. 2017 , 12, 129	4
1132	Postoperative radiotherapy with or without concurrent chemotherapy for oral squamous cell carcinoma in patients with three or more minor risk factors: a propensity score matching analysis. 2017 , 12, 184	13
1131	[25 years of the Association of Middle-German Otorhinolaryngologists (MDHNO)]. 2017 , 65, 789-792	
1130	Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity. 2017 , 8, 73925-73937	14
1129	An Environment for Guideline-based Decision Support Systems for Outpatients Monitoring. 2017 , 56, 283-293	6
1128	Radiotherapy in the Management of Orofacial Cancer. 2017 , 324-338	1
1127	Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. 2017 , 8, 332-344	17
1126	Manejo del c�ncer de cabeza y cuello: �Radioterapia a qu�n, cu�ndo y por qu�?. 2017 , 77, 81-90	2
1125	Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma. 2017 , 8, 44842-44850	7
1124	Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study. 2017 , 35, 3458-3464	29

1123	Is Induction Chemotherapy Needed to Select Patients for Deintensified Treatment of Human Papillomavirus-Associated Oropharyngeal Cancer?. 2017 , 35, 479-481	4
1122	The Team Approach in the Management of Head and Neck Cancer. 2017 , 285-291	
1121	Induction Chemotherapy for Advanced Head and Neck Cancer Patients: Outcomes of A Quasi-Experimental Study.. 2017 , 11, 54-57	
1120	Evaluation of Cisplatin Induced Toxicity in Head and Neck Cancer and Cervical Cancer During Concurrent Chemoradiotherapy. Experience of National Institute of Oncology in Morocco. 2017 , 09,	
1119	Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients. 2017 , 8, 99990-100001	29
1118	Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers. 2018 , 9, 1179670717749231	
1117	Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO). 2018 , 9, 42-47	25
1116	Multidisciplinary Care of the Head and Neck Cancer Patient. 2018 ,	5
1115	Head and Neck Cancer in the Elderly: Frailty, Shared Decisions, and Avoidance of Low Value Care. 2018 , 34, 233-244	10
1114	Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma. 2018 , 79, 9-14	5
1113	Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease. 2018 , 78, 151-155	10
1112	Practice patterns and outcomes of chemoradiotherapy versus radiotherapy alone for older patients with nasopharyngeal cancer. 2018 , 7, 1604-1611	7
1111	Clinical factors impacting on late dysphagia following radiotherapy in patients with head and neck cancer. 2018 , 91, 20180155	3
1110	[Once-a-week versus once-every-three-weeks cisplatin application in combined chemoradiotherapy for locally advanced head and neck cancer?]. 2018 , 194, 468-470	3
1109	Short- and long-term outcomes of oropharyngeal cancer care in the elderly. 2018 , 128, 2084-2093	9
1108	Radiotherapy Controversies and Prospective in Head and Neck Cancer: A Literature-Based Critical Review. 2018 , 20, 227-232	34
1107	Patterns of care and outcomes of adjuvant therapy for high-risk head and neck cancer after surgery. 2018 , 40, 1254-1262	6
1106	Impact of comorbidity on tolerability and survival following curative intent intensity modulated radiotherapy in older patients with nasopharyngeal cancer. 2018 , 9, 352-358	6

1105	Immunotherapy for recurrent/metastatic head and neck cancer. 2018 , 26, 152-156	11
1104	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. 2018 , 52, 228-240	162
1103	Concurrent cisplatin and radiotherapy versus cetuximab and radiotherapy, an unsolved problem. 2018 , 29, 779	1
1102	[Current Status of therapy and prophylaxis of oropharyngeal carcinoma]. 2018 , 97, 123-137	3
1101	Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). 2018 , 52, 637-655	69
1100	Induction chemotherapy with the EXTREME regimen in frail patients with locally advanced head and neck squamous cell carcinoma. 2018 , 13, 247-252	0
1099	Clinical value of FDG PET/CT in screening for distant metastases in head and neck squamous cell carcinoma. 2018 , 43, 875-881	6
1098	High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy. 2018 , 14, e442-e447	3
1097	Accuracy of FDG PET-CT response assessment following radiotherapy alone for head and neck squamous cell carcinoma: Retrospective analysis of 45 patients. 2018 , 43, 931-934	1
1096	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. 2018 , 124, 1415-1427	15
1095	Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?. 2018 , 29, 287-294	2
1094	Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification. 2018 , 40, 1228-1236	12
1093	Perspectives in Head and Neck Medical Oncology. 2018 , 174, 163-185	3
1092	Does the total dysphagia risk score correlate with swallowing function examined by videofluoroscopy?. 2018 , 91, 20170714	
1091	Skull base or cervical vertebral osteomyelitis following chemoradiotherapy for pharyngeal carcinoma: A serious but treatable complication. 2018 , 8, 40-44	8
1090	Late radiation-associated dysphagia in head and neck cancer patients: evidence, research and management. 2018 , 77, 125-130	35
1089	Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in F-FDG PET in Squamous Cell Carcinoma of the Head and Neck. 2018 , 8, 105	32
1088	Unknown primary squamous cell carcinoma of the head and neck: retrospective analysis of 80 cases. 2018 , 138, 590-596	11

1087	Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. 2018 , 110, 479-485		36
1086	Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults. 2018 , 124, 2993-2999		66
1085	A case of lateral retropharyngeal node metastasis from carcinoma of the tongue:. 2018 , 30, 7-13		
1084	Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options. 2018 , 80, 40-51		31
1083	Feasibility of Dose-escalated Hypofractionated Chemoradiation in Human Papilloma Virus-negative or Smoking-associated Oropharyngeal Cancer. 2018 , 30, 366-374		9
1082	Effectiveness of tomotherapy vs linear accelerator image-guided intensity-modulated radiotherapy for localized pharyngeal cancer treated with definitive concurrent chemoradiotherapy: a Taiwanese population-based propensity score-matched analysis. 2018 , 91, 20170947		3
1081	Multicenter phase I/II study of chemoradiotherapy with high-dose CDDP for head and neck squamous cell carcinoma in Japan. 2018 , 45, 1086-1092		4
1080	AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. 2018 , 40, 676-686		10
1079	Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. 2018 , 8, 4306		43
1078	Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer. 2018 , 41, 441-446		6
1077	Using primary tumor volumetry to predict treatment outcome for patients with oropharyngeal cancer who were treated with definitive chemoradiotherapy. 2018 , 14, e21-e28		1
1076	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018 , 126, 125-131	5-3	20
1075	Chemotherapy for Oral Cancer. 2018 , 62, 87-97		52
1074	Treatment, survival, and costs of oropharyngeal cancer care in the elderly. 2018 , 128, 1103-1112		4
1073	Effects of biodegradable hydrogel spacer injection on contralateral submandibular gland sparing in radiotherapy for head and neck cancers. <i>Radiotherapy and Oncology</i> , 2018 , 126, 96-99	5-3	7
1072	Primary surgery versus primary radiation-based treatment for locally advanced oropharyngeal cancer. 2018 , 128, 1353-1364		15
1071	Randomized control trial of benzydamine HCl versus sodium bicarbonate for prophylaxis of concurrent chemoradiation-induced oral mucositis. 2018 , 26, 879-886		26
1070	Biologically adapted radiation therapy. 2018 , 28, 177-183		10

1069	Adjuvant chemoradiation does not improve survival in elderly patients with high-risk resected head and neck cancer. 2018 , 128, 831-840	16
1068	Is definitive concurrent chemoradiotherapy effective for locally advanced head and neck cancer in the elderly aged ≥ 75 years: A single-institute, retrospective, cohort study. 2018 , 14, 247-255	4
1067	Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. 2018 , 144, 389-401	3
1066	Epidemiological and treatment-related factors contribute to improved outcome of oropharyngeal squamous cell carcinoma in Finland. 2018 , 57, 541-551	14
1065	Is Lipidomic the Answer to the Search of a Biomarker for Organ Preservation Protocol in Head and Neck Squamous Cell Carcinoma?. 2018 , 24, 931-935	2
1064	Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. 2018 , 36, 1269-1271	2
1063	Comparison of Comorbidity and Frailty Indices in Patients With Head and Neck Cancer Using an Online Tool. 2018 , 2, 1-9	7
1062	Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 2018 , 36, 1143-1169	108
1061	Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial. 2018 , JCO2017762518	34
1060	Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial. 2018 , 36, 3077-3083	78
1059	Different View on Larynx Preservation Evidence-Based Treatment Recommendations. 2018 , 36, 1376-1377	10
1058	Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer. 2018 , 36, 192-199	2
1057	Three-weekly cisplatin or weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma—the jury is still out. 2018 , 2, 39-39	
1056	Immunonkologie von Kopf-Hals-Tumoren. 2018 , 13, 336-349	
1055	Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer. 2018 , 138, 1146-1153	2
1054	Prognostic value of metabolic tumor burden calculated using dual-time-point ^{18}F -fluorodeoxyglucose positron emission tomography/CT in patients with oropharyngeal or hypopharyngeal cancer. 2019 , 41, 103-109	1
1053	Treatment of oral cancer using magnetized paclitaxel. 2018 , 9, 15591-15605	9
1052	Diffusion Weighted and Dynamic Contrast-Enhanced MRI as a Predictor of Treatment Response in Head and Neck Cancer to Chemoradiotherapy: The Role of Early Intratreatment Scanning. 2018 , 07,	

1051	Bei kombinierter Radiochemotherapie: Cisplatin wöchentlich oder dreiwöchentlich?. 2018 , 21, 34-35	
1050	Treatment outcomes of locally advanced hypopharyngeal squamous cell carcinoma. 2018 , 2, 17-17	0
1049	Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck. 2018 , 41, 736-743	6
1048	Induction Chemotherapy: Does It Have a Place in Oral Cavity Cancer?. 2018 , 99-103	
1047	Treatment of Elderly Patients with Head and Neck Cancer. 2018 , 285-307	
1046	Can We Expect Less Toxicities with Newer Forms of Radiotherapy?. 2018 , 181-212	
1045	Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. 2018 , 40, 2612-2620	1
1044	Critical Issues in Head and Neck Oncology. 2018 ,	1
1043	A Call to Arms: Radiation Therapy Quality Assurance in the Next Generation of Clinical Trials. 2018 , 102, 1590-1591	3
1042	Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma. 2019 , 41, 130-138	3
1041	Lower cranial nerve palsy during radiotherapy for glottic cancer in a patient with Wegener's granulomatosis: An interesting case report. 2019 , 10, 147-152	0
1040	Options of medical treatment and laryngeal function preservation in elderly patients with medial wall pyriform sinus cancer. 2018 , 11, 7441-7446	
1039	Biological PET-guided adaptive radiotherapy for dose escalation in head and neck cancer: a systematic review. 2018 , 62, 349-368	9
1038	Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy. 2019 , 41, 488-494	2
1037	Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. 2018 , 124, 3881-3889	2
1036	Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?. 2018 , 124, 4163-4164	3
1035	Early (90-day) mortality after radical radiotherapy for head and neck squamous cell carcinoma: A population-based analysis. 2018 , 40, 2432-2440	4
1034	Altered fractionation radiotherapy with or without chemotherapy in the treatment of head and neck cancer: a network meta-analysis. 2018 , 11, 5465-5483	3

1033	Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. 2018 , 86, 132-140	15
1032	Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience. 2018 , 8, e020499	3
1031	Human papillomavirus-associated oropharyngeal cancer among patients aged 70 and older: Dramatically increased prevalence and clinical implications. 2018 , 103, 195-204	20
1030	Dysphagia Management in Head and Neck Cancers. 2018 ,	2
1029	From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer. 2018 , 86, 200-205	6
1028	Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety. 2018 , 10,	5
1027	Big Data in Head and Neck Cancer. 2018 , 19, 62	22
1026	Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma. 2018 , 37, 264	13
1025	Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma. 2018 , 18, 1026	11
1024	The role of induction chemotherapy followed by surgery in unresectable stage IVb laryngeal and hypopharyngeal cancers: a case series. 2018 , 47, 62	
1023	[Genomic characterization of head and neck squamous cell carcinoma: Impact and challenges for therapeutic management]. 2018 , 105, 820-829	0
1022	Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies. 2018 , 86, 301-306	12
1021	Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis. 2018 , 124, 4486-4494	14
1020	Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality Approaches. 2018 , 8, 439	14
1019	Comparison of high-dose Cisplatin-based chemoradiotherapy and Cetuximab-based bioradiotherapy for p16-positive oropharyngeal squamous cell carcinoma in the context of revised HPV-based staging. 2018 , 23, 451-457	6
1018	IMRT - Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. 2018 , 86, 91-99	5
1017	Circulating tumor cells as biomarkers in head and neck cancer: recent advances and future outlook. 2018 , 18, 897-906	11
1016	Predictive value of single nucleotide polymorphisms in for radiation-induced normal tissue toxicity. 2018 , 11, 3901-3918	6

1015	pN status predicts outcomes in surgically treated pT1-pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study. 2018 , 275, 2787-2795	2
1014	Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts. 2018 , 131, 30-34	8
1013	Head and Neck Tumors. 2018 , 1-136	1
1012	The relationship between physical impairments, quality of life and disability of the neck and upper limb in patients following neck dissection. 2018 , 12, 619-631	12
1011	Oropharyngeal Cancer. 2018 , 171-192	
1010	Head and Neck Cancer and the Elderly Patient. 2018 , 51, 741-751	10
1009	Radiotherapy for locally advanced resectable T3-T4 laryngeal cancer-does laryngeal preservation strategy compromise survival?. 2018 , 59, 77-90	12
1008	Deep hyperthermia with the HYPERcollar system combined with irradiation for advanced head and neck carcinoma - a feasibility study. 2018 , 34, 994-1001	24
1007	Oropharyngeal cancer is no longer a disease of younger patients and the prognostic advantage of Human Papillomavirus is attenuated among older patients: Analysis of the National Cancer Database. 2018 , 83, 147-153	47
1006	Randomized controlled study comparing simultaneous modulated accelerated radiotherapy versus simultaneous integrated boost intensity modulated radiotherapy in the treatment of locally advanced head and neck cancer. 2018 , 30, 107-115	1
1005	Managing older patients with head and neck cancer: The non-surgical curative approach. 2018 , 9, 411-417	6
1004	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. 2018 , 119, 153-159	209
1003	Human papillomavirus and oropharyngeal cancer. 2018 , 42, 466-475	5
1002	Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer. 2018 , 2018, 3508795	21
1001	Nomogram for preoperative prediction of nodal extracapsular extension or positive surgical margins in oropharyngeal squamous cell carcinoma. 2018 , 83, 73-80	7
1000	Two Sides of the Same Coin: Head and Neck Cancer Treatment De-Intensification and Intensification with Induction Chemotherapy. 2018 , 102, 1-4	2
999	Transoral Robotic Surgery for Oropharyngeal Cancer. 2018 , 80, 156-170	4
998	Importance of magnesium sulfate supplementation in the prevention of hypomagnesemia and hypocalcemia during chemoradiation in head and neck cancer. 2018 , 50, 327-331	3

997	Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma. 2018 , 13, e0200137		44
996	Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: Radiotherapy target volume transformation and dose de-escalation. <i>Radiotherapy and Oncology</i> , 2018 , 128, 472-478	5-3	18
995	Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. 2018 , 15, 7497-7505		38
994	A snapshot of the evolving epidemiology of oropharynx cancers. 2018 , 124, 2893-2896		18
993	Standardtherapie von Plattenepithelkarzinomen der Mundhöhle gem Leitlinien. 2018 , 11, 5-14		2
992	Cavernous sinus involvement in human papillomavirus associated oropharyngeal squamous cell carcinoma: case report of an atypical site of distant metastasis. 2018 , 47, 32		2
991	Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018 , 129, 575-581	5-3	11
990	[Surgery or radiotherapy for oropharyngeal HPV-positive tumours?]. 2018 , 22, 481-486		0
989	Cancers of the Oral Cavity: Diagnosis and Treatment. 2018 ,		
988	Induction chemotherapy in patients with resectable laryngeal cancer: A meta-analysis. 2018 , 9, 155-162		9
987	Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report. 2018 , 9, 1769		10
986	[Hypofractionad radiotherapy for elderly with head and neck cancer]. 2018 , 22, 640-643		5
985	Unilateral cochlea sparing in locoregionally advanced head and neck cancer: a planning study. 2018 , 194, 1124-1131		1
984	Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives. 2018 , 83, 1-10		13
983	Outcomes of Patients With Sinonasal Squamous Cell Carcinoma Treated With Particle Therapy Using Protons or Carbon Ions. 2018 , 101, 1096-1103		11
982	Chemotherapy. 2018 , 291-313		
981	Early Floor of Mouth Cancer. 2018 , 420-427		
980	Advanced Oromandibular Cancer. 2018 , 475-531		

979	Lip Cancer. 2018 , 608-625		1
978	Early HPV-Related Tonsil Cancer. 2018 , 628-648		
977	Advanced HPV-Related Oropharynx Cancer. 2018 , 677-699		
976	Advanced HPV-Unrelated Pharynx Cancer. 2018 , 700-760		
975	Soft Palate Cancer. 2018 , 761-773		
974	Advanced Supraglottic Larynx Cancer. 2018 , 785-798		
973	A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx. 2018 , 41, 129-136		14
972	Locoregional Control and Toxicity in Head and Neck Carcinoma Patients following Helical Tomotherapy-Delivered Intensity-Modulated Radiation Therapy Compared with 3D-CRT Data. 2018 , 95, 61-68		7
971	Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study. 2018 , 13, e0198391		4
970	Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. 2018 , 13, e0194841		5
969	Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. 2018 , 39, 642-645		26
968	Reconstruction of oropharyngeal defects after transoral robotic surgery. Review and recommendations of the Commission of Head and Neck Surgery of the Spanish Society of Otolaryngology and Head and Neck Surgery. 2019 , 70, 235-244		3
967	The impact of margin reduction on outcome and toxicity in head and neck cancer patients treated with image-guided volumetric modulated arc therapy (VMAT). <i>Radiotherapy and Oncology</i> , 2019 , 130, 25-31	5-3	42
966	Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. 2019 , 25, 7078-7088		9
965	Patterns of utilization and comparative efficacy of altered fractionation and concurrent chemoradiation for treatment for T2N0M0 glottic carcinoma. 2019 , 8, 267-278		
964	Three-dimensional conformal radiotherapy versus intensity modulated radiotherapy with simultaneous integrated boost in the treatment of locally advanced head and neck carcinoma. 2019 , 66, 830-838		5
963	Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study. 2019 , 64, 48-56		3
962	CTX-Induktion gefolgt von Cetuximab und Bestrahlung nicht effektiver als simultane RCT. 2019 , 22, 27-29		

961	Laryngo-esophageal dysfunction free survival and propensity score matched analysis comparing organ preservation and total laryngectomy in hypopharynx cancer. 2019 , 95, 143-149	2
960	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). 2019 , 7, 184	223
959	Difficult Decisions in Head and Neck Oncologic Surgery. 2019 ,	1
958	Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. 2019 , 161, 635-642	12
957	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. 2019 , 95, 106-114	11
956	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. 2019 , 118, 112-120	5
955	Reconstruction of Oropharyngeal Defects After Transoral Robotic Surgery. Review and Recommendations of the Commission of Head and Neck Surgery of the Spanish Society of Otolaryngology and Head and Neck Surgery. 2019 , 70, 235-244	0
954	The Effects of Yoga in Helping Cancer Patients and Caregivers Manage the Stress of a Natural Disaster: A Brief Report on Hurricane Harvey. 2019 , 18, 1534735419866923	5
953	Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice. 2019 , 9, 464	28
952	Definitive radiotherapy vs. postoperative radiotherapy for lower gingival carcinomas of the mandible : A single-center report about outcome and toxicity. 2019 , 195, 819-829	6
951	Radiation therapy for elderly patients with uterine cervical cancer: feasibility of curative treatment. 2019 , 29, 622-629	4
950	nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma. 2019 , 36, 93	3
949	Clinical outcome and toxicity after simultaneous integrated boost IMRT in head and neck squamous cell cancer patients. 2019 , 98, 132-140	9
948	The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer. 2019 , 98, 48-52	6
947	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology). 2019 , 9, 1127	
946	Nanotechnology in Oral Cavity Carcinoma: Recent Trends and Treatment Opportunities. 2019 , 9,	3
945	XRCC1 (rs25487) polymorphism is associated with severe oral mucositis and poor treatment response after radiotherapy for oropharyngeal carcinoma. 2019 , 3, 37-47	1
944	Immunotherapy in head and neck cancer: The great challenge of patient selection. 2019 , 144, 102829	7

943	The 100 most cited manuscripts in head and neck cancer: a bibliometric analysis. 2019 , 133, 936-942	6
942	Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. 2019 , 121, 897-903	14
941	Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma. 2019 , 20,	19
940	Identification of inflammatory mediators associated with metastasis of oral squamous cell carcinoma in experimental and clinical studies: systematic review. 2019 , 36, 481-492	4
939	Efficacy and Feasibility of Salvage Re-Irradiation with CyberKnife for In-Field Neck Lymph Node Recurrence: A Retrospective Study. 2019 , 8,	
938	Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. 2019 , 19, 1066	8
937	Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence. 2019 , 99, 104472	3
936	Physician And Patient Barriers To Radiotherapy Service Access: Treatment Referral Implications. 2019 , 11, 8829-8833	6
935	Head and Neck Cancer. 2019 , 230-240	
934	Addition of S-1 to radiotherapy for treatment of T2N0 glottic cancer: Results of the multiple-center retrospective cohort study in Japan with a propensity score analysis. 2019 , 99, 104454	
933	Evaluation of oncologic outcomes in head and neck cancer patients 80 years old based on adherence to NCCN guideline for postoperative adjuvant treatment. 2019 , 41, 4128-4135	3
932	Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study. 2019 , 123, 36-47	10
931	Deep learning-based model for predicting progression in patients with head and neck squamous cell carcinoma. 2020 , 27, 19-28	8
930	Changing functional status within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology Study. 2019 , 41, 3924-3932	4
929	Partial pharyngolaryngectomy with infrahyoid flap: Our experience. 2019 , 40, 102271	1
928	A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy. 2019 , 129, 404-412	15
927	Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?. 2019 , 37, 2807-2814	3
926	Are Individual patient data meta-analyses still needed today in oncology? A discussion focused on Head and Neck oncology. 2019 , 58, 1333-1336	2

925	Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. 2019 , 11,	20
924	Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. 2019 , 9, 815	31
923	Lymphocyte Count Kinetics, Factors Associated with the End-of-Radiation-Therapy Lymphocyte Count, and Risk of Infection in Patients with Solid Malignant Tumors Treated with Curative-Intent Radiation Therapy. 2019 , 105, 812-823	12
922	Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. 2019 , 3, pkz055	18
921	A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. 2019 , 58, 1495-1501	14
920	Quality of Life Outcomes Following Organ-Sparing SBRT in Previously Irradiated Recurrent Head and Neck Cancer. 2019 , 9, 836	13
919	[Individualization of dose and fractionation of radiotherapy for head and neck cancers]. 2019 , 23, 784-788	
918	18 Carcinoma of the Salivary Glands. 2019 ,	
917	Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis. 2019 , 195, 1041-1049	11
916	Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer. 2019 , 97, 18-22	3
915	Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. 2019 , 19, 901	20
914	Head and Neck Tumors. 2019 , 627-762	
913	Head and Neck Cancers. 2019 , 133-196	
912	[The end of TPF induction for locally advanced head and neck cancer? Induction chemotherapy followed by cetuximab and radiotherapy is not superior to concurrent chemoradiotherapy]. 2019 , 195, 281-284	
911	Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma. 2019 , 24, 640-648	7
910	Comparing the patients' subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires. 2019 , 58, 603-609	12
909	A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. 2019 , 48, 4	17
908	Absolute Clinical Radiation Oncology Review. 2019 ,	2

907	[Immuno-oncology of head and neck tumors]. 2019 , 67, 221-235	1
906	Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide. 2019 , 103, 1151-1157	11
905	The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. 2019 , 41, 2271-2276	6
904	Head and Neck Cancers. 2019 , 43-99	
903	Impact of smoking cessation on clinical outcomes in patients with head and neck squamous cell carcinoma receiving curative chemoradiotherapy: A prospective study. 2019 , 41, 3201-3210	3
902	[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status]. 2019 , 23, 273-280	7
901	Current concepts and novel techniques in the prosthodontic management of head and neck cancer patients. 2019 , 226, 725-737	5
900	The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective. 2019 , 17, 47-50	13
899	Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer. 2019 , 13, 1927-1943	7
898	Induction chemotherapy in head and neck cancers: Results and controversies. 2019 , 95, 164-169	27
897	Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. 2019 , 116, 67-76	29
896	Benefits of deep learning for delineation of organs at risk in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2019 , 138, 68-74	5-3 39
895	Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D. 2019 , 195, 771-779	23
894	A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. 2019 , 125, 3184-3197	42
893	Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC). 2019 , 94, 93-100	6
892	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. 2019 , 25, 4955-4965	16
891	The changing therapeutic landscape of head and neck cancer. 2019 , 16, 669-683	195
890	Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma. 2019 , 36, 68	4

889	Open the Gates for Treatment De-Intensification in Head and Neck Cancer. 2019 , 37, 1854-1855		
888	cytotoxic and apoptotic induction effect of earthworm coelomic fluid of and on human oral squamous cell carcinoma-9 cell line. 2019 , 6, 347-357		15
887	Organ Function Preservation Failure after (Chemo)Radiotherapy in Head and Neck Cancer: A Retrospective Cohort Analysis. 2019 , 161, 288-296		2
886	Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?. 2019 , 39, 364-372		24
885	Integration of Checkpoint Inhibitors into the Management of Locally Advanced Head and Neck Cancer - Future Perspectives. 2019 , 31, 424-431		
884	Cost-minimization analysis of GSTP1c.313A>G genotyping for the prevention of cisplatin-induced nausea and vomiting: A Bayesian inference approach. 2019 , 14, e0213929		3
883	Undertreatment of women with locoregionally advanced head and neck cancer. 2019 , 125, 3033-3039		16
882	Sentinel lymph node biopsy for management of the N0 neck in oral cavity squamous cell carcinoma. 2019 , 120, 101-108		7
881	The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. <i>Radiotherapy and Oncology</i> , 2019 , 137, 117-124	5-3	48
880	Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study). 2019 , 11,		8
879	Platinum rechallenge in recurrent head and neck squamous cell carcinoma after primary chemoradiation. 2019 , 136, 257-261		3
878	Failure of Concurrent Chemoradiotherapy for Organ Preservation in Laryngeal Cancer: Survival Outcomes and Recurrence Patterns. 2019 , 98, E92-E96		2
877	Interobserver variability in delineation of target volumes in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2019 , 137, 9-15	5-3	23
876	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?. 2019 , 11,		22
875	Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. 2019 , 276, 1275-1281		9
874	Quality insurance in head and neck cancer multidisciplinary team meetings: A watchful eye on real-life experience. 2019 , 91, 35-38		5
873	Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. 2019 , 41, 2591-2601		12
872	Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden. 2019 , 30, 744-756		46

871	Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in cancer stem cell heterogeneity, plasticity and treatment response. <i>Radiotherapy and Oncology</i> , 2019 , 135, 1-12	5-3	14
870	A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. 2019 , 24, 751-e231		10
869	Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. 2019 , 41, 2484-2491		23
868	Guidelines in the Management of Advanced Carcinoma of the Larynx. 2019 , 77-98		
867	General Principles of Head and Neck Cancer Treatment. 2019 , 3-14		
866	Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma. 2019 , 41, 2492-2499		4
865	The occurrence of cervical metastases in squamous cell carcinoma of the tongue: Is there a rationale for bilateral neck dissection in early-stage tumors?. 2019 , 47, 1134-1138		7
864	Perineural Invasion and Perineural Tumor Spread in Head and Neck Cancer. 2019 , 103, 1109-1124		62
863	Obstetrical Outcomes of Head and Neck (Nonthyroid) Cancers: A 27-Year Retrospective Series and Literature Review. 2019 , 9, e15-e22		3
862	Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. 2019 , 120, 1003-1006		69
861	Larynx Preservation in Hypopharyngeal Carcinomas. 2019 , 163-177		
860	Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC). 2019 , 8, 2730-2739		4
859	Behandlungsstrategien beim Oropharynxkarzinom. 2019 , 25, 210-223		
858	Predictive value of computed tomography in identifying extracapsular spread of cervical lymph node metastases in p16 positive oropharyngeal squamous cell carcinoma. 2019 , 63, 500-509		9
857	Perspectives of Induction With Chemo and/or Immune Check Point Inhibition in Head and Neck Organ Preservation Treatment. 2019 , 9, 191		10
856	Acute and Long-Term Effects of Chemoradiation Therapy in Head and Neck Cancer. 2019 , 331-349		1
855	Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy. 2019 , 11,		12
854	Organ preservation for patients with anterior mucosal squamous cell carcinoma of the nasal cavity: Rhinectomy-free survival in those refusing surgery. 2019 , 41, 2741-2747		5

853	Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck. 2019 , 9, 155	11
852	The Clinical Outcomes of Locally Advanced Cervical Esophageal Squamous Cell Carcinoma Patients Receiving Curative Concurrent Chemoradiotherapy: A Population-Based Propensity Score-Matched Analysis. 2019 , 11,	4
851	Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. 2019 , 139, 201-205	7
850	A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEX) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study). 2019 , 9, 6	5
849	Evolution of self-perceived swallowing function, tongue strength and swallow-related quality of life during radiotherapy in head and neck cancer patients. 2019 , 41, 2197-2207	10
848	The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review. 2019 , 41, 2410-2429	12
847	Primäre und adjuvante Radio(chemo)therapie bei Kopf-Hals-Tumoren. 2019 , 25, 240-245	1
846	Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer. 2019 , 24, 789-797	7
845	FDG-PET/CT improves detection of residual disease and reduces the need for examination under anaesthesia in oropharyngeal cancer patients treated with (chemo-)radiation. 2019 , 276, 1447-1455	2
844	Adverse Cochlear Effects After Head and Neck Cancer Therapy. 2019 , 71, 740-747	1
843	Carcinoma of the Larynx and Hypopharynx. 2019 ,	1
842	3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis. 2019 , 14, 32	22
841	Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience. 2019 , 14, 34	6
840	How I treat squamous ENT cancer. 2019 , 4, e000542	3
839	A retrospective analysis of the treatment results for advanced synchronous head and neck and esophageal cancer. 2019 , 1, 20190015	
838	Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation. 2019 , 25, 6035-6043	1
837	A Hidden Epidemic of "Intermediate Risk" Oropharynx Cancer. 2019 , 4, 617-623	5
836	Radiation-activated prosurvival signaling pathways in cancer cells. 2019 , 3, 111-120	3

835	11 Open Management of Carcinoma of the Oropharynx. 2019,	
834	14 Carcinoma of the Hypopharynx. 2019,	
833	Rechallenge en sels de platine aprs radiochimiothrapie pour les rcdives de carcinome bidermoile des voies afodigestives suprieures. 2019, 136, 255-260	
832	Anatomic Landmarks in Transoral Oropharyngeal Surgery. 2019, 30, e101-e106	3
831	A challenging presentation of invasive nasopharyngeal sarcomatoid carcinoma. 2019, 12,	
830	Mechanisms of different response to ionizing irradiation in isogenic head and neck cancer cell lines. 2019, 14, 214	10
829	Locally advanced non-melanomatous skin cancer: Contemporary radiotherapeutic management. 2019, 99, 104443	5
828	Current Standards for Organ Preservation in Locoregionally Advanced Non-nasopharyngeal Head and Neck Cancer and Evolving Strategies for Favorable-Risk and Platinum-Ineligible Populations. 2019, 20, 89	2
827	Comparative effectiveness of simultaneous integrated boost vs sequential intensity-modulated radiotherapy for oropharyngeal or hypopharyngeal cancer patients: A population-based propensity score-matched analysis. 2019, 98, e18474	2
826	Patologil neoplilica de la vll aerodigestiva superior. 2019, 12, 5352-5363	
825	Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy. 2019, 19, 1241	6
824	Treatment of inoperable elderly head and neck cancer patients. 2019, 31, 152-159	6
823	Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck. 2019 , 31, 146-151	17
822	Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice. 2019, 27, 142-150	16
821	Development of Normal Tissue Complication Probability Model for Trismus in Head and Neck Cancer Patients Treated With Radiotherapy: The Role of Dosimetric and Clinical Factors. 2019, 39, 6787-6798	3
820	Comparative Study of Antitumor Activity between Lipophilic Bismuth Nanoparticles (BisBAL NPs) and Chlorhexidine on Human Squamous Cell Carcinoma. 2019, 2019, 1-8	2
819	Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy. 2019, 25, 7256-7265	14
818	Competing Morbidities In Advanced Head And Neck Squamous Cell Carcinoma Concurrent Chemoradiotherapy: A Strong Implication Of A Multidisciplinary Team Approach. 2019, 11, 9771-9782	0

817	11 Locally Intermediate Glottic Cancer: Chemoradiotherapy. 2019 ,		
816	Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy. <i>Radiotherapy and Oncology</i> , 2019 , 130, 89-96	53	17
815	Cancers of the Head and Neck. 2019 , 103-114		
814	Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma. 2019 , 13, 304-312		6
813	Utility of response assessment PET-CT to predict residual disease in neck nodes: A comparison with the Histopathology. 2019 , 46, 599-604		1
812	Elderly Patients with Advanced Head and Neck Carcinoma: Does Aggressive Treatment Result in Better Outcomes?. 2019 , 160, 642-650		3
811	Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. 2019 , 160, 1023-1033		11
810	Prediction of distant metastases in patients with squamous cell carcinoma of head and neck using DWI and DCE-MRI. 2020 , 42, 3295-3306		3
809	Comparing the prevalence, location, and severity of head and neck lymphedema after postoperative radiotherapy for oral cavity cancers and definitive chemoradiotherapy for oropharyngeal, laryngeal, and hypopharyngeal cancers. 2020 , 42, 3364-3374		3
808	Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy. 2020 , 21,		8
807	Immunotherapy for squamous cell carcinoma of the head and neck. 2020 , 50, 1089-1096		13
806	Evaluating Adjuvant Therapy With Chemoradiation vs Radiation Alone for Patients With HPV-Negative N2a Head and Neck Cancer. 2020 , 146, 1109-1119		5
805	A monocentric, open-label randomized standard-of-care controlled study of XONRID [®] , a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients. 2020 , 15, 193		0
804	Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. 2020 , 10, 1284		4
803	Review of clinical applications of radiation-enhancing nanoparticles. 2020 , 28, e00548		5
802	Câncer de laringe. 2020 , 49, 1-18		
801	Câncer de hipofaringe. 2020 , 49, 1-20		
800	Resource-sparing curative-intent hypofractionated-accelerated radiotherapy in head and neck cancer: More relevant than ever before in the COVID era. 2020 , 111, 105045		5

799	Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial. 2020 , 10, 16634	5
798	Phase II study of de-intensified intensity-modulated radiotherapy and concurrent carboplatin/5-fluorouracil in lateralized p16-associated oropharyngeal carcinoma. 2020 , 42, 3479-3489	1
797	Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study. 2020 , 20, 832	2
796	Prediction of Therapeutic Effects from One Course of TPF Chemotherapy for Advanced Hypopharyngeal Laryngeal Cancer. 2020 , 34, 2891-2896	1
795	Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis. 2020 , 99, e21785	1
794	Deeskalation der multimodalen Therapie von Kopf-Hals-Karzinomen. 2020 , 15, 346-361	
793	How Should We Approach Locally Advanced Squamous Cell Carcinoma of Head and Neck Cancer Patients Ineligible for Standard Non-surgical Treatment?. 2020 , 22, 118	3
792	Transoral robotic surgery in head and neck cancer. 2020 , 13, 385-388	0
791	Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial. 2020 , 15, 218	13
790	Human Bone Marrow Mesenchymal Stem Cells Modified Hybrid Baculovirus-Adeno-Associated Viral Vectors Targeting I Therapy of Hypopharyngeal Carcinoma. 2020 , 31, 1300-1311	1
789	Cancri della laringe. 2020 , 19, 1-16	
788	Chemioterapia e terapie mirate in oto-rino-laringoiatria. 2020 , 19, 1-6	
787	Comparative efficacy and safety of radiotherapy/cetuximab radiotherapy/chemotherapy for locally advanced head and neck squamous cell carcinoma patients: a systematic review of published, primarily non-randomized, data. 2020 , 12, 1758835920975355	3
786	Change in Age at Diagnosis of Oropharyngeal Cancer in the United States, 1975-2016. 2020 , 12,	3
785	Validity of Toluidine Blue test as a diagnostic tool for high risk oral potentially malignant disorders- a multicentre study in Sri Lanka. 2020 , 10, 547-551	5
784	Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases. 2020 , 24, 812-819	3
783	Outcomes and prognosticators in regionally recurrent cutaneous squamous cell carcinoma of the head and neck. 2020 , 46, 2035-2041	2
782	Enhancement of Cisplatin Cytotoxicity by Cu(II)-Mn(II) Schiff Base Tetradentate Complex in Human Oral Squamous Cell Carcinoma. 2020 , 25,	3

781 Câncer de orofaringe. **2020**, 49, 1-18

780 Faisabilité de la radiochimiothérapie postopératoire des carcinomes épidermoïdes des voies aérodigestives supérieures à haut risque de récurrence en pratique quotidienne. **2020**, 137, 337-341

779 Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas. **2020**, 107, 793-803 4

778 Prognostic impact of indoleamine 2,3-dioxygenase 1 mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma. **2020**, 5, e000646 9

777 Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial. *Radiotherapy and Oncology*, **2020**, 150, 18-25 5.3 10

776 Plasma medical oncology: Immunological interpretation of head and neck squamous cell carcinoma. **2020**, 17, 1900258 10

775 Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. **2020**, 38, 2427-2437 48

774 Lesioni maligne del velo palatino. **2020**, 19, 1-19

773 Single-Center Prospective Trial Investigating the Feasibility of Serial FDG-PET Guided Adaptive Radiation Therapy for Head and Neck Cancer. **2020**, 108, 960-968 5

772 Predicting toxicity for head and neck cancer patients undergoing radiation therapy: an independent and external validation of MDASI-HN based nomogram. **2020**, 25, 355-359

771 Positron Emission Tomography-Computed Tomography Surveillance after (Chemo)Radiotherapy in Advanced Head and Neck Squamous Cell Cancer: Beyond the PET-NECK Protocol. **2020**, 32, 665-673 1

770 Regular Ol' Intensity. **2020**, 107, 615

769 To Shy Away From Chemotherapy Is to Compromise. **2020**, 107, 616-617

768 Expression Analysis of and in Head and Neck Squamous Cell Carcinoma. **2020**, 12, 4085-4096 1

767 Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. **2020**, 126, 3426-3437 19

766 Eph/ephrin family proteins and therapeutic resistance. **2020**, 193-220

765 Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method. **2020**, 7, 218 2

764 Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. **2020**, 10, 761 6

763	The Pre-Treatment C-Reactive Protein Represents a Prognostic Factor in Patients with Oral and Oropharyngeal Cancer Treated with Radiotherapy. 2020 , 12,	5
762	Cetuximab and Radiation Therapy Versus Cisplatin and Radiation Therapy for Locally Advanced Head and Neck Cancer: Long-Term Survival and Toxicity Outcomes of a Randomized Phase 2 Trial. 2020 , 107, 469-477	7
761	Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma. 2020 , 147, 1732-1739	3
760	The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC. 2020 , 5, 4	14
759	B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. 2020 , 26, 3345-3359	45
758	Evaluation of Contrast-Enhanced Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) in the Detection of Retropharyngeal Lymph Node Metastases in Nasopharyngeal Carcinoma Patients. 2020 , 12, 1733-1739	2
757	The impact of Coronavirus (COVID-19) on head and neck cancer patients' care. <i>Radiotherapy and Oncology</i> , 2020 , 147, 84-85	5-3 47
756	Prognostic value of a 15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy. 2020 , 196, 552-560	3
755	Lesiones malignas del velo del paladar. 2020 , 49, 1-20	
754	Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?. 2020 , 107, 104860	1
753	Most Cited Articles in Head and Neck Oncology. 2021 , 100, 10615-10725	
752	Prognostic factors for lymphedema in patients with locally advanced head and neck cancer after combined radio(chemo)therapy- results of a longitudinal study. 2020 , 109, 104856	2
751	High Dose Cisplatin: Still the One?. 2020 , 107, 615-616	1
750	Penn Medicine Head and Neck Cancer Service Line COVID-19 management guidelines. 2020 , 42, 1507-1515	8
749	The 5-Ws of immunotherapy in head and neck cancer. 2020 , 153, 103041	7
748	Affective symptoms and swallow-specific quality of life in total laryngectomy patients. 2020 , 42, 3179-3187	8
747	Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer. 2020 , 106, 939-947	1
746	Chemotherapy in the definitive management of oral cancers: Where do we stand today?. 2020 , 102, 104584	5

745	From Anemia to Erythropoietin Resistance in Head and Neck Squamous Cell Carcinoma Treatment: A Carousel Driven by Hypoxia. 2020 , 13, 841-851	5
744	Volume de-escalation in radiation therapy: state of the art and new perspectives. 2020 , 146, 909-924	11
743	Clinical Significance of Vulnerability Assessment in Patients with Primary Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiation Therapy. 2020 , 108, 602-611	9
742	Synergistic effect of cisplatin chemotherapy combined with fractionated radiotherapy regimen in HPV-positive and HPV-negative experimental pharyngeal squamous cell carcinoma. 2020 , 10, 1563	5
741	Outcomes of curative (chemo)radiotherapy for patients with non-p16 positive head and neck squamous cell carcinoma who are borderline for curative treatment. 2020 , 64, 271-278	0
740	The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy - A Single Institution Experience. 2020 , 12, 1047-1067	5
739	The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality. 2020 , 10, 7	15
738	Systematic use of patient reported outcome during radiotherapy for head and neck cancer: study protocol for the national DAHANCA 38 trial. 2020 , 59, 603-607	4
737	Outcomes for Elderly Patients Aged 70 to 80 Years or Older with Locally Advanced Oral Cavity Squamous Cell Carcinoma: A Propensity Score-Matched, Nationwide, Oldest Old Patient-Based Cohort Study. 2020 , 12,	10
736	Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. 2020 , 42, 1728-1737	1
735	CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer. 2020 , 10, 243	4
734	Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?. 2020 , 15, 31	26
733	Integrated Non-targeted and Targeted Metabolomics Uncovers Amino Acid Markers of Oral Squamous Cell Carcinoma. 2020 , 10, 426	12
732	Harnessing data science to advance radiation oncology. 2020 , 14, 1514-1528	7
731	Salivary microRNAs identified by small RNA sequencing as potential predictors of response to intensity-modulated radiotherapy in head and neck cancer patients. 2020 , 43, 505-511	3
730	[Treatment de-intensification strategies for HPV-driven oropharyngeal cancer: A short review]. 2020 , 24, 258-266	1
729	Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives?. 2020 , 32, 196-202	2
728	Targeted Photodynamic Therapy of Human Head and Neck Squamous Cell Carcinoma with Anti-epidermal Growth Factor Receptor Antibody Cetuximab and Photosensitizer IR700DX in the Mouse Skin-fold Window Chamber Model. 2020 , 96, 708-717	10

727	Three-Dimensional Printed Silicone Bite Blocks for Radiotherapy of Head and Neck Cancer: Preliminary Study. 2020 , 10, 1688	4
726	Comparison of 50- and 66-Gy total irradiation doses for postoperative cervical treatment of patients with oral squamous cell carcinoma. 2020 , 107, 104708	3
725	A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. 2020 , 59, 895-903	6
724	Carcinomas of the lacrimal drainage system. 2020 , 65, 691-707	9
723	Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. 2020 , 42, 2137-2144	1
722	Combining Chk1/2 inhibition with radiation in head and neck cancer. 2020 , 301-316	
721	Routine feasibility of postoperative chemoradiotherapy in head and neck squamous cell carcinoma at high risk of recurrence. 2020 , 137, 371-375	0
720	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. 2020 , 107, 618-627	107
719	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. 2020 , 10, 363-371	3
718	Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer. 2020 , 18, 167	17
717	Patterns of regional lymph node failure of locally advanced hypopharyngeal squamous cell carcinoma after first-line treatment with surgery and/or intensity-modulated radiotherapy. 2020 , 20, 283	3
716	Factors associated with the receipt and completion of whole brain radiation therapy among older adults in the United States from 2010-2013. 2020 , 11, 1096-1102	2
715	Prediction of radiation-induced mucositis of H&N cancer patients based on a large patient cohort. <i>Radiotherapy and Oncology</i> , 2020 , 147, 15-21	5-3 6
714	Primary Advanced Squamous Cell Carcinoma of the Temporal Bone: A Single-Center Clinical Study. 2021 , 131, E583-E589	11
713	Obstructive sleep apnea in head and neck cancer survivors. 2021 , 29, 279-287	4
712	A qualitative examination of patient priorities and preferences during treatment decision-making for recurrent head and neck cancer. 2021 , 29, 377-385	1
711	Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin. 2021 , 29, 877-887	3
710	A prospective nutritional assessment using Mini Nutritional Assessment-short form among patients with head and neck cancer receiving concurrent chemoradiotherapy. 2021 , 29, 1509-1518	2

709	Prognostic significance of extranodal extension in oral cavity squamous cell carcinoma with occult neck metastases. 2021 , 50, 309-315		8
708	Management of loco-regionally advanced squamous laryngeal cancer in elderly patients. 2021 , 278, 771-779		1
707	Effects of early nutritional intervention by a nutritional support team for patients with head and neck cancer undergoing chemoradiotherapy or radiotherapy. 2021 , 43, 514-519		2
706	A real-world comparison of cisplatin vs cetuximab used concurrently with radiation in the treatment of locally advanced oropharyngeal carcinoma. 2021 , 43, 153-163		
705	Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. 2021 , 26, 40-48		17
704	ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. 2021 , 39, 38-47		22
703	[De-escalation concepts for chemoradiotherapy of HPV-positive oropharyngeal carcinomas: pros and cons]. 2021 , 69, 278-284		1
702	Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation. <i>Radiotherapy and Oncology</i> , 2021 , 154, 276-282	5-3	8
701	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. 2021 , 39, 136-144		17
700	Treating Advanced Head and Neck Cancer When Cisplatin Is Not an Option. 2021 , 39, 7-12		1
699	Clinical characteristics, treatment intent, and outcome in a consecutive 10-year cohort of oral cancer patients aged 75 years and older. 2021 , 59, 303-311		0
698	Applications of FDG PET in Oncology. 2021 ,		
697	Concomitant weekly cisplatin-based chemoradiotherapy in head and neck cancer: the value of a second measured glomerular filtration rate during treatment. 2021 , 94, 20200717		0
696	Combination therapy with lenvatinib and radiation significantly inhibits thyroid cancer growth by uptake of tyrosine kinase inhibitor. 2021 , 398, 112390		8
695	External validation of nodal failure prediction models including radiomics in head and neck cancer. 2021 , 112, 105083		4
694	Definitive intensity-modulated radiotherapy or surgery for early oral cavity squamous cell carcinoma: Propensity-score-matched, nationwide, population-based cohort study. 2021 , 43, 1142-1152		4
693	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. 2021 , 127, 1228-1237		0
692	European white paper: oropharyngeal dysphagia in head and neck cancer. 2021 , 278, 577-616		16

691	Evolving multidisciplinary treatment of squamous cell carcinoma of the head and neck in India. 2021 , 26, 100269		0
690	Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists. 2021 , 6, 100608		1
689	Oropharyngeal cancer and osteoradionecrosis in a novel radiation era: a single institution analysis. 2021 , 14, 113-121		8
688	Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project. 2021 , 43, 601-612		7
687	Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2021 , 26, 51-58		
686	Reprint of "Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up". 2021 , 113, 105042		3
685	Oncological therapy to Swedish men with metastatic penile cancer 2000-2015. 2021 , 60, 42-49		0
684	Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial. 2021 , 23, 764-772		7
683	Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study. <i>Radiotherapy and Oncology</i> , 2021 , 154, 76-86	5-3	2
682	Management of Oral Cancers. 2021 ,		
681	Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection. 2021 , 131, E846-E850		1
680	Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. <i>Radiotherapy and Oncology</i> , 2021 , 154, 70-75	5-3	6
679	Evaluation of survival of patients with locally advanced head and neck cancer treated in a single center. 2021 , 87, 3-10		4
678	Single modality radical radiotherapy is an acceptable alternative for the older patient with squamous cell carcinoma of the oesophagus. 2021 , 8,		
677	MicroRNA-133 Targets in and Human Oral Cancer Cells to Regulate Epithelial-Mesenchymal Transition. 2021 , 12, 5296-5309		1
676	Circulating Tumor Cells in Head and Neck Cancer. 2021 , 27-45		
675	Head and neck cancer: Current challenges and future perspectives. 2021 , 152, 67-102		6
674	Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer. 2021 ,		

673	Correlation between imaging and tissue biomarkers of hypoxia in squamous cell cancer of the head and neck. 2021 , 20, 228-236	1
672	Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. 2021 , 13,	23
671	Nanotechnology for Diagnosis, Imaging, and Treatment of Head and Neck Cancer. 2021 , 63-120	0
670	Moderately Hypofractionated Intensity-modulated Radiotherapy With a Simultaneous Integrated Boost for Locally Advanced Head and Neck Cancer - Do Modern Techniques Fulfil Their Promise?. 2021 , 35, 2801-2808	0
669	Results of implementation of a program of individual support of chemoradiation therapy in patients with head and neck tumors. 2021 , 10, 60-73	1
668	Radioterapia de los cánceres otorrinolaringológicos. 2021 , 50, 1-11	
667	Comparison of Conventional Fractionation and Accelerated Fractionation With Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer. 2021 , 35, 411-415	1
666	Divergent Roles of Induction Chemotherapy in Patients with Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Population-Based Matched Cohort Study.	
665	Re-Irradiation for Local Relapses or Second Primaries: When and how?. 2021 , 247-275	
664	Variation of treatment decision-making for laryngeal cancer in Japan a retrospective observational study using a claim- and electronic medical record-based database. 2021 , 3, 88-95	
663	Predicting the efficacy of chemoradiotherapy for locally advanced human papilloma virus-related oropharyngeal squamous cell carcinoma using one course of TPF chemotherapy. 2021 , 278, 3497-3506	
662	Larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction: A promising treatment for selected cervical esophageal squamous cell carcinoma. 2020 , 31, 948-954	
661	Prognostic factors on surgically and non-surgically treated oral squamous cell carcinoma: Advances in survival in fifteen years of follow up. 2021 , 13, e240-e249	0
660	New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era. 2021 , 10,	2
659	Paciente gran superviviente con cáncer de cabeza y cuello metastásico y tratamiento con inmunoterapia. 2021 , 13, 1429.e1-1429.e3	
658	Efficacy of second and subsequent lines of chemotherapy for recurrent and metastatic head and neck cancer. 2021 , 48, 161-165	
657	Role of Non-coding RNAs on the Radiotherapy Sensitivity and Resistance of Head and Neck Cancer: From Basic Research to Clinical Application. 2020 , 8, 637435	1
656	Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes. 2021 , 127, 1984-1992	1

- 655 Microscopic Extranodal Extension in HPV-Negative Head and Neck Cancer and the Role of Adjuvant Chemoradiation. **2021**, 165, 536-549
- 654 Cáncer de cabeza y cuello. **2021**, 13, 1393-1401
- 653 Prognostic Factors Predict Oncological Outcome in Older Patients With Head and Neck Cancer Undergoing Chemoradiation Treatment. **2020**, 10, 566318 1
- 652 Radiotherapy for locally advanced head and neck cancer in elderly patients: results and prognostic factors a single cohort. **2021**, 26, 12-19
- 651 Quality metrics for head and neck cancer treated with definitive radiotherapy and/or chemotherapy. **2021**, 43, 1788-1796 1
- 650 Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. **2021**, 43, 1641-1651 1
- 649 Prospective Evaluation of Sarcopenia in Head and Neck Cancer Patients Treated with Radiotherapy or Radiochemotherapy. **2021**, 13, 3
- 648 Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. **2021**, 43, 1592-1603 0
- 647 Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer center. **2021**, 149, 139-148 1
- 646 Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. **2021**, 23, 1801-1810 2
- 645 Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. **2021**, 146, 135-144 4
- 644 Nanomedicine in Cancer Clinics: Are We There Yet?. **2021**, 9, 43-55 9
- 643 Statistical fundamentals on cancer research for clinicians: Working with your statisticians. **2021**, 27, 75-84 1
- 642 A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. **2021**, 114, 105171 6
- 641 Cancro dell'ipofaringe. **2021**, 20, 1-19
- 640 The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry. **2021**, 127, 2453-2464 2
- 639 Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. **2021**, 36, S217-S224 3
- 638 Cellular SPION Uptake and Toxicity in Various Head and Neck Cancer Cell Lines. **2021**, 11, 3

637	Induction Chemotherapy Plus Simultaneous Modulated Accelerated Radiation Therapy in Non-operative Hypopharyngeal and Supraglottic Laryngeal Squamous Cell Carcinoma: Long-Term Outcome of a Prospective Phase 2 Study. 2021 , 11, 637978			1
636	Risk factors for distant metastasis in locoregionally controlled oral squamous cell carcinoma: a retrospective study. 2021 , 11, 5213			3
635	Distant Metastasis in Carcinoma Oral Cavity: Incidence and Prognostic Factors. 2021 , 42, 046-050			
634	Radioterapia dei cancri oto-rino-laringoiatrici. 2021 , 20, 1-10			
633	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , 2021 , 156, 281-293 ⁵⁻³			34
632	Excision repair cross-complementing group 2 upregulation is a potential predictive biomarker for oral squamous cell carcinoma recurrence. 2021 , 21, 450			0
631	Change in Physical Performance Correlates with Decline in Quality of Life and Frailty Status in Head and Neck Cancer Patients Undergoing Radiation with and without Chemotherapy. 2021 , 13,			2
630	A Super-Enhancer Driven by FOSL1 Controls miR-21-5p Expression in Head and Neck Squamous Cell Carcinoma. 2021 , 11, 656628			4
629	Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study. 2021 , 23, 1666-1677			0
628	Comprehensive toxicity risk profiling in radiation therapy for head and neck cancer: A new concept for individually optimised treatment. <i>Radiotherapy and Oncology</i> , 2021 , 157, 147-154	5-3		13
627	Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers. 2021 , 21, 360			4
626	The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer. 2021 , 12, 937-944			3
625	Taste dysfunction following radiotherapy to the head and neck: A systematic review. <i>Radiotherapy and Oncology</i> , 2021 , 157, 130-140	5-3		5
624	Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck. 2021 , 43, 2807-2821			2
623	Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: the Concept of Chemo-Selection (KCSG HN13-01). 2021 ,			0
622	Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina. 2021 , 38, 2613-2630			1
621	When is a surgical multidisciplinary approach required in the management of head and neck non-melanoma skin cancer and in advanced head and neck pathologies involving skin?. 2021 , 41, S145-S157			
620	Improved local control in p16 negative oropharyngeal cancers with hypermethylated MGMT. <i>Radiotherapy and Oncology</i> , 2021 , 157, 234-240	5-3		

619	Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy. 2021 , 13,	4
618	Nutritional Care in Patients with Head and Neck Cancer during Chemoradiotherapy (CRT) and Bioradiotherapy (BRT) Provides Better Compliance with the Treatment Plan. 2021 , 13,	0
617	Treatment outcomes in patients with supraglottic laryngeal cancer: a single centre study. 2021 , 141, 649-655	1
616	Platinum ineligibility in squamous cell carcinoma of the head and neck: consensus from Central America and the Caribbean. 2021 , 17, 1963-1971	
615	Treatment patterns in older patients with locally advanced head and neck squamous cell carcinoma: Results from an EORTC led survey. 2021 , 12, 1261-1265	1
614	Asymptomatic swallowing disorders may be present in individuals with laryngeal and hypopharyngeal cancer treated with chemo-radiotherapy. 2021 , 1	0
613	Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. 2021 , 28, 71-78	1
612	Predicting survival in head and neck cancer: External validation and update of the prognostic model OncologIQ in 2189 patients. 2021 , 43, 2445-2456	1
611	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. 2021 , 13,	6
610	Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient. 2021 , 12, 678028	1
609	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. 2021 , 26, e1508-e1513	5
608	Radiation-Induced Oral Mucositis in Head and Neck Cancer Patients. Five Years Literature Review. 2021 , 16, 151-165	
607	Genetic Variants of DNA Repair Genes as Predictors of Radiation-Induced Subcutaneous Fibrosis in Oropharyngeal Carcinoma. 2021 , 11, 652049	0
606	Platinum-induced nausea and vomiting in patients treated for head and neck cancer. 2021 , 108, 449-454	
605	Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. 2021 , 11, 640392	4
604	De-Escalation Strategies of (Chemo)Radiation for Head-and-Neck Squamous Cell Cancers-HPV and Beyond. 2021 , 13,	6
603	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. 2021 , 22, 727-736	10
602	Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma - Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes. 2021 , 11, 664304	3

601	Matched pair analysis for comparison of survival outcome of alternative regimens to standard three-weekly cisplatin-based concurrent chemoradiation of head and neck cancer. 2021 , 9, 913	1
600	Nasopharyngeal Carcinoma in Children: Clinical Cases. 2021 , 20, 155-165	
599	Application of BRACE Method to Address Treatment Selection Bias in Observational Data.	
598	Rolle der Strahlentherapie in der Behandlung des CUP-Syndroms. 2021 , 27, 663-669	
597	We have met the Enemy and (S)He is Us. 2021 , 43, 2685-2687	
596	To what extent has the last two decades seen significant progress in the management of older patients with head and neck cancer?. 2021 , 47, 1398-1405	2
595	Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer. 2021 , e1425	4
594	Neoantigen evolution in head and neck cancer progression: where do we go from here?. 2021 , 12, 1124-1125	
593	Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). 2021 , 162, 103345	2
592	Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood. 2021 , 22, 38	2
591	Induction Chemotherapy Followed by Radiation Therapy Versus Surgery Followed by Concurrent Chemo-Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Oral Cavity. 2021 , 13, e15723	
590	Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy. 2021 , 97, 102192	3
589	Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. 2021 , 139, 109668	2
588	Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration. 2021 , 28, 2409-2419	1
587	Comparing the Effectiveness of Non-Surgical and Surgical Treatment Modalities in the Management of Oral Cancer: A Systematic Review and Meta-Analysis. 2021 , 2, 110-120	
586	NTCP Modeling of Late Effects for Head and Neck Cancer: A Systematic Review. 2021 , 8, 95-107	2
585	Retropharyngeal lymph node-sparing radiotherapy in patients with oropharyngeal carcinoma. 2021 , 39, 99-106	0
584	Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors. 2021 , 13,	5

583	Methodologies to Increase the Level of Evidence of Real-life Proton Therapy in Head and Neck Tumors. 2021 , 8, 328-338	2
582	N3 (> 6 cm) squamous cell carcinoma of the head and neck: outcomes and predictive factors in 104 patients. 2021 , 41, 221-229	
581	Prophylactic gastrostomy in locally advanced head and neck cancer: results of a national survey among radiation oncologists. 2021 , 21, 656	1
580	Pignat's anterior vertical partial laryngectomy in the elderly and frail patients. 2021 , 71,	0
579	Interobserver variability in organ at risk delineation in head and neck cancer. 2021 , 16, 120	3
578	The Efficacy and Adverse Events in Patients with Head and Neck Cancer Following Radiotherapy Combined with S-1 Therapy: A Meta-Analysis. 2021 , 13,	
577	Care Disparities Across the Health Care Continuum for Older Adults: Lessons From Multidisciplinary Perspectives. 2021 , 41, 1-10	1
576	DNA methylation association with stage progression of head and neck squamous cell carcinoma. 2021 , 134, 104473	2
575	Functional Larynx Preservation in Patients With Locally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx Treated With Induction Chemotherapy vs. Concurrent Chemoradiation Alone. 2021 , 13, e16310	0
574	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. 2021 , 43, 3331-3344	3
573	Current status of systemic therapy in head and neck cancer. 2021 , 1-16	0
572	The biology of combination immunotherapy in recurrent metastatic head and neck cancer. 2021 , 136, 106002	3
571	Identification of Natural Compounds to Inhibit Sonic Hedgehog Pathway in Oral Cancer. 2021 ,	0
570	Texture analysis of PET images for predicting response to induction chemotherapy for oral squamous cell carcinoma. 2021 , 3, 100145	
569	?????????. 2021 , 124, 1027-1029	
568	Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus. 2021 , 12, 652054	3
567	Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma. 2021 , 37,	
566	Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy. 2021 , 88, 813-823	1

565	Epidemiological Trends of Head and Neck Cancer: A Population-Based Study. 2021 , 2021, 1738932	2
564	Effect of Concurrent Chemoradiation for Advanced Head and Neck Malignancy in a Tertiary Care Centre, Kerala. 2021 , 10, 2094-2098	
563	Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial. 2021 , 151, 201-210	0
562	The role of age in treatment decisions for oral cavity squamous cell carcinoma: Analysis of the National Cancer Database. 2021 , 118, 105330	0
561	Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population--A SEER-based analysis from 2000 to 2016. 2021 , 10, 6070-6077	2
560	A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation With Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck. 2021 , 13, e16505	
559	Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers. 2021 , 11, 712944	0
558	Lymph Node Ratio Predictive of Survival in Node-Positive Head and Neck Cancer.	
557	Approach to Oligometastatic Cancer in the Elderly Patient. 2021 , 23, 122	2
556	Risk stratified follow up for head and neck cancer patients - An evidence based proposal. 2021 , 119, 105365	1
555	Trends in Cancer Treatment for Oral Cavity, Oropharynx, and Larynx in 2016 Versus 2009: SEER Patterns of Care Studies. 2021 , 34894211037194	
554	Generational Study of Laryngeal Cancer Cases[Comparison of Middle-Aged, Early-Stage Elderly and Late-Stage Elderly Patients][2021 , 124, 1179-1186	
553	Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma. 2021 , 17, 3037-3050	1
552	Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma. 2021 , 11, 733917	4
551	Induction Chemotherapy for Advanced Oral Cavity Cancer. 2021 , 23, 129	2
550	Tactics of chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the pharynx with index of metastatic regional lymph nodes stage N3. 2021 , 11, 25-30	
549	The scope of liquid biopsy in the clinical management of oral cancer. 2021 ,	1
548	Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. 2021 , 11, 727433	6

547	Human Papillomavirus-Negative Oropharyngeal Cancer Survival Outcomes Based on Primary Treatment: National Cancer Database Analysis. 2021 , 1945998211047169	0
546	Recurrence Patterns After IMRT/VMAT in Head and Neck Cancer. 2021 , 11, 720052	1
545	A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic. 2021 , 30, 50-59	1
544	Prognostic factors in elderly patients with T1 glottic cancer treated with radiotherapy. 2021 , 11, 17717	0
543	Risk factors associated with the mortality rate of oral squamous cell carcinoma patients: A 10-year retrospective study. 2021 , 100, e27127	2
542	Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy. 2021 , 19, 380	
541	Role of Organ Preservation in Locally Advanced Hypopharyngeal Carcinoma.	
540	Mitogen-activated protein kinase-activated protein kinase-2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancer. 2021 ,	0
539	Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study. 2021 ,	5
538	Elective management of regional nodal basins in cutaneous squamous cell carcinoma of the head and neck: Controversies and contemporary perspectives. 2021 , 120, 105432	1
537	Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. 2021 , 11, 738626	1
536	Hypopharyngeal Cancer: Staging, Diagnosis, and Therapy.	1
535	Clinical outcome and prognostic factors in recurrent oral squamous cell carcinoma after primary surgical treatment: a retrospective study. 2021 , 1	3
534	Therapeutic strategies for systemic therapies of human papillomavirus-related oropharyngeal cancer. 2021 , 124, 952-961	1
533	Head and neck cancer. 2021 ,	36
532	Patient-Reported Toxicity and Quality-of-Life Profiles in Patients With Head and Neck Cancer Treated With Definitive Radiation Therapy or Chemoradiation. 2021 , 111, 456-467	8
531	Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: A prospective, observational study. 2021 , 121, 105475	1
530	Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma. 2021 , 121, 105480	2

529	Impact of sarcopenia in locally advanced head and neck cancer treated with chemoradiation: An Indian tertiary care hospital experience. 2021 , 121, 105483	5
528	Survival analysis of patients with advanced hypopharyngeal cancer comparing patients who received primary surgery to those who received chemoradiation: An analysis of the NCDB. 2021 , 121, 105470	0
527	The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis. 2021 , 121, 105454	2
526	Prognostic functional MR imaging parameters in head and neck squamous cell carcinoma: A systematic review. 2021 , 144, 109952	1
525	Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial. 2021 , 122, 105517	2
524	Treatment Outcomes of Head and Neck Cancer Patients in the Elderly Receiving Different Chemoradiation Combinations: A Single-Center Experience. 2021 , 44, 521-529	
523	Electronic cigarette aerosols alter the expression of cisplatin transporters and increase drug resistance in oral cancer cells. 2021 , 11, 1821	2
522	[The role of chemoradiotherapy in curative treatment of head and neck cancer]. 2021 ,	0
521	Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. 2021 , 119-137	
520	Is there a Role for Adjuvant Targeted and Immunotherapies in Patients with Locoregionally-Advanced Head and Neck Cancer?. 2021 , 205-219	
519	Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer. 2021 , 155-179	1
518	Encyclopedia of Gerontology and Population Aging. 2021 , 1-12	
517	Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. 2021 , 114, 405-411	
516	Progress in head-and-neck cancer: Promise versus reality. 2021 , 9, 1	
515	Evaluation of apoptotic effect of crocin, cisplatin, and their combination in human oral squamous cell carcinoma cell line HN5. 2021 , 18, 70	2
514	Machine Learning-Guided Adjuvant Treatment of Head and Neck Cancer. 2020 , 3, e2025881	8
513	Oropharynx. 559-570	2
512	Human papillomavirus oropharynx carcinoma: Aggressive de-escalation of adjuvant therapy. 2021 , 43, 229-237	8

511	Cancer of the Lip and Oral Cavity. 2010 , 131-144		1
510	Multidisciplinary Management of Oral Cavity and Maxillary Sinus Cancers. 2011 , 363-380		1
509	Multidisciplinary Management of Hypopharyngeal Carcinoma. 2011 , 431-455		2
508	Head and Neck Cancers. 2020 , 57-105		3
507	Principles and New Approaches in Surgical Reconstruction. 2016 , 575-589		1
506	Chemotherapy in Head and Neck Squamous Cell Cancer. 2016 , 53-68		1
505	Patient and Treatment Factors in Concurrent Chemoradiotherapy. 2017 , 189-201		3
504	Interaction of Chemotherapy and Radiation. 2012 , 65-82		9
503	Definitive radiotherapy or surgery for early oral squamous cell carcinoma in old and very old patients: A propensity-score-matched, nationwide, population-based cohort study. <i>Radiotherapy and Oncology</i> , 2020 , 151, 214-221	5:3	11
502	Treatment outcomes of laryngectomy compared to non-surgical management of T laryngeal carcinomas: a 10-year multicentre audit of 179 patients in the northeast of England. 2020 , 134, 1103-1107		1
501	Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck. 2021 , 51, 173-179		6
500	Concurrent Radiotherapy and Triweekly Carboplatin for the Definitive Treatment of Locally Advanced Laryngeal Carcinoma. 2018 , 41, 595-600		0
499	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a novel gain of function.		1
498	Tannic acid-induced apoptosis in FaDu hypopharyngeal squamous cell carcinoma. 2019 , 44, 43-49		3
497	Practice Patterns for Oropharyngeal Cancer in Radiation Oncology Centers of Turkey. 2014 , 100, 284-288		1
496	The history of head and neck surgery. 2011 , 25-30		1
495	Advances in the management of squamous cell carcinoma of the head and neck. 2014 , 6, 44		61
494	Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study. 2016 , 11, e0150032		7

493	Locally advanced head and neck cancer. 2013 , 237-44	4
492	Evaluation of Acute Toxicity and Early Clinical Outcome in Head and Neck Cancers Treated With Conventional Radiotherapy and Simultaneous Integrated Boost Arc Radiotherapy. 2017 , 8, 117-121	6
491	Combination of concurrent targeted and immune-therapy with nivolumab and cetuximab: new perspectives for squamous cell carcinoma treatment. 2020 , 10, 111-117	0
490	Decreased radiation doses to tongue with "stick-out" tongue position over neutral tongue position in head and neck cancer patients who refused or could not tolerate an intraoral device (bite-block, tongue blade, or mouthpiece) due to trismus, gag reflex, or discomfort during intensity-modulated radiation therapy. 2016 , 7, 53029-53036	7
489	A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC). 2016 , 7, 70185-70193	26
488	Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. 2017 , 8, 3870-3880	30
487	Multiparametric imaging using F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. 2017 , 8, 62606-62621	26
486	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. 2017 , 8, 54434-54443	12
485	The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials. 2017 , 8, 102371-102380	7
484	Predictive value of 1H MR spectroscopy and 18F-FDG PET/CT for local control of advanced oropharyngeal and hypopharyngeal squamous cell carcinoma receiving chemoradiotherapy: a prospective study. 2017 , 8, 115513-115525	1
483	Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects and poor outcome in patients with advanced head and neck squamous cell carcinoma. 2018 , 9, 18198-18213	14
482	Sponge-supported cultures of primary head and neck tumors for an optimized preclinical model. 2018 , 9, 25034-25047	6
481	MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer. 2015 , 6, 12625-36	24
480	High expression of myoferlin is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with HPV-status. 2016 , 7, 18665-77	24
479	Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells. 2016 , 7, 23542-51	16
478	Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients. 2016 , 7, 37297-37304	14
477	Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival. 2016 , 7, 31723-37	13
476	Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined. 2018 , 6, 229	15

475	Cycle number of neoadjuvant chemotherapy might influence survival of patients with T1-4N2-3M0 nasopharyngeal carcinoma. 2018 , 30, 51-60	9
474	Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review. 2017 , 18, 60-74	5
473	Definitive Intensity-modulated Radiation Therapy in Elderly Patients with Locally Advanced Oropharyngeal Cancer. 2017 , 31, 455-459	6
472	Multimodal guided self-help exercise program to prevent speech, swallowing, and shoulder problems among head and neck cancer patients: a feasibility study. 2014 , 16, e74	32
471	Prognostic role of diffusion weighted and dynamic contrast-enhanced MRI in loco-regionally advanced head and neck cancer treated with concomitant chemoradiotherapy. 2019 , 53, 39-48	6
470	Cisplatin Weekly Versus Every 3 Weeks Concurrently with Radiotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinomas: What Is the Best Dosing and Schedule?. 2020 , 21, 799-807	1
469	Systemic therapy strategies for head-neck carcinomas: Current status. 2012 , 11, Doc03	14
468	PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell carcinoma of the head and neck. 2017 , 31, 1-10	33
467	RADIOTHERMOMETRIC PERSONALISATION OF CHEMO- AND RADIOTHERAPY FOR PATIENTS WITH ADVANCED (III, IVA AND IVB) STAGES MALIGNANT LESIONS OF ORAL CAVITY, THROAT AND EPIGLOTTIS. 2019 , 24, 296-311	1
466	Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review. 2015 , 7, 1716-42	9
465	Neoadjuvant chemotherapy in oral cancers: Selecting the right patients. 2015 , 36, 148-53	16
464	Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. 2015 , 36, 161-5	18
463	Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers. 2016 , 143, 145-59	10
462	Palliative radiotherapy in locally advanced head and neck cancer after failure of induction chemotherapy: comparison of two fractionation schemes. 2013 , 19, 139-45	5
461	A Randomized Controlled Trial Evaluating the Role of Honey in Reducing Pain Due to Radiation Induced Mucositis in Head and Neck Cancer Patients. 2015 , 21, 268-73	27
460	Geriatric oncology: The need of the hour. 2013 , 2, 200-1	1
459	Organ preservation strategies: Review of literature and their applicability in developing nations. 2014 , 3, 147-50	8
458	Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy. 2014 , 3, 217-20	5

457	The Indian scenario of head and neck oncology - Challenging the dogmas. 2016 , 5, 105-10	22
456	Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer. 2017 , 6, 64-68	4
455	Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy. 2017 , 54, 453-457	2
454	Cetuximab in combination with chemoradiotherapy for nasopharyngeal carcinoma: A meta-analysis. 2018 , 55, 196-200	2
453	Neoadjuvant Chemotherapy for Larynx Preservation: Has it Lost Importance?. 2018 , 39, 227-233	1
452	Analgesic and Opioid Use in Pain Associated with Head-and-Neck Radiation Therapy. 2018 , 24, 176-178	4
451	Early Competing Deaths in Locally Advanced Head-and-Neck Cancer. 2018 , 24, 446-450	3
450	Intensity-modulated radiation therapy in head-and-neck carcinomas: Potential beyond sparing the parotid glands. 2020 , 16, 425-433	3
449	Burden of acute toxicities in head-and-neck radiation therapy: A single-institutional experience. 2019 , 8, 120-123	6
448	A prospective randomized study comparing concurrent chemoradiation with weekly and 3 weekly cisplatin in locally advanced oropharyngeal carcinoma. 2019 , 8, 178-182	2
447	Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study. 2019 , 8, 108-111	4
446	Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience. 2019 , 8, 52-56	2
445	Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer. 2012 , 44, 227-34	4
444	Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers. 2013 , 4, e1	17
443	Chemotherapy advances in locally advanced head and neck cancer. 2014 , 5, 966-72	11
442	Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches. 2016 , 7, 15-26	13
441	Benefit of Cisplatin With Definitive Radiotherapy in Older Women With Cervical Cancer. 2019 , 17, 969-975	6
440	Oral and Oropharyngeal Reconstruction with a Free Flap. 2016 , 17, 45-50	5

- 439 Is FDG -PET-CT a valuable tool in prediction of persistent disease in head and neck cancer. **2013**, 14, 4847-51 11
- 438 Weekly Cisplatin-Based Concurrent Chemoradiotherapy for Treatment of Locally Advanced Head and Neck Cancer: a Single Institution Study. **2015**, 16, 7309-13 5
- 437 Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment. **2015**, 16, 7331-5 3
- 436 Identification of HPV Integration and Genomic Patterns Delineating the Clinical Landscape of Cervical Cancer. **2015**, 16, 8041-5 1
- 435 Treatment outcome for head and neck squamous cell carcinoma in a developing country: University Malaya Medical Centre, Malaysia from 2003-2010. **2015**, 16, 2903-8 5
- 434 Three Weekly Versus Weekly Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma. **2016**, 17, 1617-23 13
- 433 Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis. **2018**, 6, e5655 12
- 432 Late Feeding Tube Dependency in Head and Neck Cancer Patients Treated with Definitive Radiation Therapy and Concurrent Systemic Therapy. **2020**, 12, e7683 3
- 431 Head and Neck Cancers. **2021**, 707-729
- 430 Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. **2021**, 111, 1131-1139 2
- 429 Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis. **2021**, 10, 1 1
- 428 A Rational Approach to Unilateral Neck RT for Head and Neck Cancers in the Era of Immunotherapy. **2021**, 13, 1 1
- 427 Curative-Intent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck in Sri Lanka: The Impact of Radiotherapy Technique on Survival. **2021**, 33, 765-772 1
- 426 Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab. **2021**, 11, 762366 1
- 425 Pretreatment Systemic Immune-Inflammation Index Predict Needs for Teeth Extractions for Locally Advanced Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. **2021**, 17, 1113-1121 0
- 424 Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?. **2021**, 25, 811-815 1
- 423 Treatment modalities, adverse events, and survival outcomes in older patients with head and neck squamous cell carcinoma. **2021**, 43, 3935-3945 2
- 422 Notch signaling in oral pre-cancer and oral cancer. **2021**, 38, 139 1

421	Clinical Diagnostic Imaging Study of Osteoradionecrosis of the Jaw: A Retrospective Study. 2021 , 10,	3
420	The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications. 2021 , 13,	4
419	Pembrolizumab in the first-line treatment of advanced head and neck cancer. 2021 , 21, 1321-1331	1
418	Perineural invasion/lymphovascular invasion double positive predicts distant metastasis and poor survival in T3-4 oral squamous cell carcinoma. 2021 , 11, 19770	3
417	[Update Treatment HPV-16-positive Oropharyngeal Carcinoma]. 2021 , 100, 832-844	0
416	Nutritional interventions in patients with head and neck cancer undergoing chemoradiotherapy: Current practice at the Dutch Head and Neck Oncology centres. 2021 , e13518	1
415	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. 2021 , 158, 17-26	1
414	Onkologie II. 2009 , 311-354	
413	Oropharyngeal Cancer. 2010 , 117-129	
412	Chemoradiation for Laryngeal Cancer: Present Scenario. 2010 , 2, 215-221	
411	Larynx and Hypopharynx Cancer. 2010 , 145-163	
410	Concurrent chemoradiotherapy with alternate-day administration of S-1 for locally advanced squamous cell carcinoma of the head and neck -Preliminary results. 2010 , 36, 363-368	1
409	Intérêt de la photothérapie au laser pour le traitement des mucites de la cavité buccale. Présentation d'un cas et revue de la littérature. 2010 , 16, 171-176	1
408	Programs of Organ and Function Preservation. 2011 , 327-332	
407	Head and Neck Cancer in the Elderly. 2011 , 553-588	
406	Terapia medica integrata nei carcinomi squamocellulari. 2011 , 195-207	
405	Translational Research in Head and Neck Oncology. 2011 , 179-189	
404	Phase I Study Methodology in Head and Neck Oncology. 2011 , 307-315	

- 403 Evidence-Based Head and Neck Oncology: Principles and Pitfalls. **2011**, 317-325
- 402 Multidisciplinary Management of Oropharynx Carcinomas. **2011**, 401-430
- 401 Intensity-Modulated Radiation Therapy for Head and Neck Cancer. **2011**, 267-279
- 400 Carcinoma dell'ipofaringe. **2011**, 321-329
- 399 Combined altered fractionated radiation therapy and chemotherapy for head and neck cancer. **2011**, 37, 460-463
- 398 Les cancers de la sphère ORL. **2011**, 199-216
- 397 Induction Chemotherapy in Head and Neck Cancers. **2011**, 71-118
- 396 Hoofd-halstumoren. **2011**, 273-316
- 395 Carcinoma del cavo orale. **2011**, 361-370
- 394 Tossicità acuta da trattamento: terapia di supporto. **2011**, 227-236
- 393 Molecular Mechanism of Cisplatin Resistance in Head and Neck Cancers. **2011**, 104, 161-170
- 392 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61
- 391 Oropharyngeal Cancer. **2012**, 585-617
- 390 A Multidisciplinary Approach to Cancer. **2012**, 17-24
- 389 Potential Molecular Targets: From Bench to Bedside. **2012**, 1-16
- 388 Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck.
- 387 A Case with Hypopharyngeal Perforation after Concurrent Chemoradiotherapy for Hypopharyngeal Carcinoma. **2012**, 105, 661-666
- 386 A comparative study of survival rates after treatment with induction chemotherapy or concurrent chemoradiotherapy in locoregionally advanced head and neck squamous cell carcinoma. **2012**, 38, 368-373

- 385 Chemotherapy and Radiotherapy for Elderly Head and Neck Cancer Patients. **2012**, 63, 367-373 1
- 384 Overview. **2012**, 543-551
- 383 EGFR-directed therapies in squamous cell carcinoma of the head and neck. **2012**, 60-71
- 382 Systemic Therapies in the Management of Head and Neck Cancer. **2012**, 99-113
- 381 Synchronous Chemoradiotherapy in Patients with Stage III and IV Head and Neck Cancer: Comparing Cisplatin with Capecitabine. **2012**, 03, 1045-1051
- 380 Chemotherapy and Molecular Target Therapy Combined with Radiation Therapy. **2012**, 61, 21-29
- 379 Clinical trial design in advanced head and neck cancer: from past experiences to future perspectives. **2012**, 2, 473-481 1
- 378 Management of human papillomavirus-induced oropharynx cancer. **2012**, 368-71 1
- 377 Kopf-Hals-Tumoren. **2013**, 431-515
- 376 Regionale Chemotherapie bei Kopf-Hals-Tumoren. **2013**, 79-120
- 375 The Role of Radiotherapy for Unresectable Locally Advanced Head and Neck Cancer. **2013**, 64, 320-326
- 374 . **2013**, 23, 301-305
- 373 Tumors of the skin, the CNS and the head and neck. **2013**, 72-89
- 372 The fractionation conundrum: Are we still missing a piece of the puzzle?. **2013**, 2, 197
- 371 Controversies in the Management of Advanced Vulvar Cancer. **2014**, 185-196
- 370 Therapeutics: Pharmacology, Chemotherapy, Radiation Oncology. **2014**, 105-114
- 369 Projections: Novel Therapies for HPV-Negative Cancers of the Head and Neck. **2014**, 343-359
- 368 Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and New Approaches. **2014**, 205-231

- 367 Stage III and IV Head and Neck Cancer: Does Everyone Need Chemotherapy?. **2014**, 03, 26-28
- 366 Cancer of the Head and Neck. **2014**, 1037-1070.e6
- 365 Head and Neck Cancer Treatment in the Elderly. **2014**, 65, 388-394 2
- 364 Management of locally and regionally advanced nasopharyngeal carcinoma with chemoradiotherapy. **2014**, 75-96
- 363 Oropharynx. **2015**, 115-139
- 362 Current Systemic Therapy Options for Head and Neck Cancers. **2015**, 17-31
- 361 Head and Neck Cancers. **2015**, 373-379
- 360 Hyper-fractionated Intensity Modulated Radiation Therapy (HF-IMRT) in Head and Neck Cancer: The Technical Feasibility and Results of a Short Clinical Series. **2015**, 9, XR01-XR04 2
- 359 Treatment Outcomes of Alternating Chemoradiotherapy for Nasopharyngeal Carcinoma. **2015**, 6, 103-110 o
- 358 Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck. **2015**, 81-87
- 357 Head and Neck Tumors: Viewpoint on Fractionated Radiation Therapy and Chemotherapy. **2015**, 549-562
- 356 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79
- 355 The Care of the HPV-Negative Head and Neck Cancer Patient: Presentation, Prognosis, Treatment. **2015**, 111-127
- 354 Laryngeal cancer and oral mucositis. **2015**, 213-224
- 353 Re-emergence of Surgery in the Management of Head & Neck Cancer. **2015**, 24, 79-88
- 352 General principles of head and neck cancer management. 503-511
- 351 Oral cavity. 524-541
- 350 Larynx and hypopharynx. 542-558

- 349 Analysis of Concurrent Chemoradiotherapy (CRT) with S-1 for Oropharyngeal and Hypopharyngeal Carcinoma. **2016**, 147, 80-81
- 348 Concepts of Radiotherapy in Cancer of Unknown Primary. **2016**, 125-149
- 347 The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with previously untreated squamous cell carcinoma of the head and neck. **2016**, 42, 428-431 2
- 346 Surgery for elderly patients aged over seventy-five with head and neck cancer. **2016**, 42, 382-389
- 345 The Association between the Metabolic Tumor Volume and the Prognosis in Patients with Laryngeal Carcinoma. **2016**, 28, 57-60 3
- 344 Presentation and Treatment of a Patient with Three Primary Head and Neck Cancers: A Case Report. **2016**, 5, 1-3
- 343 De zorg voor patiënten met hoofd-halstumoren. **2016**, 111-125
- 342 Induction Chemotherapy in Head and Neck Cancers. **2016**, 73-122
- 341 Phase I Study Methodology in Head and Neck Oncology. **2016**, 731-742
- 340 Multidisciplinary Management of Oral Cavity and Maxillary Sinus Cancers. **2016**, 405-428
- 339 Onkologie. **2016**, 177-212
- 338 Review of Induction Chemotherapy for Head and Neck Cancer Possibility of Limited Surgery **2016**, 109, 521-531 0
- 337 Programs of Organ and Function Preservation. **2016**, 569-574
- 336 Multidisciplinary Management of Hypopharyngeal Carcinoma. **2016**, 511-537
- 335 Oropharynx Cancer. **2016**, 27-49
- 334 Toward unifying CCRT regimens for head and neck cancer in Niigata prefecture. **2016**, 42, 70-75
- 333 Translational Research in Head and Neck Oncology. **2016**, 215-227
- 332 Intensity-Modulated Radiation Therapy for Head and Neck Cancer. **2016**, 301-315

- 331 Conformal re-irradiation of recurrent head and neck tumors. **2016**, 5, 54
- 330 Multidisciplinary Management of Oropharynx Carcinomas. **2016**, 475-510
- 329 Head and Neck Brachytherapy: A Description of Methods and a Summary of Results. **2016**, 71-143 1
- 328 Hyaluronan-mediated ferric oxide nanoparticles causes apoptosis of CD44 expressing head and neck squamous cell carcinoma cells. **2016**, 4, 424
- 327 Role of PET/CT in Radiotherapy Treatment Planning. **2017**, 577-608
- 326 Current and Emerging Role of Chemotherapy in Oral Cancer. **2017**, 127-146 1
- 325 Aspiration pneumonitis following bioradiotherapy for head and neck cancer. **2017**, 43, 83-89
- 324 Hoofd-halstumoren. **2017**, 251-291
- 323 Chemotherapy for Elderly Patients with Head and Neck Cancer. **2017**, 68, 202-203
- 322 Kopf-Hals-Tumoren beim alten und geriatrischen Patienten. **2017**, 1-11
- 321 Malignome des Kopf- und Halsbereichs. **2017**, 581-604
- 320 To review the role and issue of pharmacotherapy for head and neck cancer clarified from previous clinical trials. **2017**, 43, 425-429
- 319 The current state of radiotherapy in patients with oropharyngeal squamous cell carcinoma. A radiation therapist's view. **2017**, 6, 4
- 318 Neoadjuvant chemotherapy for unresectable oral cancers: Optimizing outcomes?. **2017**, 54, 394-396
- 317 General Principles of Head and Neck Cancer Management. 503-511
- 316 Oral Cavity. 524-541
- 315 Larynx and Hypopharynx. 542-558
- 314 Oropharynx. 559-570

- 313 False Positive Positron Emission Tomography / Computed Tomography Scans in Treated Head and Neck Cancers. **2017**, 9, e1146 6
- 312 Management of Head and Neck Tumours. **2018**, 11-16
- 311 BENEFITS OF INTENSITY-MODULATED RADIOTHERAPY (IMRT) IN PATIENTS WITH HEAD AND NECK MALIGNANCIES- A SINGLE INSTITUTION EXPERIENCE. **2017**, 4, 4305-4309
- 310 Optimal Surgery in Elderly Patients with Head and Neck Cancer. **2017**, 28, 181-184
- 309 Irradiation of HPV-associated oropharyngeal cancer: Is less really more?. **2018**, 9, 12546-12547 1
- 308 Survey of the Period of Tapering of a Strong Opioid Analgesic for Oral Mucositis Resulting from Concomitant Chemoradiotherapy for Head and Neck Cancer after the End of Treatment. **2018**, 13, 305-311
- 307 Identification of Acquired Notch3 Dependency in Metastatic Head and Neck Cancer.
- 306 Kopf-Hals-Tumoren beim alten und geriatrischen Patienten. **2018**, 299-309
- 305 Retrospective analysis of platinum-based concurrent chemoradiotherapy using 3D conformal radiation therapy for hypopharyngeal cancer. **2018**, 44, 32-38
- 304 The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma. **2018**, 397-438
- 303 Photoimmunotherapy for Cancer Metastasis Treatment. **2018**, 55-63
- 302 Preventive Strategies in Radiation-Associated Dysphagia. **2018**, 321-331
- 301 Swallowing Dysfunction After Radiotherapy and Chemotherapy. **2018**, 305-320
- 300 Possibilities of chemoradiation treatment primary locally advanced head and neck tumors. **2018**, 7, 68 1
- 299 What is the Current Evidence Base for Management of Oropharyngeal Cancer?. **2018**, 9, 47-53 0
- 298 Treatment Paradigms in HPV-Associated SCCHN. **2018**, 585-615
- 297 Supportive care is mandatory for successful radiotherapy and chemoradiotherapy in patients with head and neck tumors. **2018**, 7, 75
- 296 Biopolymeric materials for targeted drug delivery in the therapy accompanying radiation treatment of patients with head and neck tumors. **2018**, 76-82

295 ??????????. **2018**, 121, 882-886

1

294 Validity of Treatment for Patients with Head and Neck Squamous Cell Carcinoma with Distant Metastasis Detected at the First Examination. **2018**, 121, 1288-1293

293 Investigation of the Adverse Events and Efficacy of Docetaxel+Cisplatin+5-Fluorouracil in Patients with Head and Neck Squamous Cell Carcinoma. **2018**, 121, 1486-1492

292 Role of Oral Glutamine in Prevention and Treatment of Oral Mucositis in Head and Neck Cancer Patients Receiving Chemoradiation. **8**, 5-9

291 ??????????????. **2018**, 121, 1458-1462

290 First-line chemotherapy for head and neck squamous cell carcinoma. Optimal strategy. **2019**, 8, 14-20

289 Traitements médicaux des cancers du larynx. **2019**, 123-136

288 ALTERED FRACTIONATION RADIOTHERAPY FOR HEAD AND NECK CANCER. **2019**, 17, 368-376

287 Concurrent chemoradiotherapy for head and neck cancers in older patients: Outcomes and their determinants. **2019**, 56, 261-266

3

286 The tolerability of cisplatin with chemoradiotherapy in head and neck carcinoma. **2019**, 29, 143-147

285 Guidelines in Management of Carcinoma of the Hypopharynx. **2019**, 135-154

284 Biomedizinische Physik in der Krebstherapie. **2019**, 303-311

283 Head and Neck Tumors in Older Adults: Systemic Treatments and Combination with Local Strategies. **2019**, 1-13

282 Landmark Trials in Selected Head and Neck Cancers. **2019**, 217-239

281 Is There a Role for Induction Chemotherapy in the Treatment of Advanced Head and Neck Cancer?. **2019**, 351-358

280 Analysis of prognostic factors and patterns of failure in patients of oropharyngeal squamous cell carcinoma treated by definitive radiotherapy in a tertiary care cancer center of Northern India. **2019**, 10, 122

279 Squamous Cell Carcinoma of the Head and Neck. **2019**, 697-720

1

278 Human Papillomavirus-Related Head and Neck Cancer. **2019**, 45-68

- 277 Treatment intensity in locoregionally advanced head and neck cancer: recent investigation leads to new questions.. **2019**, 8, S188-S194
- 276 Successful treatment of recurrent metastatic nasopharyngeal carcinoma with nivolumab: a case report. **2019**, 9, 99-104
- 275 Evaluation of Thyroid Dysfunction in Patients with Head and Neck Cancer Receiving Radiation Therapy or Chemoradiation. **2019**, 8, 3155-3160 1
- 274 Novel and Emerging Chemotherapeutic Agents in Head and Neck Cancer. **2020**, 117-128
- 273 Oropharynx Cancer. **2020**, 217-223
- 272 Altered Fractionation Radiotherapy. **2020**, 185-189
- 271 High Dose-Rate Brachytherapy in Recurrent High-Risk Head and Neck Cancer. **2019**, 6,
- 270 Locally Advanced Oral Tongue Cancer: Is Organ Preservation a Safe Option in Resource-Limited High-Volume Setting?. **2020**, 10, 158-163 0
- 269 Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer. **2020**, 9, 43-46 1
- 268 Does a 6-point scale approach to post-treatment 18F-FDG PET-CT allow to improve response assessment in head and neck squamous cell carcinoma? A multicenter study. **2020**, 4, 8 0
- 267 Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. **2020**, 12, e8105
- 266 Comparison of long-term treatment outcomes of T2N0M0 laryngeal squamous cell carcinoma using different treatment methods. **2020**, 20, 921-930 0
- 265 Accelerated Radiotherapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancers: Evaluation of Response and Compliance. **2020**, 21, 1399-1407
- 264 ?????????? ?????? **2020**, 123, 443-448 1
- 263 Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase-3 pathway in oral cancer. **2020**, 20, 154 0
- 262 Pulmonary Screening Practices among Otolaryngology-Head & Neck Surgeons across Saudi Arabia in the Post-treatment Surveillance of Head and Neck Squamous Cell Carcinoma: A Cross-Sectional Study (Preprint).
- 261 Pulmonary Screening Practices of Otolaryngology-Head and Neck Surgeons Across Saudi Arabia in the Posttreatment Surveillance of Squamous Cell Carcinoma: Cross-sectional Survey Study.. **2022**, 11, e24592 0
- 260 MR-Guided Adaptive Radiotherapy for Head and Neck Cancer: Prospective Evaluation of Migration and Anatomical Changes of the Major Salivary Glands. **2021**, 13, 1

- 259 Effectiveness of reduced- versus standard-dose radiotherapy on survival and radiation-associated toxicity in patients with human papillomavirus associated oropharyngeal squamous cell carcinoma: a systematic review protocol. **2021**,
- 258 The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin. **2021**, 1
- 257 Role of metronomic therapy for advanced oral cancers and predictors of response: A multi-institutional feasibility study. **2021**, 0
- 256 A frequentist one-step model for a simple network meta-analysis of time-to-event data in presence of an effect modifier. **2021**, 16, e0259121 0
- 255 Molecular Targeted Therapy for Advanced Oral Cancer. **2020**, 359-385
- 254 Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers. **2020**, 14, 1155 2
- 253 F-18 FDG PET Tests in Head and Neck Cancer. **2021**, 51-69
- 252 Treatment tolerability and outcomes in elderly patients with head and neck cancer. **2021**, 43, 858-873 4
- 251 Results of a survey on elderly head and neck cancer patients on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). **2020**, 40, 405-409 2
- 250 Principles of Management of Head and Neck Cancers. **2021**, 409-425
- 249 Neoplasms of the Oral Cavity and Oropharynx. **2021**, 427-447
- 248 Multimodality Therapy for Locoregional Nasopharyngeal Carcinoma-A Decision Tool for Treatment Optimization. **2020**, 3, e2030672 0
- 247 Reciprocal activation of HEY1 and NOTCH4 under SOX2 control promotes EMT in head and neck squamous cell carcinoma. **2021**, 58, 226-237 3
- 246 Screening von Kopf-Hals-Tumoren. **2020**, 1-8
- 245 Chemotherapy: Where we have been and where we are going. **2020**, 17-38
- 244 Overview of head and neck cancer management. **2020**, 1-32
- 243 Combining radiation and chemotherapy to improve the therapeutic ratio. **2020**, 49-63
- 242 Hoofd-halskanker. **2020**, 261-291

- 241 Head and Neck Tumors in Older Adults: Systemic Treatments and Combination with Local Strategies. **2020**, 759-771
- 240 Transoral surgery for hypopharyngeal cancer arising in the radiotherapy field. **2020**, 46, 254-257
- 239 ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. **2020**, B-1-B30-3
- 238 Authors' reply to Kuriakose et al., Mallick et al., and Chaukar et al.. **2020**, 3, 390
- 237 Treatment outcome of hypopharyngeal cancer: A single institutional experience. **2020**, 46, 328-333
- 236 Modified 3-weekly cisplatin or cisplatin-5-fluorouracil 5-day infusion as the concurrent chemoradiotherapy regimen in locally advanced squamous cell carcinoma of the head and neck: Comparison of efficacy and toxicity. **2020**, 7, 17
- 235 Introduction: Leaps and bounds. **2020**, 1-15
- 234 Translating Targeted Radiosensitizers into the Clinic. **2020**, 17-33
- 233 Development of chemotherapy for head and neck cancer, and current status of treatment strategy in clinical practice. **2020**, 32, 130-133
- 232 Patterns of regional lymph node failure of locally advanced hypopharyngeal squamous cell carcinoma after first-line treatment with surgery and/or intensity-modulated radiotherapy.
- 231 Recurrence of Lymph Node Micrometastases After Radiotherapy for Head and Neck Carcinoma: A Propensity Score-matched Study.. **2021**, 1, 165-172
- 230 Patterns of regional lymph node failure of locally advanced hypopharyngeal squamous cell carcinoma after first-line treatment with surgery and/or intensity-modulated radiotherapy.
- 229 Recurrent squamous cell carcinoma of head and neck: results of treatment in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in 2012-2016. **2020**, 10, 20-28
- 228 Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. **2021**, 12, 6340 2
- 227 Quimioterapia y terapias dirigidas en otorrinolaringología. **2020**, 49, 1-6
- 226 Feasibility and efficacy of chemoradiotherapy with concurrent split-dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for locally advanced head and neck cancer. **2020**, 13, 35 1
- 225 Role of Systemic Therapy. **2021**, 255-272
- 224 Guidelines in Management of Carcinoma of the Gingivobuccal Complex. **2021**, 113-131

223	Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival. 2021 , 25, e433-e442	0
222	Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience. 2020 , 31, 1074-1083	0
221	Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy. 2012 , 32, 297-303	16
220	Case report: Down-staging locally advanced head and neck cancer in an HIV infected patient in a limited resource setting. 2013 , 25, 53-5	
219	Is there a role for postoperative radiotherapy following open partial laryngectomy when prognostic factors on the pathological specimen are unfavourable? A survey of head and neck surgical/radiation oncologists. 2013 , 33, 311-9	10
218	Hazards and risks in oncology: radiation oncology. 2013 , 12, Doc03	4
217	Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation + Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis. 2015 , 5, 1017-31	28
216	IKK phosphorylation of NF- κ B at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancer. 2015 , 5, 3098-110	11
215	Pattern of Gustatory Impairment and its Recovery after Head and Neck Irradiation. 2017 , 29, 319-327	5
214	Inhibition of WNT7A- β -catenin signaling pathway sensitizes oral squamous cell carcinoma to cisplatin. 2018 , 11, 4926-4933	3
213	CD38 triggers inflammasome-mediated pyroptotic cell death in head and neck squamous cell carcinoma. 2020 , 10, 2895-2908	5
212	Nimotuzumab combined with radiotherapy for the treatment of hypopharyngeal cancer - A case report from a tertiary cancer center. 2021 , 7, 285-288	
211	Evaluation of apoptotic effect of crocin, cisplatin, and their combination in human oral squamous cell carcinoma cell line HN5. 2021 , 18, 70	
210	Cetuximab: Its role in patients unfit for cisplatin. 2021 , 124, 105654	
209	Cisplatin induces TRPA1-mediated mechanical allodynia in the oral mucosa. 2022 , 133, 105317	0
208	Treatment Outcomes and the Safety of Chemoradiotherapy With High-Dose CDDP for Elderly Patients With Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Study. 2021 , 8, 753049	
207	The Impact of Histopathological Features on the Prognosis of Oral Squamous Cell Carcinoma: A Comprehensive Review and Meta-Analysis. 2021 , 11, 784924	4
206	Management of sinonasal cancers: Survey of UK practice and literature overview. 2021 ,	

205	Prognostic Value of Preoperative Mean Platelet Volume and a Predictive Nomogram in Oral Squamous Cell Carcinoma Patients Based on Real-World Data. 2021 , 13, 8495-8509	1
204	Randomized Phase III, Double Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. 2021 ,	2
203	Radiation necrosis of the bone, cartilage or cervical soft-tissues following definitive high-precision radio(chemo)therapy for head-neck cancer: uncommon and under-reported phenomenon. 2021 , 1-22	
202	83/m mit Schwellung am Hals. 1	
201	Is There an Interplay between Oral Microbiome, Head and Neck Carcinoma and Radiation-Induced Oral Mucositis?. 2021 , 13,	3
200	Definitive radiotherapy for squamous cell carcinoma of the oral cavity: a single-institution experience. 2021 , 55, 467-473	
199	Radioimmunotherapy and Targeted Radiotherapy of Squamous Cell Carcinoma of the Head and Neck. 2022 , 457-469	
198	Intra-arterial chemotherapy targeting metastatic cervical lymph nodes in head and neck cancer. 2021 , 141, 1063-1069	
197	Prognostic impact of matted lymphadenopathy in patients with oropharyngeal squamous cell carcinoma treated with definitive chemoradiotherapy. 2021 , 123, 105623	1
196	Patterns-of-Care Analysis for Radiotherapy of Elderly Head-and-Neck Cancer Patients: A Trinational Survey in Germany, Austria and Switzerland.. 2021 , 11, 723716	2
195	Oropharynx. 2022 , 21-36	
194	Hyaluronic Acid Carrier-Based Photodynamic Therapy for Head and Neck Squamous Cell Carcinoma.. 2021 , 37, 102706	0
193	Evaluation of quantitative imaging parameters in head and neck squamous cell carcinoma. 2019 ,	1
192	Tumors: Oto-Rhino-Laryngology. 2021 , 5279-5291	
191	Adjuvant chemoradiotherapy in elderly patients with head and neck cancer: a monoinstitutional, two-to-one pair-matching analysis.. 2022 , 198, 159	1
190	Solid Tumours and Update on Modern Medical Oncology Interventions. 2022 , 23-38	
189	Comprehensive analysis of circRNA-miRNA-mRNA in oral squamous cell carcinoma.. 2022 , 138, 105346	0
188	Age-specific oncogenic pathways in head and neck squamous cell carcinoma - are elderly a different subcategory?. 2022 , 1	0

187	Evolution of a Paradigm Switch in Diagnosis and Treatment of HPV-Driven Head and Neck Cancer-Striking the Balance Between Toxicity and Cure.. 2021 , 12, 753387		3
186	Eustachian Tube Functions in Concurrent Chemoradiotherapy for Head and Neck Cancer Patients. 1		
185	Clinical Significance of Frailty on Treatment Outcome in Nongeriatric Patients With Head and Neck Cancer and Esophageal Cancer Undergoing Curative-Intent Concurrent Chemoradiotherapy.. 2022 , 29, 10732748211045276		1
184	Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy.. 2022 , 14,		2
183	Treatment outcomes of proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for locally advanced oral cancer in the elderly.. 2022 ,		0
182	Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC.		
181	Landscape of mortality during and within thirty days after non-palliative radiotherapy across eleven major cancer types.. <i>Radiotherapy and Oncology</i> , 2022 ,	5-3	
180	Radiotherapy for oral cavity cancers.. 2021 , 26, 189-189		0
179	Management of oropharyngeal squamous cell carcinoma.. 2021 , 26, 174-174		1
178	Radiotherapy for hypopharynx cancers.. 2021 ,		0
177	Reducing target volume in definitive radiotherapy for human papillomavirus-associated tonsil cancer.. 2022 ,		
176	Bias Reduction through Analysis of Competing Events (BRACE) Correction to Address Cancer Treatment Selection Bias in Observational Data.. 2022 ,		0
175	Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial.. <i>Radiotherapy and Oncology</i> , 2022 ,	5-3	1
174	Comparison of Volumetric Quantitative PET Parameters Before and After a CT-Based Elastic Deformation on Dual-Time 18FDG-PET/CT Images: A Feasibility Study in a Perspective of Radiotherapy Planning in Head and Neck Cancer.. 2022 , 9, 831457		
173	The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm.. 2022 , 126, 105766		1
172	Head and Neck Cancer in Older Adults with Frailty. 2022 , 467-480		
171	Induction Chemotherapy in Low-Risk HPV+ Oropharyngeal Cancer.. 2022 , 23, 54		
170	Surgical stage in sequential therapy of unresectable oral cancer T3-4bN0-3M0: evaluation of treatment results. 2022 , 11, 41-49		

169	Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.. 2022,	2
168	Response-Adapted Treatment Following Radiotherapy in Patients With Resectable Locally Advanced Hypopharyngeal Carcinoma.. 2022, 5, e220165	1
167	Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival.. 2022, 10,	2
166	Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma.. 2022, 1	2
165	Long-term cognitive, psychosocial, and neurovascular complications of unilateral head and neck irradiation in young to middle-aged adults.. 2022, 22, 244	
164	Burden of oral cancer in Asia from 1990 to 2019: Estimates from the Global Burden of Disease 2019 study.. 2022, 17, e0265950	2
163	Response letter to the editor of radiotherapy and oncology regarding the paper "Stereotactic body radiotherapy for head and neck skin cancer" by IS Voruganti et al.. <i>Radiotherapy and Oncology, 2022</i>	5:3
162	Cell Signaling Pathways That Promote Radioresistance of Cancer Cells.. 2022, 12,	3
161	PROSPECTIVE STUDY COMPARING CONCURRENT CHEMORADIATION WITH OR WITHOUT GEFITINIB IN TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CARCINOMA. 82-86	
160	Kurative Radiochemotherapie von Kopf-Hals-Tumoren. 2022, 43, 120-132	
159	Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatin-ineligible renal dysfunction: A retrospective study. 2022, 23,	
158	Improving the Education of Radiation Oncology Professionals in Geriatric Oncology: Where Are We and Where Should We Be?. 2022, 32, 109-114	0
157	Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.. 2022, 127, 105772	0
156	Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma.. <i>Radiotherapy and Oncology, 2022,</i>	5:3
155	Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis.. 2022,	0
154	Concurrent Cetuximab-based bioradiotherapy versus Cisplatin-based Chemoradiotherapy in the Definitive Management of Favourable Biology Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma: Systematic Review and Meta-analysis.. 2022,	0
153	Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [F]FMISO PET/CT.. <i>Radiotherapy and Oncology, 2022,</i>	5:3 3
152	The role of induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A nationwide population-based matched study.. 2022, 128, 105848	0

151	The dogma of Cetuximab and Radiotherapy in head and neck cancer - A dawn to dusk journey.. 2022 , 34, 75-81	0
150	Toxicity of induction chemotherapy in head and neck cancer: The central role of skeletal muscle mass.. 2021 ,	1
149	Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.. 2021 , 12, CD006386	0
148	Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment.. 2021 ,	
147	Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma.. 2021 ,	2
146	Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib.. 2021 , 27, 1610008	1
145	Feasibility, SAR Distribution, and Clinical Outcome upon Reirradiation and Deep Hyperthermia Using the Hypercollar3D in Head and Neck Cancer Patients. 2021 , 13,	2
144	Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients.. 2021 , 16, 239	1
143	Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines.. 2022 , 28, 19	5
142	Usefulness of Melatonin and Other Compounds as Antioxidants and Epidrugs in the Treatment of Head and Neck Cancer.. 2021 , 11,	0
141	Head-and-neck cancer radiotherapy recommendations during the COVID-19 pandemic: Adaptations from the Indian subcontinent. 2020 , 3, 424	4
140	Does chemoradiotherapy benefit older patients with squamous cell carcinomas of the head-and-neck?. 2020 , 3, 580	
139	Safety and efficacy of concurrent chemoradiotherapy for head-and-neck cancers in older versus younger patients: Post hoc analysis of a randomized controlled trial. 2020 , 3, 482	1
138	The radiosensitizing effect of Ethujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines.. 2022 , 1	0
137	Disadvantaged Subgroups Within the Global Head and Neck Cancer Population: How Can We Optimize Care?. 2022 , 42, 1-10	
136	Radiation Therapy in Older Adults With Cancer: A Critical Modality in Geriatric Oncology.. 2022 , JCO2102656	1
135	Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials.. 2022 , 21, 101426	5
134	Data_Sheet_1.pdf. 2019 ,	

133 Data_Sheet_1.docx. **2020**,

132 Data_Sheet_1.docx. **2020**,

131 Table_1.DOCX. **2019**,

130 Age Alone Is Not a Barrier to Concurrent Chemoradiotherapy for Advanced Head and Neck Cancer.. **2022**, 34894221086087

129 Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer.. **2022**, 12, 834068 ○

128 Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients.. **2022**, ○

127 Sarcopenia and Treatment Toxicity in Older Adults Undergoing Chemoradiation for Head and Neck Cancer: Identifying Factors to Predict Frailty.. **2022**, 14, ○

126 Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis.. **2022**, 12, 868490

125 Clinical Outcomes of Treatment for Hypopharyngeal Cancer at Tokushima University Hospital. **2022**, 158, 163-170

124 Influence of radiotherapy on dental implants placed in individuals before diagnosed with head and neck cancer: focus on implant-bed-specific radiation dosage.. **2022**, ○

123 Comparison of Patients With Head and Neck Cancer in Randomized Clinical Trials and Clinical Practice: A Systematic Review.. **2022**, ○

122 Hospital Price Transparency Rule Exposes Muddied Costs for Head and Neck Radiotherapy in One State.. **2022**, 45, 268-272

121 Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges. **2022**, 14, 2587 ○

120 Validation of Monte Carlo ¹³¹I radiopharmaceutical dosimetry workflow using a 3D printed anthropomorphic head and neck phantom.

119 Intra-arterial chemoradiotherapy for locally advanced buccal mucosal cancer in an elderly patient with multiple comorbidities: A case report. ○

118 Non-invasive imaging of oral potentially malignant and malignant lesions: A systematic review and meta-analysis. **2022**, 130, 105877 1

117 MR-geführte Dosisescalation bei Kopf-Hals-Tumoren. ○

116 Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma. **2022**, 14, 2499 1

115	Using Next-Generation Sequencing and Bioinformatic Methods to Predict New Genes That May Be Regulated by CD47 in Oral Squamous Cell Carcinoma. 2022 , 44, 2243-2256	0
114	De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma—Where Are We Now?. 2022 , 29, 3668-3697	1
113	Management of Older Adults with Locally Advanced Head and Neck Cancer. 2022 , 14, 2809	1
112	Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?. 2022 , 34, 196-203	2
111	Long-term Survivorship and Non-cancer Competing Mortality in Head and Neck Cancer: A Nationwide Population-Based Study in South Korea.	0
110	Timing of radiotherapy and chemotherapy start for patients treated with definitive concurrent chemoradiation for head and neck cancer. 1-7	
109	Reduction in severity of radiation-induced dermatitis in head and neck cancer patients treated with topical aloe vera gel: A randomized multicenter double-blind placebo-controlled trial. 2022 , 102164	1
108	Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients with Head and Neck Region Tumours. 2022 , 10, 1484	
107	The Promise of Circulating Tumor DNA in Head and Neck Cancer. 2022 , 14, 2968	1
106	Simultaneous Modulated Accelerated Radiotherapy (SMART) with Dysphagia Aspiration-Related Structures (DARS) Sparing: Do We Have a Role for Dose Condensation in Locally Advanced Head and Neck Cancer.	
105	Deoxyshikonin Mediates Heme Oxygenase-1 Induction and Apoptotic Response via p38 Signaling in Tongue Cancer Cell Lines. 2022 , 23, 7115	0
104	Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 in locally advanced laryngeal cancer as prognostic indicators of relapse and survival. 2022 , 22,	
103	Cost-Effectiveness of Pembrolizumab for the first line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. 1-46	
102	Gambogic Acid Induces HO-1 Expression and Cell Apoptosis through p38 Signaling in Oral Squamous Cell Carcinoma. 1-17	0
101	TREATMENT OUTCOME AND TOXICITY OF HYPOFRACTIONATED RADIOTHERAPY WITH CONCOMITANT CHEMOTHERAPY VERSUS CONVENTIONAL FRACTIONATED CONCOMITANT CHEMORADIATION IN LOCALLY ADVANCED HEAD-AND-NECK CARCINOMA: A COMPARATIVE STUDY. 167-171	0
100	Senescent cell-derived extracellular vesicles recruit antigen presenting cells and limit squamous carcinoma recurrence.	
99	Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: neoadjuvant and adjuvant approaches. 2022 , 102437	0
98	Acute toxicity in patients treated with concurrent chemoradiotherapy with proton versus intensity-modulated radiation therapy for nonmetastatic head and neck cancers.	

97	A Multidisciplinary Approach to Cancer: A Radiation Oncologist's View. 2023 , 19-27	
96	Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. 2022 , 13,	3
95	FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer. 2022 , 12, 1245	1
94	Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy. 12,	0
93	Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary result of a randomized phase 2 trial.	
92	Neck Lymph Node Recurrence in HNC Patients Might Be Predicted before Radiotherapy Using Radiomics Extracted from CT Images and XGBoost Algorithm. 2022 , 12, 1377	
91	Disparities in Oral Cancer Stage at Presentation in a High HIV Prevalence Setting In Sub-Saharan Africa. 2022 ,	
90	Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer. 2022 ,	0
89	Evaluating the role of the self-assembling topical haemostat PuraBond [®] in Transoral Robotic Surgery (TORS) for oropharyngeal cancer: A case series. 2022 , 80, 104302	0
88	Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study.	2
87	Upfront transoral robotic surgery (TORS) versus intensity-modulated radiation therapy (IMRT) in HPV-positive oropharyngeal cancer: real-world data from a tertiary comprehensive cancer center. 1-14	
86	Use of Photobiomodulation in Patients With Head and Neck Cancer Treated in an Oncology Service.	
85	GPNMB-Positive Cells in Head and Neck Squamous Cell Carcinoma: Their Roles in Cancer Stemness, Therapy Resistance, and Metastasis. 28,	0
84	Current Evidence of a Deintensification Strategy for Patients with HPV-Related Oropharyngeal Cancer. 2022 , 14, 3969	1
83	Contribution of surgery in management of T4b head and neck cancers: A retrospective review. 2022 , 43, 103543	0
82	Reirradiation for Head and Neck Cancer. 2022 , 153-172	0
81	Oxidative Stress Player in Head and Neck Cancer Therapy Response. 2022 ,	0
80	Advances in Surgery and Reconstruction: TORS, TLM. 2022 , 25-43	0

- 79 De-intensification Strategies for Head and Neck Cancer. **2022**, 1-12 ○
- 78 Systemic Therapy Advances in Head and Neck Cancer. **2022**, 61-72 ○
- 77 Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model. **2022**, 23, 9872 ○
- 76 Comparison between three age-stratified cohorts reveals poor prognosis of young patients with tongue carcinoma. 12, ○
- 75 Photoimmunotherapy with surgical navigation and computed tomography guidance for recurrent maxillary sinus carcinoma. **2022**, ○
- 74 Predicting local persistence/recurrence after radiation therapy for head and neck cancer from PET/CT using a multi-objective, multi-classifier radiomics model. 12, ○
- 73 Randomized Phase II study of Physiologic MRI-directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer. ○
- 72 The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma. **2022**, 14, 4694 ○
- 71 Primary concurrent chemoradiation therapy with triweekly cisplatin as a standard protocol in patients aged ≥5 years with head and neck squamous cell carcinoma. ○
- 70 CORRELATION OF AN ELECTRONIC GERIATRIC ASSESSMENT WITH RECEIPT OF ADJUVANT RADIATION AND CHEMOTHERAPY IN OLDER ADULTS WITH HEAD AND NECK CANCER. **2022**, 101096 ○
- 69 Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. **2022**, ○
- 68 A 13-Year Single Institutional Experience with Definitive Radiotherapy in Hypopharyngeal Cancer. **2017**, 46, 32-36 1
- 67 Pattern of failure among HNSCC: An institution-based study. **2021**, 1, 58 ○
- 66 Role of palliative chemoradiation in locally advanced head and neck cancer: A case series done in a tertiary care center in Uttar Pradesh. **2021**, 1, 98 ○
- 65 Study of comparison of acute toxicities between sequential intensity-modulated radiation therapy and simultaneous integrated boost intensity-modulated radiation therapy in head-and-neck cancers. **2022**, 0 ○
- 64 Neoplasms of the Head and Neck. 1-28 ○
- 63 Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. ○
- 62 Pembrolizumab versus cetuximab, concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase 2 trial. **2022**, 2

61	Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer.	1
60	Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma. 12,	0
59	Recent advances in the oncological management of head and neck cancer and implications for oral toxicity. 2022 , 233, 737-743	0
58	A Randomized Study to Evaluate Efficacy and Toxicity Profile of Paclitaxel+carboplatin as Neo-adjuvant Chemotherapy in Locally Advanced Supraglottic and Hypopharyngeal Primaries.	0
57	Self-Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer. 2203263	0
56	Associations between patient-reported late effects and systemic cytokines in long-term survivors of head and neck cancer treated with radiotherapy.	0
55	Oropharyngeal and Hypopharyngeal Tumours and Their Treatment. 2022 , 147-167	0
54	Study to evaluate the acute toxicities and response to concurrent chemoradiotherapy with weekly cisplatin versus cisplatin and paclitaxel in locally advanced head-and-neck cancer. 2022 , 0	0
53	Amifostine Has Chemopreventive Effects in a Mouse Skin Carcinogenesis Model.	0
52	Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial. 2022 , 22,	0
51	Amifostine Has Chemopreventive Effects in a Mouse Skin Carcinogenesis Model.	0
50	Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide. 2022 , 14, 5689	0
49	Long-term update of NRG/RTOG 0522: a randomized phase III trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer. 2022 ,	0
48	Patient-reported outcomes in terms of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced oropharyngeal cancer patients treated with definitive chemo-radiotherapy: Swall PEG study. 2022 , 23,	0
47	Surgical site complications of isolated salvage neck dissection post-radiotherapy and post-chemoradiotherapy: A cohort analysis (1997-2017). 2022 ,	0
46	Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients.	1
45	Physical Function and Nutrition in Patients with Esophageal Cancer and Head and Neck Cancer. 2022 , 461-491	0
44	Ex Vivo Functional Assay for Evaluating Treatment Response in Tumor Tissue of Head and Neck Squamous Cell Carcinoma. 2023 , 15, 478	0

- 43 A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer. **2023**, 40, ○
- 42 miR-551a and miR-551b-3p target GLIPR2 and promote tumor growth in high-risk head and neck cancer by modulating autophagy. **2022**, 100085 ○
- 41 Oropharynx und Larynx. **2022**, 171-187 ○
- 40 Oropharyngeal Carcinoma with a Special Focus on HPV-Related Squamous Cell Carcinoma. **2023**, 18, 515-535 ○
- 39 Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. ○
- 38 Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer. **2023**, 15, 672 ○
- 37 Prevention of Pharyngocutaneous Fistula After Total Laryngectomy by Otolaryngologists and Multidisciplinary Team Efforts Against Adverse Events of Chemoradiotherapy. **2022**, 34, 71-76 ○
- 36 Management of Older Patients with Head and Neck Cancer: A Comprehensive Review. ○
- 35 Dil kanserli hastalarda preoperatif neoadjuvan kemoterapinin prognostik rolü. **2023**, 4, 106-111 ○
- 34 DOSE AND VOLUME DE-ESCALATION OF RADIOTHERAPY IN HEAD AND NECK CANCER. **2023**, 103994 ○
- 33 In vitro evaluation of photon and carbon ion radiotherapy in combination with cisplatin in head and neck squamous cell carcinoma cell lines. 13, ○
- 32 Adjuvant PD-1 antibody in recurrent, previously irradiated oral cavity cancer treated with salvage surgery. **2023**, 40, 100623 ○
- 31 Epidemiology and survival analysis of head and neck cancer: Results from comprehensive care center in North India. **2023**, 6, 100022 ○
- 30 Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?. **2023**, 186, 103986 ○
- 29 Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. **2023**, 138, 106311 ○
- 28 Treatment Considerations for Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin. **2023**, 24, 147-161 ○
- 27 Radio-Chemo-Therapie. **2022**, 263-295 ○
- 26 Hypofractionated, Dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase-I HYDRA trial. ○

- 25 Pre-chemoradiotherapy low hemoglobin levels indicate increased osteoradionecrosis risk in locally advanced nasopharyngeal cancer patients. **2023**, 280, 2575-2584 1
- 24 Effect of lymphoid volume irradiation on radiation-induced lymphopenia in head and neck cancers. **2023**, 27, 145-153 0
- 23 Impact of weight loss on treatment interruption and unplanned hospital admission in head and neck cancer patients undergoing curative (chemo)-radiotherapy in Hong Kong. 0
- 22 Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning. **2023**, 52, 0
- 21 Evaluation of Concomitant Systemic Treatment in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Radiotherapy. **2023**, 6, e230090 0
- 20 Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy. **2023**, 18, e0282015 0
- 19 Functional Outcomes After Transoral Plus Lateral Pharyngotomy Approach for Advanced Oral and Oropharyngeal Tumors. **2023**, 7, 0
- 18 Metronomic adjuvant chemotherapy evaluation in locally advanced head and neck cancers post radical chemoradiation: a randomised trial. **2023**, 100162 0
- 17 The Role of Perioperative C-Reactive Protein in Predicting the Prognosis of Epithelial Ovarian Carcinoma. Volume 15, 233-243 0
- 16 Reply to A. Abner et al. 0
- 15 Treatment and outcome among patients with laryngeal squamous cell carcinoma in the Stockholm population-based study. **2023**, 8, 441-449 0
- 14 Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha. **2023**, 210, 115492 0
- 13 Clinical and Therapeutic Considerations for Older Adults with Head and Neck Cancer. Volume 18, 409-422 0
- 12 Impact of Irradiation on the Adhesive Performance of Resin-Based Dental Biomaterials: A Systematic Review of Laboratory Studies. **2023**, 16, 2580 0
- 11 Prognostic Significance of Proliferative Markers: Cyclin D1 and CENPF in Oral Squamous Cell Carcinoma Patients: A Cohort Study. 0
- 10 Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population. 0
- 9 Treatment Intensification in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: What Are the Options and for Whom?. **2023**, 129-164 0
- 8 Weekly versus 3-weekly cisplatin along with radiotherapy for locoregionally advanced non-nasopharyngeal head and neck cancers: Is the equipoise in literature addressed yet?. 0

- 7 Potential of combination therapy with lenvatinib and radiation for thyroid cancer. **2022**, 73, 1-5 ○
- 6 CUP-Syndrom □ Tumorerkrankung mit unbekanntem Primärtumor. **2021**, 1-30 ○
- 5 Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer. ○
- 4 Prognostic relevance of pre-treatment inflammatory biomarkers along with other clinicopathological and treatment factors in oral cavity cancers. **2023**, 19, 212 ○
- 3 The predictive value of pretreatment hemoglobin-to-platelet ratio on osteoradionecrosis incidence rates of locally advanced nasopharyngeal cancer patients managed with concurrent chemoradiotherapy. **2023**, 23, ○
- 2 Intensity Modulated Radiotherapy in Head and Neck Cancer: Initial Experience of the First Treated Cases from North-East India. ○
- 1 Automated tracking of morphologic changes in weekly magnetic resonance imaging during head and neck radiotherapy. ○